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Summary 
In the last decade, multipotent mesenchymal stromal cells (MSCs) demonstrated 
a significant therapeutic efficacy, particularly in cell therapy approaches aiming at 
tissue regeneration. MSCs exert their action via trophic support, induction of 
angiogenesis, immunomodulation and reduction of necrosis at affected tissues. 
Importantly, these regenerative and protective properties are largely associated 
to MSC secretome. Unfortunately, cell-based approaches not always meet the 
criteria for a smooth translation to the clinic. For instance, the use of stem cells in 
pathologies with a very short therapeutic window, such as few hours, is not 
compatible with the requested minimal criteria for MSC release, before 
administration to the patient. 
Notwithstanding, in the regenerative medicine field, the MSC mechanism of 
action paradigm was recently extended to include the action of extracellular 
vesicles (EVs), which are cytoplasm-containing cellular bodies secreted by a 
wide range of cell types. Intriguingly, many studies reported that EVs generated 
by MSCs are able to recapitulate the majority of the regenerative properties of 
parental MSCs. 
Starting from these premises, the objectives of the present doctoral research 
project were: to address EV-mediated cell-to-cell communication as novel MSC 
mechanism of action; to address reprogrammed MSC-EV generation; to define, 
for the first time in the literature, stem cell EV molecular content (e.g.: miRNome), 
comparing reprogrammed to non-reprogrammed MSC-EVs; to challenge stem 
cell-EV therapeutic potential in a model of acute tissue damage, as a proof-of-
concept for feasibility and effectiveness of a stem cell-based albeit cell-free 
regenerative strategy. Intriguingly, EVs may be produced in a ready-to-use 
formulation, so that clinicians could use them as soon as a therapeutic need 
arises, also in the case of an urgent one. In this way, EV-shuttled MSC 
regenerative properties could exert beneficial effects also on pathologies 
currently lacking any cell therapy option. 
 
 
To develop this innovative therapeutic strategy, MSCs were isolated from 
different tissues and their biological properties were evaluated in order to choose 
the MSC source most suitable for the implementation of the project. Thus, both 
MSC transcriptome and immunophenotype were addressed. MSCs from adult 
sources (e.g.: bone marrow) showed senescence-related features in vitro, 
correlated to donor’s age in vivo. On the other hand, MSCs from perinatal tissues 
(e.g.: cord blood) showed a phenotype more similar to that of pericytes, which are 
the in vivo progenitors of MSCs. Therefore, cord blood was chosen as MSC 
source, also in the prospective of clinical translation, since public banking of cord 
blood units for clinical use already exists worldwide. 
Next, thanks to an extended analysis of the stromal populations present in cord 
blood, a MSC subpopulation showing higher proliferation properties and 
significantly longer telomeres was isolated. In addition, the standard cord blood 
MSC isolation protocol was improved, leading to an efficiency of 80%. Eventually, 
MSC secretome-associated anti-inflammatory and anti-apoptotic properties were 
observed in vitro and in vivo. In order to investigate if EVs contributed to MSC 
paracrine properties, MSC-EV secretion and regenerative properties were 
assessed. The MSC-EV therapeutic effectiveness was challenged in an in vitro 
model of acute tissue damage. Intriguingly, MSC-EVs could rescue damage-
induced cell mortality, showing the same protective effect of parental MSCs. 
In spite of the use of a high proliferative cord blood MSC subpopulation, primary 
cultures still show a limited lifespan. In order to increase their replicative potential 
and to better exploit their EV production, induced cellular reprogramming was 
tested on MSCs as an alternative to traditional immortalization techniques. In this 
way, MSC-derived cell lines endowed with unlimited lifespan were generated, 
and permanent modification of their genome was avoided. The next step was to 
confirm the generation of EVs from reprogrammed MSCs, since reprogramming 
drastically changes cell identity. Furthermore, the EV miRNome load of 
reprogrammed and non-reprogrammed MSCs was addressed. Importantly, the 
majority of miRNAs were common between the two samples, indicating that 
reprogramming did not change the EV miRNA content. This result could have 
relevant consequences on the functional features of reprogrammed MSC-EVs, 
since EV-mediated miRNA transfer from donor to target cells was proposed as 
one of MSC mechanisms of action. 
  
In the last part of this doctoral research, stem cell (non-reprogrammed and 
reprogrammed MSCs)-EV therapeutic effectiveness was addressed and 
compared to that of parental MSCs. In order to do that, an organotypic ex vivo 
mouse model of brain ischemia was used. This model recapitulated the 
modulation of some ischemic damage-related parameters, including increased 
secretion of inflammatory cytokines, high tissue necrosis and the impairment of 
neuronal and astrocytic cell populations. Therefore, this model mimicked early 
phase events of brain ischemia, whose thrombolytic clinical treatment must be 
administered within 3-6 hours of first signs of ischemia. Notably, stem cell-EVs 
were tested for the first time in this pathological context to verify their potential 
role in tissue regeneration. Strikingly, stem cell-EV administration to affected 
tissues showed significant neuroprotective properties, which were comparable to 
those of parental MSCs. Importantly, the ischemic damage-related parameters 
previously described were rescued. In particular, inflammatory-associated 
parameters underwent the most statistically significant decrease, showing levels 
similar to or better than those of the uninjured brain tissue. This is of uttermost 
importance, considering that chronic inflammation is detrimental to tissue 
regeneration. 
To conclude, the results of the present PhD thesis confirmed the feasibility of 
stem cell EV-based therapies in regenerative medicine approaches. In the future, 
this innovative EV therapy may be applied to pathological contexts currently 
without a cell therapy option. In the framework of advanced therapy medicinal 
products, the new drug would be the EVs, rather than the parental stem cells. 
Finally, EVs could play the role of ready-to-use anti-inflammatory molecule 
carriers, in order to guarantee a rapid therapeutic action for the regeneration of 
injured tissues. 
Sommario 
 
Negli ultimi anni, le cellule stromali mesenchimali multipotenti umane (CSM) 
hanno mostrato una grande efficacia terapeutica, soprattutto in approcci di 
terapia cellulare aventi come obiettivo la rigenerazione tissutale. L’azione delle 
CSM avviene attraverso supporto trofico, induzione di angiogenesi, modulazione 
della risposta immunitaria e diminuzione della necrosi a livello dei tessuti colpiti. 
Inoltre, recente letteratura ha dimostrato che queste capacità rigenerative e 
protettive sono in larga parte associate al secretoma delle CSM. Purtroppo, gli 
approcci di terapia cellulare non sono sempre traslabili alla clinica. Ad esempio, 
l’utilizzo di cellule staminali in patologie caratterizzate da una finestra terapeutica 
molto stretta, dell’ordine di poche ore, non è compatibile con la necessità di 
scongelare e valutare i minimi standard di qualità delle CSM prima della 
somministrazione al paziente. 
Nonostante ciò, il paradigma del meccanismo d’azione delle CSM nel campo 
della medicina rigenerativa si è ulteriormente arricchito. Infatti, molti recenti studi 
hanno dimostrato che le vescicole extracellulari, ossia porzioni di citoplasma 
delimitate da membrana cellulare secrete dalle CSM, sono in grado di riprodurre 
la maggior parte delle proprietà rigenerative delle CSM stesse. 
Date queste premesse, gli obiettivi del progetto di ricerca del presente Dottorato 
sono stati i seguenti: indagare la comunicazione intercellulare tramite vescicole 
extracellulari quale innovativo meccanismo d’azione delle CSM; studiare la 
produzione di vescicole extracellulari da parte di CSM riprogrammate, e, per la 
prima volta in letteratura, definirne il contenuto molecolare (es.: miRNoma), a 
confronto con le CSM d’origine; testare il potenziale terapeutico di vescicole 
extracellulari da cellule staminali in un modello di danno tissutale acuto, come 
proof-of-concept della funzionalità di una strategia terapeutica cell-free. Infatti, le 
vescicole extracellulari potrebbero essere prodotte in formulazioni pronte all’uso, 
a immediata disposizione per ogni richiesta clinica, anche urgente. In questo 
modo le proprietà rigenerative delle CSM potrebbero essere veicolate dalle 
vescicole extracellulari anche in contesti patologici attualmente senza alcuna 
opzione di terapia cellulare. 
Per lo sviluppo di questa innovativa strategia terapeutica, CSM isolate da vari 
tessuti sono state caratterizzate e confrontate in base al loro trascrittoma e al loro 
immunofenotipo, allo scopo di valutarne le proprietà biologiche e quindi scegliere 
le CSM più adatte all’implementazione del progetto di Dottorato. Le CSM da 
tessuti adulti (e.g.: midollo osseo) hanno mostrato in vitro caratteristiche di 
senescenza correlate all’età del donatore in vivo. Al contrario, le CSM da tessuti 
perinatali (e.g.: sangue di cordone ombelicale) hanno mostrato un fenotipo più 
simile a quello dei periciti, ossia i progenitori delle CSM in vivo. Quindi, tenuto 
conto anche della traslabilità clinica, il sangue di cordone ombelicale è stato 
scelto come fonte di CSM, visto che la raccolta e la crioconservazione di unità di 
sangue placentare a fini terapeutici è già una realtà clinica. In seguito, un’analisi 
estesa delle popolazioni stromali presenti nel sangue di cordone ombelicale ha 
portato alla definizione di una sottopopolazione di CSM dotata di maggiori 
capacità proliferative e con una lunghezza del telomero significativamente più 
alta. Inoltre il protocollo standard di isolamento delle CSM da sangue di cordone 
ombelicale è stato migliorato, arrivando ad un’efficienza di circa 80%. Infine, le 
proprietà anti-infiammatorie e anti-apoptotiche del secretoma delle CSM sono 
state studiate sia in vitro che in vivo. Al fine di verificare se le vescicole 
extracellulari contribuissero alle proprietà paracrine delle CSM, se ne è 
caratterizzata la secrezione e se ne sono indagate le proprietà rigenerative. Una 
chiara efficacia terapeutica da parte delle vescicole extracellulari di CSM è stata 
dimostrata in un modello in vitro di danno tissutale acuto, in cui le vescicole 
extracellulari hanno eguagliato i risultati ottenuti con le CSM stesse. 
Nonostante l’utilizzo di CSM dalle elevate proprietà proliferative, la loro lifespan in 
coltura, in quanto cellule primarie, rimane limitata. Allo scopo di aumentarne il 
potenziale replicativo e di sfruttarne al meglio così la produzione di vescicole 
extracellulari, le CSM sono state sottoposte alla riprogrammazione cellulare 
indotta. In questo modo sono state generate linee cellulari derivate da CSM dal 
potenziale di crescita illimitato, evitando però di modificarne il genoma come nelle 
tradizionali tecniche di immortalizzazione. Siccome la riprogrammazione implica 
una modificazione radicale dell’identità della cellula d’origine, il passo successivo 
è stato quello di confermare la capacità di questa nuova popolazione di generare 
vescicole extracellulari, poi opportunamente caratterizzate.  
In particolare, il miRNoma delle vescicole extracellulari da cellule riprogrammate 
è stato oggetto di studio e di confronto con quello delle vescicole extracellulari 
delle CSM d’origine. Si è così potuto dimostrare che la maggior parte dei miRNA 
era presente nelle vescicole extracellulari sia prima che dopo la 
riprogrammazione. Ciò indica che il processo di riprogrammazione non ne ha 
alterato in modo sostanziale il contenuto. Questo potrebbe avere importanti 
ricadute sugli aspetti funzionali delle vescicole extracellulari da CSM 
riprogrammate. Infatti è stato ipotizzato che il trasferimento di miRNA specifici da 
cellule donatrici a cellule target mediato dalle vescicole extracellulari sia uno dei 
meccanismi d’azione delle CSM. 
Nell’ultima parte di questo progetto di Dottorato, l’utilità terapeutica delle 
vescicole extracellulari da cellule staminali (CSM e CSM riprogrammate) è stata 
confrontata con quella delle CSM d’origine. A tale scopo è stato utilizzato un 
modello ex vivo di ischemia cerebrale, in cui è stato osservato il movimento di 
alcuni parametri di danno ischemico acuto, tra cui un picco di produzione di 
citochine infiammatorie, una forte necrosi tissutale e una riduzione delle 
popolazioni cellulari neuronali e astrocitiche.  Questo particolare modello mima 
infatti la fase acuta di questa condizione patologica, il cui trattamento a base di 
agenti trombolitici deve avvenire entro 3-6 ore dall’insorgenza dei primi sintomi. 
Quindi le vescicole extracellulari prodotte dalle CSM riprogrammate sono state 
testate per la prima volta in questo contesto patologico per verificare se 
potessero esercitare una funzione rigenerativa. La loro somministrazione al 
tessuto colpito dal danno ischemico ha generato uno spiccato effetto 
neuroprotettivo, pari a quello delle CSM d’origine, che ha riportato a valori simili a 
quelli del tessuto cerebrale non danneggiato i parametri di danno sopra descritti. 
Il risultato più interessante e statisticamente significativo è stato soprattutto a 
carico di quei parametri legati ai processi infiammatori, i quali sfavoriscono il 
recupero del danno tissutale. 
In conclusione, i risultati presentati in questa tesi di Dottorato confermano la 
possibilità di utilizzo di vescicole extracellulari secrete da cellule staminali in 
strategie di medicina rigenerativa. Questa innovativa extracellular vesicle therapy 
potrebbe in futuro essere applicata in contesti patologici per i quali ad oggi non è 
praticabile una terapia cellulare.  
A questo punto, nel quadro dei prodotti medicinali per le terapie avanzate, il 
“farmaco” non sarebbe più la cellula staminale, ma le rispettive vescicole 
extracellulari. Queste acquisirebbero così il ruolo di carrier di molecole 
antinfiammatorie, pronte all’uso e capaci di garantire un’azione terapeutica 
tempestiva per la rigenerazione di tessuti danneggiati. 
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Chapter 1 
 
 
 
Development of a stem cell-based 
albeit cell-free regenerative 
approach 
 
 
 
Nowadays, human stem cells are being widely tested, or already effectively used, 
in clinical protocols referring to the general area of regenerative medicine. 
Whether the therapeutic rationale roots on differentiation or “drugstore”-like 
properties, stem cell clinical trial numbers steadily increase (Fig. 1.1). 
 
Figure 1.1. Stem cells in translational research. Source: ClinicalTrial.gov; search terms: (“cell therapy” 
OR “regenerative medicine” OR “advanced medicinal product” OR “Tissue Engineering”) AND “stem cell”; 
09/11/2016. 
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Despite the high expectations regarding stem cell-based therapies, many hurdles 
have frequently impeded their complete fulfillment so far (e.g.: [1, 2]), as shown 
by the number of phase 3 and 4 clinical trials, compared to total approved studies 
(Fig. 1.2). 
 
Figure 1.2. Stem cell clinical trial phases. Source: ClinicalTrial.gov; search terms: (“cell therapy” OR 
“regenerative medicine” OR “advanced medicinal product” OR “Tissue Engineering”) AND “stem cell”, filtered 
for phase 0, 1, 2, 3 or 4; 09/11/2016. 
 
Various reasons behind this have been proposed, ranging from inadequacy of 
pre-clinical models to heterogeneity of cell preparations, i.e. inter- and intra-stem 
cell donor variability [3-7]. Yet, one major issue in this field is that the precise 
stem cell mechanisms of action (MoA) are often not fully understood and 
characterized, in spite of a demonstrated functionality [8-10]. This happens also 
for multipotent mesenchymal stromal cells (MSCs), which are frequently used in 
reason of a plethora of secretome-associated properties (e.g.: [11-13]). 
Recently, extracellular vesicles (EVs) budding from stem cells were shown to 
recapitulate many therapeutic properties ascribed to their cellular counterpart [12, 
14-16]. Thus, it is of utmost importance to assess if EVs play a role in MSC 
secretome-associated MoA. If this is the case, EVs may be used to develop more 
affordable cell-free regenerative approaches, keeping in mind that the more 
thoroughly the MoA is defined, the more consistent the clinical outcome will be. 
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1.1 Introduction 
As a branch of translational research, regenerative medicine ultimate goal is “to 
regenerate, replace or repair cells, tissues or even organs” (cited from [17]). Such 
a concept was first theorized in 1992 by L. Kaiser as “A new branch of medicine 
[...] that attempts to change the course of chronic disease and [...] (to) regenerate 
tired and failing organ systems” (cited from [18]). The starting point of this field is 
that many regenerative processes may be indeed observed in nature, for 
invertebrates and vertebrates alike, involving complete or partial limb 
regeneration (e.g.: Axolotl limbs, human pediatric fingertips) [19, 20], or internal 
organ reconstitution (e.g.: adult human liver) [21]. Thus, the underlying ratio is to 
mimic, substitute, trigger or aid endogenous processes to restore impaired 
physiological functions. 
Different approaches, aiming at the development of the so-called advanced 
therapy medicinal products (ATMPs), have been used so far to achieve such a 
goal, ranging from cell therapy, modulation of stem cell biology, tissue 
replacement, gene therapy, bioengineering or a combination of them [22]. In 
particular, cell therapy approaches rely on the assumption that a dynamic system 
such as a living cell would modulate its behavior responding to the extracellular 
environment of the target tissue. Thus, a more refined therapeutic action and a 
better clinical outcome would be guaranteed, compared to traditional 
pharmacological treatments. Yet, the path a cell therapy protocol must follow 
implies very high costs and many technical and regulatory hurdles to cope with. 
In this scenario, it is not trivial to underline that the simpler is the better: the 
simpler the ATMP formulation and the production workflow, the easier to 
standardize the process and to obtain consistent ATMP batches and clinical 
results. 
Concerning stem cell types currently used in cell therapy, multipotent 
mesenchymal stromal cells (MSCs) gained a prominent role, representing a third 
of total stem cell clinical trials1. MSC widespread use is due to their multipotent 
differentiation capabilities (i.e.: bone and cartilage reconstruction), but also in 
reason of MSC secretome-associated properties.  
                                                 
1 Source: ClinicalTrial.gov; search terms: (“cell therapy” OR “regenerative medicine” OR “advanced 
medicinal product” OR “Tissue Engineering”) AND “stem cell”, for total stem cell trials; (“cell therapy” OR 
“regenerative medicine” OR “advanced medicinal product” OR “Tissue Engineering”) AND “mesenchymal”, 
for MSC trials. 
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As an instance, MSCs are successfully employed in clinical protocols requiring 
immunomodulation (e.g.: graft-versus-host disease) [23]; nonetheless, 
angiogenic, anti-inflammatory and anti-apoptotic effects can be attained, too [24-
26]. Unfortunately, the precise molecular and biological processes (mechanisms 
of action, MoA), which allow MSCs to exert such regenerative functions, have 
often been so far quite elusive. Revising the literature, MSC MoA paradigm 
changed swiftly in the last decade, switching from transdifferentiation to tissue 
modulation [27], not without causing sometime fierce scientific debates [28-30]. 
Admittedly, this issue could be in part responsible of inconsistencies observed in 
the effectiveness of some MSC-based clinical trials [31, 32]. Hence, in spite of 
the clinical interest aroused by MSCs, it is of paramount importance to achieve 
first a more accurate definition of what MSC MoAs are, in order to better control 
MSC therapeutic action and to achieve more satisfying and consistent clinical 
outcomes. 
In this context, recent findings demonstrated that some MSC secretome-
associated properties might be partially ascribed not only to secreted soluble 
factors, but also to the so-called extracellular vesicles (EVs) [33]. These are 
membrane-enclosed particles, which contain biologic material from the cell of 
origin cytoplasm [34]. In the frame of cell-to-cell communication mechanisms, 
EVs represent a peculiar solution to the problem of horizontal transfer of bioactive 
molecules across the extracellular space, toward distant organism compartments. 
The extent EVs participate in the already known MSC secretome-associated 
properties is presently under debate and it will complete the current MSC MoA 
paradigm. 
In the following sections, the scientific background that accounts for the 
development of a stem cell-based albeit cell-free regenerative approach is 
introduced, focusing on the advantages of MSCs as stem cell source and on the 
aforementioned novel cell-to-cell communication mechanism as candidate carrier 
of stem cell-derived regenerative information. 
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1.2 Motivation for a cell-free stem cell-based strategy 
Multipotent mesenchymal stromal cells (MSCs) are extensively used in clinical 
applications in reason of their regenerative properties. This implies that they are 
already available at the clinical-grade level. Therefore, their use for the 
development of a cell-free therapeutic approach is feasible and promising. 
Innovative therapeutic agents could be detected from the dissection of MSC 
secretome, since many MSC applications rely on their capacity to release 
bioactive molecules, rather than on their differentiation properties. The next 
paragraphs illustrate why, in our working hypothesis, extracellular vesicles (EVs) 
could play that role. 
 
1.2.1 “Curative” versus “replacement-focused” stem cell 
paradigm 
In the field of regenerative medicine, two main stem cell paradigms might be 
distinguished. In the first case, stem cells are used for their differentiation 
properties and translational research is focused on cell, tissue or organ 
replacement strategies. In the second, the stem cell secretome is seen as a 
therapeutic tool per se. Thus, cells are introduced into patients, so that they can 
unleash their secretome at the target tissue to exert a regenerative effect. This 
last approach, that can be referred to as “curative”, has been heavily relying on 
the use of MSCs. Thanks to their anti-apoptotic and anti-inflammatory secretome 
properties, MSCs were proven effective in a variety of pathological conditions, 
where control of the immune system response or treatment of acute tissue 
damage is needed. On the other hand, a “replacement-focused” approach is 
based on the stem cell potency degree, in order to generate a specific set of 
differentiated cell types starting from the same undifferentiated cell. From this 
point of view, multipotent MSCs have in vitro differentiation abilities limited to the 
mesodermal lineage (i.e.: bone, cartilage, adipose tissue) [35], if compared to 
pluripotent stem cells, which can give rise to derivatives of all the three germ 
layers [36]. Furthermore, it is worth noting that while pluripotent stem cells 
present serious safety issues related to their high tumorigenic risk, MSCs are 
completely safe [37]. 
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This seemingly dual and contrasting nature of MSCs may be attributed to their in 
vivo function, postulated as tissue niche regulation [38]. As a matter of facts, 
MSCs reside virtually in any vascularized tissue of the body, as their in vivo 
precursors are pericytes [39], which are cells wrapped around capillaries and 
venules. Depending on the tissue of origin or pathological condition, pericytes 
can exert trophic functions (e.g.: angiogenesis and endothelial cell survival) [40] 
or physical support (e.g.: maintenance of the blood-brain barrier) [41], or they can 
even differentiate into tissue-specific cells and replace the damaged ones (e.g.: 
skeletal muscle regeneration) [42]. As a consequence, MSCs can be isolated 
from many vascularized adult tissues, such as the bone marrow [35] and the 
adipose tissue [43], but also from perinatal tissues, such as the cord blood [44] or 
the Wharton’s jelly [45]. As already mentioned, the tissue of origin influences 
MSC behavior and properties in vitro. In particular, a piece of literature is starting 
to point out how donor age is important to determine stem cell potential and 
biological features [46]; this aspect will be discussed more in detail in Chapter 2. 
In conclusion, MSCs represent a valid option as a stem cell type whose 
secretome could be employed to vehicle cell-free regenerative messages, 
already observed in traditional cell-based approaches, to affected tissues. 
 
1.2.2 A novel cell-to-cell communication mechanism 
The term “extracellular vesicle” (EV) was recently coined to describe a 
heterogeneous set of membrane-encircled cytoplasm-containing bodies of cell 
origin, whose cargo comprises a wide range of nucleic acids (e.g.: DNA, mRNA, 
miRNA) and proteins. A growing body of literature is showing how some, if not all, 
MSC properties may be ascribed to the action of EVs. Examples range from 
modulation of differentiation properties (e.g.: stimulation of osteogenic program in 
recipient cells) [47] to immunomodulatory effects (e.g.: promotion of anti-
inflammatory M2 macrophage phenotype acquisition) [48]. It is worth noting that 
the same properties were demonstrated in the past for non-fractionated MSC-
conditioned media, in which the role of soluble factors was studied [49-51].  
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It is likely that such contribute was predominant over the one exerted by EVs 
present in the same MSC-conditioned medium, unnoticed by the researchers. 
Notwithstanding, it can be envisioned that EVs could act as a delayed courier of 
the same messages conveyed by more rapid intracellular signaling pathway-
activating soluble factors. While the latter are free to interact swiftly with cell 
receptors in the extracellular environment, the former, in addition, may need 
either to be internalized by the cell or to fuse with the cell membrane to deliver 
their bioactive content and to influence cell physiology. 
From these premises, EVs were considered optimal candidates as cell-free 
carriers of stem cell-generated regenerative clues. 
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1.3 State of the art 
 
1.3.1 Exosomes and microvesicles 
Extracellular vesicles (EVs) represent an elegant and evolutionally conserved 
cell-to-cell communication strategy, exploited by both prokaryotic and eukaryotic 
cells. The involvement of EVs in pathological conditions is under intense study, 
as their role could be that of disease biomarkers or also of disease-propagating 
agents. EVs were shown to have a role also in the maintenance of homeostasis 
and of cell physiological functions, even though this aspect have been less 
investigated. Since their discovery in 1946 by Chargaff and West [52], as 
procoagulant platelet-derived particles in normal plasma, under the name of 
“platelet dust” [53], EVs were then observed during bone calcification [54], in cell 
cultures [55], in seminal plasma [56] and as tumor-originating cell fragments [57]. 
In all these cases, the researchers were observing microvesicles (MVs), cellular 
microparticles generated by outward budding and fission of cellular plasma 
membranes. It was only in 1983 when ultrastructural studies demonstrated that 
vesicles are also produced as intraluminal vesicles contained in multivesicular 
bodies, which, upon fusion with the plasma membrane, are released in the 
extracellular space [58]. These particles were later characterized in transformed 
B lymphocytes and called exosomes [59]. Yet, in spite of distinct biogenesis 
pathways, unambiguous markers distinguishing these two populations still lack 
[60]. This is due in part to inefficiency of current isolation methodologies in the 
purification of homogeneous classes of vesicles, whereas they actually yield 
composite vesicle mixtures [61]. Waiting for more accurate isolation 
methodologies and definitive vesicle subpopulation markers, the general term 
“extracellular vesicle” was adopted by the field. It is important to underline that 
this could be further complicated by the presence of apoptotic bodies, so that 
thoroughly characterization of the EV source is pivotal for consistent results. 
Nonetheless, a classification of EVs by physical parameters has become a 
common practice [62]: exosomes are usually described as particles 30-100 nm in 
size; MVs range from 50 to 1,000 nm; apoptotic bodies show greater variability 
and higher sizes (500-5,000 nm) (Fig. 1.3). 
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Even though CD9, CD63 and CD81 were initially considered exosome-specific 
markers, they were subsequently observed also in MVs and apoptotic bodies [69-
72]. Thus, many efforts will be necessary to define reliable EV markers.  
With regard to RNA, it was observed that EVs incorporate preferentially <700 nt 
RNA molecules, hinting at a predominance of small RNA species, as miRNAs 
[73, 74]. Yet, the presence of intact mRNAs was also demonstrated [75]. For 
proteins and RNAs alike, the mechanisms that control sorting to EVs remain 
elusive. Whereas protein incorporation seems dependent on aspecific 
mechanisms related to EVs biogenesis, such as tetraspanin-enriched plasma 
membrane microdomain formation or the membrane curvature machinery [76-
78], RNAs were demonstrated to undergo more regulated processes [79]. The 
enrichment of certain RNAs, compared to parental cells, was ascribed to active 
sorting mechanisms relying on the coordinated action of nucleotide motifs and 
RNA-binding proteins [80]. 
Being carriers of biological information, EV uptake and biodistribution 
mechanisms are crucial aspects, too, currently under research. The importance 
of surface-exposed receptors and ligands was already demonstrated, in particular 
for glycan-binding proteins [81-83]. Specifically, surface glycosylation patterns 
could play an essential role in EV uptake [67, 84-87], in a heparin sulphate 
proteoglycan-dependent manner [88, 89]. After the interaction with the target cell 
is established, EVs may trigger intracellular signaling pathways, undergo 
internalization, or transfer lipids and functional receptors [34]. Internalization was 
observed to occur mostly by phagocytosis, but also macropinocytosis and direct 
fusion may be involved [89-93]. The choice among these mechanisms would be 
influenced by recipient cell capabilities, or also by extracellular environment pH 
conditions. For instance, similar membrane fluidity is needed for direct fusion, 
something that occurs only at acidic pH in the case of plasma membranes and 
EVs [90, 94-97]. Biodistribution was shown to be dependent on cell source, 
injection site, availability of target sites and physiological conditions. In some 
cases, it was regulated by specific adhesion molecules (e.g.: CD169, ICAM1) 
[98-101].  
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A study with rat red blood cell-EVs found out that EVs were retained mostly in the 
liver (44.9%) and bone (22.5%), but also in skin (9.7%), muscle (5.8%), spleen 
(3.4%), kidney (2.7%), and lung (1.8%) [102]; almost complete clearance of EVs 
from blood circulation was observed after 5 minutes. Yet, another study using 
melanoma-derived EVs showed preferential uptake in lungs and spleen after 
intravenous injection [103], but with a similar half-life. This very short half-life was 
confirmed by other studies, and in all cases complete clearance was assessed 
within 30 minutes [102, 103]. Human platelet concentrate-derived EVs 
represented an exception, with a half-life of 5.5 hours, probably depending on 
lower organ uptake, as complement-induced lysis would be escaped by EV 
surface CD55 and CD59-mediated protection [104]. A recent report investigated 
biodistribution of mouse EVs from different cell sources and different routes of 
administration. Strikingly, EVs were retained in different tissue compartments for 
48 hours. More importantly, both EV cell source and administration route 
significantly influenced biodistribution. For instance, dendritic cell EVs localized 
preferentially in the spleen, whereas myoblast cell line EVs were found at higher 
amounts in the liver; intra-venous delivery enhanced spleen EV uptake, while 
intra-peritoneal and sub-cutaneous deliveries increased gastro-intestinal tract EV 
uptake. 
 
1.3.1.1 Methodological considerations on extracellular vesicle isolation 
Various approaches can be employed to isolate and purify EV preparations. Even 
though no definitive methodology is currently available, the most used in research 
laboratories is ultracentrifugation [105]. This technique allows separation for both 
density and size at 100,000 g, and it assures higher purity if coupled with the use 
of gradients. The disadvantages are possible EV aggregation and laborious or 
multi-step protocols to remove dead cells and debris from the sample before EV 
harvest. Precipitation with volume-excluding polymers is a faster and simpler 
alternative, but it lacks size specificity and it needs a final polymer purification 
step for very small amounts of sample. Another option is size-exclusion 
chromatography, which guarantees high purity in a single-step process, although 
it currently works only on a small scale. Tangential-flow filtration represents the 
most promising method in terms of scalability. It is fast and it efficiently enriches 
the sample; nonetheless, additional steps are needed to obtain higher purity. 
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Furthermore, EVs were proved to maintain hematopoietic stem cells 
undifferentiated [111] and to support their expansion [112], to promote 
angiogenesis [113], but also to be able to act as carriers of exogenous 
molecules, such as anti-cancer pharmaceuticals [114]. In addition, an effective 
role of MSC-EVs as tissue repair agents is under investigation, with an increasing 
amount of more and more robust data. 
Summarizing some reports, EVs were found to protect bone marrow 
hematopoietic cells after irradiation injury [115], adult or fetal brain tissues after 
stroke [116-118], renal tubular cells after ATP depletion-driven or chronic/acute 
kidney injury [119-122], mesangial cells from hyperglycemia [123], pancreas and 
lung from acute inflammation [124, 125], retinal cells by laser injury [126], liver 
from hepatic ischemia [127], and heart from acute myocardial infarction [128]. 
Intriguingly, even though the exact MoA of EVs is not frequently investigated, 
some of the aforementioned reports point at miRNAs as the key molecules 
horizontally transferred by EVs to alter the phenotype of target cells. 
In conclusion, EV-triggered cellular plasticity and phenotype modulation could 
contribute to tissue regeneration by the delivery of bioactive molecules to affected 
organs, in alternative to stem cell transdifferentiation. 
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1.4 Rationale for cell-free regenerative approaches 
A “cellular”-to-“vesicular” therapeutic paradigm switch would allow the preparation 
of “off-the-shelf” Advanced Therapy Medicinal Products (ATMPs) with equivalent 
functionality, but different application areas. Homogeneous batches of 
extracellular vesicles (EV)-based ATMPs could be produced, tested for efficacy, 
and stored for later ready-to-use application. Many patients suffering from 
pathological conditions for which a therapeutic time window lasts few hours (e.g.: 
thrombolytic therapy within 3-6 hours for stroke), could benefit from a prompt EV-
based treatment. Admittedly, the same rapidity is utterly unfeasible with cell-
based treatments, as longer preparation and unavoidable post-thawing analyses, 
addressing at least viability, must be completed by highly qualified operators, 
before release to patient bedside. Indeed, the very identity of EVs as non-living 
entities would allow dealing with them more like as pharmaceuticals, something 
still hard and tricky to do with cells. In particular, EVs showed less vulnerability to 
freezing procedures [129], and EV lyophilization was proposed as a feasible 
storage option to consider [130], which would allow easier usage and availability 
in the clinical practice. Additionally, EVs possess the intriguing biological feature 
of privileged access to the blood-brain barrier (BBB), which was reported in both 
directions through a still to define route [131-133]. This property is of high value 
since cells can cross the BBB only if such structure is disrupted [134]. 
From an industrial perspective, EVs could be generated as byproducts of other 
ATMP productions, resulting in a higher return for nearly the same economic 
investment. In the current situation, many biotechnology companies already 
produce EVs in the context of cell manufacturing for other purposes, but they 
discard them as waste. Thus, minimal revisions of cell culture processes would 
lead to an easy harvest of both cells and EVs at the same time. 
Taken together, these considerations justify the development of a cell-free 
therapeutic approach based on the use of EVs. 
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1.5 Aim of the thesis 
The aim of this doctoral project is to explore the feasibility of stem cell-derived 
extracellular vesicle (EV) use as an effective therapeutic strategy, testing their 
regenerative functionality in a proof-of-concept model of tissue damage. In order 
to do that, some issues will be addressed: the selection of the more appropriate 
multipotent mesenchymal stromal cell (MSC) source; the evaluation of MSC 
vesicular secretion properties; the use of induced reprogramming to obtain 
immortalized cell lines preserving the secretion properties of the starting stem 
cells; the therapeutic potentiality of EVs to protect an injured tissue. 
 
The presentation of the results is organized as follows: 
• In Chapter 2, the advantages and disadvantages of different MSC sources 
are discussed, and a protocol for the efficient isolation of MSCs from cord 
blood (CBMSCs) is implemented; 
• Chapter 3 deals with CBMSC secretion properties, with a focus on EV 
production and function; 
• In Chapter 4, the reprogramming of CBMSCs into a pluripotent state is 
presented as an option to obtain long-lived cell lines; in addition, EVs are 
proposed as a new feature of pluripotent cell biology; 
• In Chapter 5, stem cell EV efficacy as a regenerative tool is challenged in 
an ex vivo organotypic mouse model of brain ischemia, compared to 
traditional treatment by parental stem cells; 
• Chapter 6 discusses implications and future challenges of this research 
and of EV-based therapy. 
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Chapter 2 
 
 
 
Isolation of multipotent 
mesenchymal stromal cells 
from cord blood 
 
 
 
2.1 Motivations for cord blood as stem cell source 
As commented earlier (paragraph 1.3.1), multipotent mesenchymal stromal cells 
(MSCs) can be isolated from both adult and perinatal tissues. Even though bone 
marrow-derived MSCs have been considered so far the gold standard in the field, 
it is now becoming more and more evident how donor age affects MSC 
properties in vitro and in vivo. The main in vitro effect is earlier senescence entry 
and decreased growth properties [46, 135-137], which affect cell expansion 
feasibility and vivo functionality [138-140]. At the molecular level, adult MSCs 
present shorter telomeres and decreased, if not absent, telomerase activity, 
compared to perinatal MSCs [141-144]. Importantly, impaired telomere structure 
is linked to replicative senescence and genomic instability [145, 146], a 
phenomenon that would be delayed in perinatal MSCs, if subjected to the same 
telomere erosion rate. 
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Among birth-associated tissues, cord blood offers specific advantages over adult 
or other perinatal stem cell sources in terms of easy and safe tissue collection. 
Both adipose tissue and bone marrow need surgical procedures to be harvested, 
and so it is quite rare to have access to healthy donors. Also amniotic fluid, a very 
promising source of different kind of stem and progenitor cells, rely on 
amniocentesis, an invasive technique which present some minor risks for both 
the mother and the baby, and therefore it is performed as a prenatal test only in 
presence of significant genetic risks. Moreover, it has been demonstrated how 
MSCs from cord blood possess superior stemness properties in terms of 
differentiation potential and wound healing, compared to MSCs isolated from the 
umbilical cord Wharton's jelly [147]. It is worth noting that a plethora of other 
gestational tissues are currently under investigation as MSC sources [148]. Yet, 
notwithstanding noticeable efforts addressing MSC properties from different 
sources, comparative studies still produce often contrasting results [149]. 
In order to unveil molecular aspects distinguishing adult from perinatal MSCs, 
biological triplicates of MSCs from various sources (i.e.: bone marrow, adipose 
tissue, cord blood, Wharton’s jelly, perivascular cells, amniotic fluid), and skin 
fibroblasts as stromal non-stem control, were characterized for their 
immunophenotype, by extensive flow cytometry, and for their transcriptome, by 
PCR-array (see Appendix II.a for detailed protocols). 
Statistically significant increased levels of pericytic surface marker Neural/Glial 2 
(NG2) and CD56 were found for all perinatal MSCs, compared to adult MSCs 
(Fig. 2.1, a and b, respectively). Since pericytes are considered the in vivo 
progenitors of in vitro MSCs, higher NG2 expression could hint at a more “naive” 
or less committed state of perinatal MSCs; furthermore, CD56 is known to play a 
crucial role in cell-cell adhesion during embryonic development [150]. Therefore, 
these results would be in line with the aforementioned notions regarding 
senescence-related feature of adult versus perinatal MSCs. In contrast, adult 
MSCs were enriched, even though with high variability, in CD271-positive cells 
(Fig. 2.1, c), a neural crest cell marker that was proposed to discriminate a bone 
marrow MSC subpopulation with superior stemness and differentiation properties 
[151, 152]. 
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Figure 2.1. Adult and perinatal multipotent mesenchymal stromal cell (MSC) specific surface 
markers. In a), b) and c) surface marker expression is shown for Neural/Glial antigen 2 (NG2), CD56 and 
CD271, respectively, normalized to stromal non-stem control (human foreskin fibroblast, HSF); mean and 
standard error of the mean for single MSC types (n=3) or for adult (n=6) versus perinatal (n=12) MSC groups 
(separated by dotted line) is presented. Statistical analysis: Kolmogorov-Smirnov normality test, followed by 
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t-test; * p<0.05. The dendrogram in d) was generated by single linkage clustering; height parameter 
represents relative distance between clusters. Principal component analysis in e) shows grouping of MSCs 
by source, centered on HSF, relative to principal component (PC)1 and PC2 variables. ADMSC, adipose 
tissue MSC; BMMSC, bone marrow MSC; CBMSC, cord blood MSC; WJMSC, Wharton’s jelly MSC; PVC, 
perivascular cells; AFC, amniotic fluid cells; adult, MSCs from adult sources (grey bar); perinatal, MSCs from 
perinatal sources (black and white stripes). 
 
Intriguingly, cluster analysis revealed that the complete immunophenotype panel 
was sufficient to group and discriminate adult and perinatal MSCs (Fig. 2.1, d). In 
addition, Principal Component Analysis (PCA) was applied to the flow cytometry 
data, plotted against fibroblasts as control (Fig. 2.1, e). PCA showed a clear 
separation of adult from perinatal MSCs, which again underlined how MSCs from 
the two sources possessed distinct phenotypes. 
From the transcriptome analysis, Insulin-like Growth Factor 1 (IGF1) was found to 
be almost undetectable in perinatal MSCs, whereas it was expressed in adult 
MSCs (Fig. 2.2, a), as confirmed by Real Time qRT-PCR (Fig. 2.2, b). 
 
 
Figure 2.2. Insulin-like Growth Factor 1 (IGF1) discriminates adult and perinatal multipotent 
mesenchymal stromal cells (MSCs). An elaboration of IGF1 PCR-array data is pictured in a); color 
intensity represents gene expression magnitude for each MSC type (n=3), as shown in the legend (min, 
minimum value; avg, average value; max, maximum value); see Appendix II.a for complete PCR-array 
heatmap. In b), IGF1 Real Time qRT-PCR data (gene expression) normalized to stromal non-stem control 
(human skin fibroblast, HSF) are presented. In c), the amount of IGF1 secreted into the culture medium 
(secretion), measured by ELISA assay, is shown. In b) and c), mean with standard error of the mean of adult 
MSCs (n=6) versus perinatal MSCs (n=12) is presented. Statistical analysis: Kolmogorov-Smirnov normality 
test, followed by t-test; ** p<0.01; *** p<0.001. ADMSC, adipose tissue MSC; BMMSC, bone marrow MSC; 
CBMSC, cord blood MSC; WJMSC, Wharton’s jelly MSC; PVC, perivascular cells; AFC, amniotic fluid cells; 
adult, adult MSCs (orange bar); perinatal, perinatal MSCs (green bar). 
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This result is of uttermost importance, as it confirms that the donor age of source 
tissues can affect molecular properties of MSCs. Notably, higher signaling 
triggered by IGF1 pathway activation leads to earlier senescence and decreased 
lifespan [153, 154], a biological feature shown by adult MSCs, as previously 
commented. To confirm these data, IGF1 secretion was also assessed. In 
accordance, adult MSCs produced higher amounts of IGF1 (Fig. 2.2, c), 
compared to perinatal MSCs, even though the difference was less marked, 
compared to the transcriptional level. 
All these data point at perinatal MSCs as a better option to develop cell therapy 
protocols, mainly because they are described as less senescent cells, endowed 
with superior stemness and differentiation properties.  
Switching point of view with a clinical translation perspective, a crucial feature 
possessed by cord blood MSCs is the lower risk regarding transmission of 
pathogens. This is due to the protection exerted by the placental interface 
between fetus and mother [155]. A peculiar aspect of cord blood is that no full 
Human Leukocyte Antigen (HLA) compatibility with the recipient is needed for 
successful transplantation, as other tissues require, in reason of lower 
immunogenicity and lower risk of chronic graft-versus-host disease [156], a 
biological feature possessed also by cord blood MSCs [157]. Another aspect that 
support the use of cord blood as MSC source is that international networks of 
cord blood banks already exist, which store clinical-grade cord blood units 
available mainly for hematopoietic stem cell transplantation into onco-
hematological pediatric patients. Thus, the collection of cord blood is a common 
practice in hospitals worldwide, and so it is the donation of cord blood units, in the 
case they do not satisfy banking quality criteria, for research purposes. As a 
matter of facts, a collaboration with the Milano Cord Blood Bank (MICB) was 
established to allow the implementation of this doctoral project. 
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2.2 Isolation of MSCs from cord blood 
The main drawback of cord blood (CB) as multipotent mesenchymal stromal cell 
(MSC) source is that MSCs are found at a lower frequency in this tissue, 
compared to other sources, as described by [136]. Thus, this and other issues, 
concerning efficient isolation of MSCs from cord blood, will be addressed in the 
following paragraphs. 
 
2.2.1 Dissection of the cord blood stromal component 
Despite the intriguing features of CB as MSC source, translation to the clinic has 
to face one major obstacle, which is inconsistency of isolation protocols, due to 
the low frequency of MSCs in CB, compared to other sources. A small number of 
reports proposed experimental conditions for high efficiency isolation of 
CBMSCs, but the success rate is still controversial and they often require very 
fresh and abundant CB units [158, 159]. Furthermore, CB was reported to give 
rise to distinct stromal populations in terms of morphology, isolation frequency, 
proliferation rate, differentiation potential and surface markers [160-163]. In order 
to address these issues, 243 CB units were processed (see Appendix I.a and I.d 
for detailed protocols). Importantly, to evaluate whether a CB unit was 
successfully processed, only colonies composed by at least 10 ﬁbroblastic-like 
cells were considered, in accordance to previous studies [159]. This standard 
was adopted to facilitate the assessment of colony formation within the context of 
CB primary stromal cell culture, characterized by a mixed cell environment. The 
methodological approach was based on the immunodepletion of non-
mesenchymal cell populations (negative selection of T lymphocytes by CD3, 
monocytes by CD14, B lymphocytes by CD19, red blood cells by glycophorin A 
and granulocytes by CD66b) from CB mononuclear cells before seeding. The 
ratio behind this choice was indeed to remove adherent and non-adherent 
‘‘contaminant’’ cell types, often observed in CB cultures, which could hamper the 
attachment of CBMSCs to the culture surface and the subsequent generation of a 
colony [158, 164]. Among the adherent non-clonogenic ‘‘contaminant’’ cells, there 
were osteoclast-like poli-nucleated cells with very large cytoplasm, and spindle-
shaped cells with short and stretched cytoplasmic extensions (Fig. 2.3, a). 
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Figure 2.3. Dissection of cord blood stromal cells. Non-mesenchymal stromal cells are frequent in cord 
blood primary cultures (a, representative image). Among them non-proliferating fibroblast-like cells (indicated 
by arrows) and poli-nucleated (2-7 distinguishable nuclei) cells with a very large cytoplasm (dashed circles). 
In b), representative growth curves of CBMSCs grouped by similar cumulative population doubling (CPD) 
values (vertical axis) and longevity (horizontal axis) are shown. In the boxes the means (n=3, black 
rectangle) and deviation standards (vertical bars) of CPDs for each passage are shown. Table c) 
summarizes mean number (n=2) of colony forming unit-fibroblasts (CFU-Fs) and related clonogenic potential 
(percentage of clonogenic cells out of the total amount of seeded cells) for two long-living (LL)- and two short 
living (SL)-CBMSC populations at passage (P) 4. Representative images of CFU-F assay are shown in d): 
LL-CBMSC colonies are bigger and more easily detectable, compared to SL-CBMSCs, whose colonies are 
very small and difficult to detect (indicated by arrows). Mean telomere length (n=3) with standard error of the 
mean (black bars) for LL- and SL-CBMSCs at different passages are shown in e); in the box, representative 
P1 LL- and SL-CBMSCs show dramatic differences in telomere length, presented as mean (n=3) and 
standard deviation (black bars). Statistical analysis: Z-score formula-based normality test, followed by t-test; 
**p<0.01. CB, CBMSC; LL-CB, LL-CBMSC; SL-CB, SL-CBMSC. 
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Whereas the former are the result of fusion of monocytes [165], which probably 
escaped the immunodepletion treatment, the immunophenotyping of the latter 
revealed high expression of CD105 (>95%) and CD45 (>95%) and no presence 
of CD90-positive cells (<5%), both indicating presence of mature endothelial 
cells. 
Stromal colonies composed of fibroblast-like cells were obtained from 40% of 
total processed CB units, and the majority of them (90%) were detected within 4 
weeks (a median of 16 days) after seeding. Following long-term culture of the 
isolated colonies, a dissection of the CB stromal component was obtained: while 
half of them failed to establish a CBMSC population, the remaining ones 
generated CBMSCs showing two distinct in vitro behaviors in terms of growth and 
clonogenic properties. One population demonstrated higher proliferation kinetics 
and delayed senescence, whereas the other showed impaired growth and shorter 
lifespan. In reason of their growth properties, the former were named long-living 
(LL)-CBMSCs and the latter short-living (SL)-CBMSCs. Cumulative Population 
Doubling (CPD) was used as an indicator of replicative potential, and a threshold 
of CPD=15 was defined to distinguish LL- from SL-CBMSCs (Fig. 2.3, b). At 
passage 5, SL-CBMSCs tended to reach plateau and arrest growth, while LL-
CBMSCs continued to grow until higher CPD peaks (CPD>30). Interestingly, LL-
CBMSCs were capable to generate many secondary colonies under low density-
seeding conditions (colony forming unit-fibroblasts assay), whereas SL-CBMSCs 
failed (Fig. 2.3, c and d). 
Since lifespan is a major difference between LL-CBMSCs and SL-CBMSCs, the 
role of replicative senescence as stem cell regulator [166] was investigated. 
Thus, telomere length, as direct contributor of cellular senescence, was 
assessed. The results showed that LL-CBMSCs possessed statistically 
significant longer telomeres, compared to SL-CBMSCs (Fig. 2.3, e), and that this 
feature was maintained until late passages. 
Both LL- and SL-CBMSCs grew in adherence to plastic surfaces, with a 
fibroblast-like morphology (Fig 2.4, a), and they showed a typical MSC 
immunophenotype (Fig 2.4, b); their differentiation potential into mesodermal 
derivatives was also investigated (Fig 2.4, c), as requested by the ISCT MSC 
definition criteria presented in paragraph 1.3.1.  
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Figure 2.4. Long-living cord blood-multipotent mesenchymal stromal cells (LL-CBMSCs) fulfill all 
MSC definition criteria. LL-CBMSCs showed typical MSC morphology (a, representative image), 
expression of MSC canonical markers (b, representative immunophenotype), and capability to differentiate 
into mesodermal derivatives (c, representative images): Oil Red O-positive adipocytes (A, left panel); Alizarin 
Red S-positive osteoblasts (O, central panel); alcian blue-positive chondroblasts (C, right panel) constitute 
the AOC MSC differentiation panel. 
 
Concerning the differentiation potential, some differences were found. 
Adipogenesis was slower and the intracellular fat droplets generated were 
smaller and fewer compared to MSCs from adult sources, as already reported in 
the literature [167]. This is thought to be due to the perinatal origin of these cells, 
for which molecular programs related to adult organism physiology are still 
inactive or silenced [168]. Osteogenesis was present in both population, even 
though LL-CBMSCs tended to produce larger calcium deposits, compared to SL-
CBMSCs. Chondrogenesis was detected for LL-CBMSCs, but seemed somehow 
impaired for SL-CBMSCs, indicating a lower differentiation potential. 
 
This paragraph is a modified excerpt of Appendix I.a and I.d. 
 
26 
 
2.2.2 Increasing the efficiency of cord blood stromal colony 
generation 
In spite of the advances in the knowledge of different stromal populations present 
in CB, the establishment of CBMSCs remained a low efficiency process, because 
only a half of processed CB units generated MSC colonies. In order to improve 
the efficiency of the aforementioned isolation protocol and at the same time to 
generate CBMSCs showing the same or improved qualities of LL-CBMSCs, 
alternative cell culture conditions relying on a chemically defined medium were 
applied to the LL-CBMSC isolation protocol (see Appendix I.b for detailed 
protocols). 
A total number of 100 CB units were processed following different approaches. 
The idea was to determine which isolation procedure offered the best 
environment to facilitate MSC progenitor attachment to the growth surface and to 
better support the proliferation of stromal colonies (see figure 2.5 for the complete 
schematic). 
 
Figure 2.5. Experimental schematic. In the isolation experiments, importance of coating (a) and serum (b) 
was assessed. Whole blood, non-fractioned cord blood; immunodepleted fraction, cord blood mononuclear 
cells after immunodepletion treatment; positive event, appearance of bona fide MSC colony. 
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In a first series of isolations, the importance of collagen I-III coating was 
investigated for the optimal use of a chemically defined medium (for complete 
formulation see Appendix Ib). Whole blood samples (WB) versus 
immunodepleted fractions (ID) were compared, and again the appearance of the 
first fibroblastic colony composed of at least 10 cells was considered as a positive 
event. Positive events on coated surfaces were obtained from five WB (14 total 
units) and from two ID (5 total units). On the contrary, no positive event was 
observed without the coating (5 WB and 11 ID) (Fig. 2.5, a). In a second set of 
experiments, the addition of a standard percentage of serum was investigated as 
a possible replacement of collagen I-III coating, based on the common practice of 
coating plastic surfaces with serum. In this way, positive events were obtained 
from three WB (6 total units) and from 17 ID (30 total units), representing the 
most efficient isolation strategy for the experimental conditions herein reported 
(Fig. 2.5, b).  
The analysis of CB unit characteristics demonstrated that the observed results 
were not biased by differences between the experimental groups in terms of time 
elapsed from CB collection to processing (Fig. 2.6, a) or WBC content (Fig. 2.6, 
b), two crucial parameters for CBMSC isolation [158, 159]. The evaluation of 
processed sample volume revealed that no statistically significant differences 
were present within WB (WB coating and WB serum conditions; Fig. 2.6, c) and 
ID (ID coating and ID serum conditions; Fig. 2.6, d) experimental groups.  
Following this experimental design, the use of serum as a substitute for collagen 
I-III coating to culture the CB immunodepleted fraction appeared as the most 
promising approach to ameliorate further the generation of MSC colonies, due to 
its higher isolation efficiency. Thus, in order to further improve this rate of positive 
events, l-glutamine supplementation, as a further energy source for cultured cells, 
was tested in ID isolation experiments (complete medium), along with a 
preference for significantly richer-in-volume CB units, compared to the other 
immunodepleted samples (ID serum and l-glutamine condition; Fig. 2.6, d). Under 
these conditions, positive events were observed in almost 80% of the processed 
samples (23 out of 29 units) (Fig. 2.5, b). Following this isolation procedure, the 
previously observed presence of “contaminant” adherent cell types, already 
described in paragraph 2.2.1, were dramatically decreased. 
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Figure 2.6. Cord blood unit characteristics. The following cord blood unit parameters were evaluated for 
whole blood (WB) and immunodepleted fraction (ID) isolation experiments: time from collection to processing 
(a), white blood cell (WBC) content (d) and processed volume (c, d). Box and whiskers graphs show 25th and 
75th percentiles (plot hinges), median, minimum and maximum values (a, b) or 10th and 90th percentiles with 
outside values (c, d). Statistical analysis: non-parametric Kruskal-Wallis test, followed by Dunn’s multiple 
comparisons tests. **p<0.01; ***p<0.005; ****p<0.001; ns=statistically non-significant difference. 
 
The CBMSCs generated by this improved protocol were thoroughly characterized 
(n=3). First of all, they were positive for canonical MSC markers CD90, CD105 
and CD73, while they were negative for CD45 and CD34; a more extensive flow 
cytometry panel revealed also expression of NG2 and CD56, but almost no 
expression of CD271, resembling the data presented in paragraph 2.1 (data 
shown in Appendix I.b). Maintenance of tri-lineage differentiation potential was 
assessed (data shown in Appendix I.b). In addition, the established CBMSC 
populations showed enhanced growth properties, with regard to both CPD peak 
values (Fig. 2.7, a and b) and CFU-F assay (Fig. 2.7, c), compared to LL-CBMSC 
cultured in standard conditions.  
29 
 
Telomere length was also assessed (Fig. 2.7, d): in spite of a dramatic and 
significant decrease in mean telomere length comparing passage 0 to passage 1 
CBMSCs, this parameter was subsequently maintained at a constant length 
(statistically non-significant differences between P1 and P9 CBMSCs). 
 
 
Figure 2.7. Cord blood-multipotent mesenchymal stromal cell (CBMSC) growth properties. CBMSC 
growth curves (a) and mean proliferation rate (b, n=3) with standard deviation are presented. A 
representative image of CBMSC Colony forming unit-fibroblast (CFU-F) assay is shown in c). Mean CBMSC 
telomere length (d, n=3) for each analyzed passage (P), is shown as percentage of P0 with standard 
deviation. Statistical analysis: D’Agostino & Pearson omnibus normality test, followed by one-way analysis of 
variance (ANOVA) and Newman-Keuls multiple comparison tests; *p<0.05. CPD, cumulative population 
doubling. 
 
This paragraph is a modified excerpt of Appendix I.b. 
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2.3 Conclusions 
A previously widespread notion described MSCs deriving from different tissue 
compartments as a homogeneous group of stem cells, endowed with the same 
biological features. Yet, it has become clear that the tissue of origin determines 
MSC stemness properties. A comparative study of MSCs isolated from six 
different sources revealed substantial differences between them, correlated to 
their perinatal or adult harvest. Moreover, a senescence-associated feature as 
Insulin-like Growth Factor 1 (IGF1) expression was found to be increased in adult 
compared to perinatal MSCs. Based on these data and other clinical-related 
advantages, cord blood (CB) was chosen as stem cell source. From the 
dissection of the CB stromal component, long-living (LL)- and short-living (SL)-
CBMSCs were characterized. In this context, LL-CBMSCs stood out for their 
increased lifespan and differentiation properties. Thus, they were considered the 
best option to develop regenerative medicine approaches. An interesting point to 
underline is that telomere length showed statistically significant differences 
between LL- and SL-CBMSCs at very early cell culture stages, so that it could be 
used as a predictive parameter of culture outcome. In this way, clinically relevant 
LL-CBMSCs could be selected a priori. Eventually, since isolation rate is a major 
issue for LL-CBMSC clinical translation, an improved procedure leading to nearly 
80% MSC colony generation efficiency was described, solving one major issue in 
CBMSC clinical translation feasibility. 
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Chapter 3 
 
 
 
Re-defining cord blood 
multipotent mesenchymal 
stromal cell paracrine 
properties 
 
 
 
Multipotent mesenchymal stromal cell (MSC) paracrine potential is extensively 
described in the literature, as reviewed in paragraph 1.3. Nonetheless, the role 
extracellular vesicles (EVs) play in secretome-associated MSC properties still 
needs to be elucidated. In order to discern EV secretome contribution from that of 
MSC-secreted soluble factors, different proof-of-concept in vitro and in vivo injury 
models addressing secretome in toto, or LL-CBMSC EVs compared to LL-
CBMSC conditioned medium, were used. In either cases, the focus was 
maintained on LL-CBMSC anti-apoptotic and anti-inflammatory properties, which 
are considered essential to set up a pro-regenerative environment, which allows 
a damaged tissue to ameliorate its condition. Therefore, the generation and 
characterization of EVs from LL-CBMSCs were addressed, and their feasibility as 
regenerating agents mimicking parental cell properties was tested. 
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3.1 Anti-apoptotic and anti-inflammatory properties of 
cord blood multipotent mesenchymal stromal cells 
 
Initially, an in vitro model of renal acute damage, caused by the 
chemotherapeutic agent cisplatin, was implemented (see Appendix I.d for 
detailed protocol). First, the secretion of immunomodulatory molecules was 
assayed. Human renal cells produced significantly higher amounts of cytokines 
upon damage, compared to the same cells in non-contact co-culture with LL-
CBMSCs (Fig. 3.1). 
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Figure 3.1. Long-living (LL)-cord blood (CB) multipotent mesenchymal stromal cell (MSC) secretory 
profile. Renal cells were damaged (untreated cells), damaged and co-cultured with LL-CBMSCs (treated 
cells), or cultured without damage (steady state). Results are reported as mean (n=5) with standard 
deviation, and they are expressed as pg per mL per 106 cells. Statistical analysis: z-score formula-based 
normality test, followed by t-test; *p-value<0.05; **p-value<0.01; *** p-value<0.001. TNF?, tumor necrosis 
factor ?; IL10, interleukin 10; INF?, interferon ?; IL12, interleukin 12; HGF, hepatocyte growth factor; FGF, 
basic fibroblast growth factor; VEGF, vascular endothelial growth factor; HB-EGF, heparin binding-
endothelial growth factor. 
 
In particular, Tumor Necrosis Factor (TNF?) and Interleukin (IL)10 underwent a 
statistically significant reduction (Fig. 3.1, a and b, respectively), but also 
Interferon (INF)? and IL12 showed a similar trend (Fig. 3.1, c and d, respectively). 
Among all the time points analyzed, 72 hours appeared the most effective in the 
rescue of the damage-induced inflammatory profile. 
Second, the production of growth factors known to exert anti-apoptotic effects 
was investigated [169-172]. Higher amounts of these factors were released into 
the co-culture medium, compared to untreated damaged renal cells. In particular, 
Hepatocyte Growth Factor (HGF) and basic Fibroblast Growth Factor (FGF) 
showed the most relevant and statistically significant differences (Fig. 3.1, a and 
b, respectively), even though also Vascular Endothelial Growth Factor (VEGF) 
and Heparin Binding (HB)-Endothelial Growth Factor (EGF) showed increasing 
trends in secreted protein levels (Fig. 3.1, a and b, respectively). 
Concerning in vivo experiments, anti-inflammatory properties of LL-CBMSCs 
were assessed in a spinal cord injury mouse model (see Appendix I.c for detailed 
protocols). First, the capacity of LL-CBMSCs to modulate resident microglia and 
recruited macrophages at the injured site was assessed, by flow cytometry. 
Therefore, CD11bpos/CD45low microglia and CD11bpos/CD45high macrophages 
were detected in the injured tissue, and their amount evaluated: mice treated with 
LL-CBMSCs showed a significantly increased amount of recruited macrophages, 
compared to untreated mice (Fig. 3.2, a). Furthermore, inflammatory (TNF?) and 
anti-inflammatory Arginase (Arg) I gene expression at the injured tissue was 
assessed to investigate LL-CBMSC ability to modulate pro-inflammatory (M1) 
and anti-inflammatory (M2) phenotypes, respectively. TNF? mRNA was 
significantly increased in LL-CBMSC treated injured mice (1.5-fold change), 
compared to untreated injured mice (Fig 3.2, b).  
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Noteworthy, a much more relevant and significant mRNA level increase in anti-
inflammatory Arg I was observed (10-fold change), compared to untreated injured 
mice (Fig 3.2, c). These results suggested a skew toward a M2 pro-regenerative 
environment for the LL-CBMSC treated injured tissue. 
 
Figure 3.2. Modulation of inflammation. In a), microglia (?) to macrophages (macro) ratio in the injured 
tissue of untreated (injury) or LL-CBMSC treated (LL-CBMSCs) mice is shown (n=5–7 per group). In b) and 
c), gene expression of M1/M2 polarization markers in the injured tissue of untreated or LL-CBMSCs treated 
mice is shown (n=10–14 per group). Mean with standard error of the mean is reported. Statistical analysis: 
Mann Whitney test; *p<0.05, **p<0.01. TNF?, tumor necrosis factor ?. 
 
Modified excerpts from Appendix I.c and I.d. 
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3.2 Regenerative extracellular vesicles from cord blood 
multipotent mesenchymal stromal cells 
Following reports defining a prominent role of extracellular vesicles (EVs) in 
multipotent mesenchymal stromal cell (MSC) secretome-associated properties, 
the generation of EVs by long-living (LL)-cord blood (CB) MSCs was studied (see 
Appendix II.b for detailed protocols). Scanning electron microscopy analysis 
confirmed production of EVs by LL-CBMSCs, as outward structures protruding 
from the cell surface (Fig. 3.2, a). Interestingly, EV secretion was located in the 
peripheral protrusions of the cells and it was particularly concentrated at the 
edges of the plasma membranes. 
 
Figure 3.3. Long-living (LL)-cord blood (CB) multipotent mesenchymal stromal cell (MSC) 
extracellular vesicle (EV) characterization. EVs were detected by scanning electron microscopy as 
outward structures protruding from the cell surface (a); representative EVs are indicated by arrows. Table b) 
summarizes EV size and count per cell for two representative LL-CBMSC populations, assessed by 
nanoparticle tracking analysis; mean (n=10) with standard deviation is reported. Flow cytometry analysis (c) 
revealed positivity for carboxyfluorescein ester (CFSE), which produced fluorescence in the fluorescein 
isothiocyanate channel (FITC-A) (P2), demonstrating that LL-CBMSC EVs are intact cytoplasm containing 
membrane-enclosed particles; SSC-A, side scatter. Transmission electron microscopy (d) visualized the 
ultrastructural morphology of isolated EVs; intact membrane is indicated by arrows. 
 
Then, EV size was assessed by nanoparticle tracking analysis (NTA), which 
revealed a size range of 40–700 nm, although the mean values laid between 230 
nm and 270 nm (Fig. 3.2, b). Interestingly, the observed particle size suggested 
the absence of apoptotic bodies, which usually fall into the size range of 1-5 ?m. 
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NTA was also used for EV quantification: in one day, LL-CBMSCs produced up to 
5,000 EVs per cell (Fig. 3.2, b). To assess EV integrity, carboxyfluorescein 
diacetate succinimidyl ester (CFDA-SE) staining was performed. CFDA-SE can 
passively diffuse through cellular membranes thanks to its acetate groups, which 
are subsequently removed by cytoplasmic esterases. This converts CFDA-SE 
into a fluorescent carboxyfluorescein succinimidyl ester (CFSE). Flow cytometry 
analysis showed that >85% of the detected events were CFSE positive, which 
indicated that EVs were intact cytoplasm-containing membrane-enclosed bodies 
(Fig. 3.2, c); moreover, 50% of total CFSE-positive events expressed CD63 and 
CD81 EV markers. Finally, transmission electron microscopy images showed a 
morphology consistent with pure EV preparations (Fig. 3.2, d). 
In order to study the role of EVs in LL-CBMSC secretome-associated properties, 
the renal acute injury in vitro model previously used (paragraph 3.1) was 
repeated with slight modifications (see Appendix II.b for detailed protocols). 
Human renal cells were damaged with cisplatin and, after drug removal, LL-
CBMSC conditioned medium or 20,000 LL-CBMSC EVs per cell were added. Cell 
viability was monitored at 24, 48 and 72 hours, by the MTT assay. Notably, the 
72-hour time point showed the higher and most significant rescue in viability 
(81% compared to undamaged cells), in line with what presented for modulation 
of inflammation and growth factor production in the previous paragraph (Fig. 3.4). 
At 24 hours, the EV-driven effect was still not detectable, while at 48 hours a 
relevant viability increase was already appreciable (70% compared to 
undamaged cells). Notably, also conditioned medium showed viability rescue, but 
with a lower efficiency (67% compared to undamaged cells), while untreated cells 
continued to die (36% compared to undamaged cells). 
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Figure 3.4. Long-living (LL)-cord blood (CB) multipotent mesenchymal stromal cell (MSC) 
extracellular vesicles (EVs) rescue damaged renal cells mimicking parental cell properties. In the 
graph, renal cell viability assessed by MTT assay is normalized to undamaged control (100% viability); mean 
(n=6) with standard deviation is shown. Statistical analysis: Kolmogorov-Smirnov normality test, followed by 
two-way ANOVA and Tukey’s multiple comparison test; ****p<0.0001. 
 
These paragraphs are modified excerpts from Appendix II.b. 
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3.3 Conclusions 
Long-living (LL)-cord blood (CB) multipotent mesenchymal stromal cells (MSCs) 
were shown to produce extracellular vesicles (EVs), which were able to 
recapitulate parental MSC secretome-associated properties in a proof-of-concept 
in vitro model of acute damage. Moreover, anti-inflammatory and anti-apoptotic 
LL-CBMSC paracrine properties were demonstrated in two different in vitro and in 
vivo models of tissue injury. This hinted at a broad protective mechanism, which 
relied on modulation of the inflamed environment. This is a relevant feature of LL-
CBMSCs, because inflammation can be detrimental to tissue regeneration [173-
175]. In summary, these results support the use of EVs as therapeutic agents, 
able to convey stem cell regenerating properties. 
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Chapter 4 
 
 
 
Induction of pluripotency in 
cord blood multipotent 
mesenchymal stromal cells 
 
 
 
4.1 Motivation for a pluripotent stem cell source of 
extracellular vesicles 
One major drawback of LL-CBMSCs as extracellular vesicles (EV) source is that, 
unlike pluripotent stem cells, they are primary cells with limited lifespan in vitro. 
Even though LL-CBMSCs can be extensively expanded thanks to their growth 
properties, an immortalized cell line would have the advantage of an unlimited 
use. In addition, preservation of EV therapeutic features after immortalization 
would have to be demonstrated. Admittedly, LL-CBMSCs from different donors 
may present differences in EV therapeutic potential, which should be addressed 
every time a new LL-CBMSC population is isolated. All considered, an 
immortalized cell line would represent a more homogeneous EV cell source, 
compared to primary MSCs. Consequently, also flaws in EV quality and efficacy 
would be reduced. Unfortunately, the current immortalization protocols rely on the 
permanent genetic modification of the target cells, through the integration of viral 
DNA in the genome. Hence, EV safety issues, such as tumorigenic risk and 
genome instability, would have to be fully addressed, as a prerequisite for any 
clinical application. 
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Giving these premises, the feasibility of reprogramming as a tool to extend LL-
CBMSC lifespan in vitro was explored. Indeed, this technique induces 
pluripotency in differentiated cells, leading to a much more extensive in vitro 
lifespan. Reprogramming is achieved by transient overexpression of key 
transcription factors involved in the so-called pluripotency gene network, which 
governs self-renewal and pluripotency of pluripotent stem cells. Taking 
advantage of a specific methodology, which does not rely on the genetic 
modification of the target cell, but still induce a permanent change of its biological 
identity, major safety issues related to traditional immortalization protocols would 
be reduced. 
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4.2 Derivation of induced pluripotent stem cells 
LL-CBMSCs reprogramming was achieved using a non-integrating viral-based 
system, which guarantees the expression of the classic four reprogramming 
factors (OCT4, SOX2, KLF4, cMYC). This methodology is zero-fingerprint, 
because no exogenous DNA is integrated into the host genome and the vector 
remains in the cytoplasm, so that the genetic information of the reprogrammed 
cell is not altered. Moreover, only one infection is needed to obtain successful 
reprogramming, compared to viral-free reprogramming methods [176] (for 
detailed protocol see Appendix III.a). 
First, the feasibility of LL-CBMSCs infection and forced exogenous protein 
expression was investigated. For this purpose, an emerald green fluorescent 
protein (emGFP)-expressing variant of this system was used. LL-CBMSCs were 
successfully infected and the protein expressed (Fig. 4.1, a and b).  
 
Figure 4.1. Reprogramming long-living (LL)-cord blood (CB) multipotent mesenchymal 
stromal cells (MSCs). The feasibility of LL-CBMSC infection was tested using an emerald green 
fluorescent protein (emGFP)-expressing virus (a, bright field; b, fluorescence); multiplicity of infection=5 is 
shown. In c), infected LL-CBMSCs still show a fibroblast-like morphology at day 1. In d), a bona fide 
reprogrammed colony growing onto a non-reprogrammed LL-CBMSC layer is visible (dashed circle). 
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Second, the reprogramming protocol was applied to LL-CBMSCs, using MOI=5, 
and the cells were monitored for the appearance of colonies. Cell morphology 
changes were not visible the first day (Fig. 4.1, c), whereas small colonies 
composed of highly packed cells with epithelial-like shape were detected starting 
one week after (Fig. 4.1, d). Notably, mesenchymal-to-epithelial transition is one 
major event that has to take place to reprogram cells toward pluripotency [177]. It 
is also important to underline that the protocol did not rely on the use of a layer of 
feeder cells, usually mouse embryonic fibroblasts (MEFs) or human foreskin 
fibroblasts (HFFs), to sustain the reprogramming process. This was possible 
thanks to the feeder properties of LL-CBMSCs, which were demonstrated to be 
able to act as a substitute for traditional feeder cells [178]. 
After LL-CBMSC-derived bona fide hiPSC colonies (referred to as hiPSCs from 
now on) reached confluence at week 3 post-infection, hiPSC lines (n=3) were 
generated by manual mechanical “picking” of single colonies, using a 150 ?m 
diameter needle mounted on a stripper micropipette. Notably, this choice 
guarantees more intra-population homogeneity, compared to bulk or clone-
pooled subcloning techniques [179]. The established hiPSC lines grew for more 
than 40 passages and showed a typical pluripotent stem cell morphology, 
growing as densely packed epithelial-like cells forming colonies with well-defined 
edges (Fig. 4.2, a). In order to assess the immunophenotypic status of hiPSCs, 
the expression of classic MSC markers was addressed, by flow cytometry. 
Noteworthy, human leukocyte antigens A, B and C (HLA-ABC) expression on 
hiPSC membrane surface was drastically reduced, compared to parental LL-
CBMSCs (Fig. 4.2, b), in line with the pluripotent stem cell phenotype. On the 
contrary, CD90 and CD44 were retained, even though the signal intensity was 
strongly reduced; interestingly, the pluripotent control showed almost no positivity 
for CD44. Analogous to HLA-ABC, CD73 expression was completely lost in 
hiPSCs (Fig. 4.2, b). Therefore, HLA-ABC and CD73 represent a minimal 
immunophenotype panel that could be useful to assess the successful 
reprogramming of MSCs. Finally, to ensure the maintenance of genomic stability, 
the karyotype of parental and reprogrammed cells was investigated. Importantly, 
no chromosomal abnormalities were detected (Fig. 4.2 c). 
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Figure 4.2. Long-living (LL)-cord blood (CB) multipotent mesenchymal stromal cell (MSC)-
derived bona fide pluripotent stem cells. In a), a representative pluripotent colony with epithelial-like 
morphology is shown. In b), the immunophenotype of a representative hiPSC line, assessed by flow 
cytometry, is presented; the horizontal axis reports fluorescence intensity in a logarithmic scale, the vertical 
axis reports event count as percentage of maximum count for each sample. The karyotype of the generated 
cell lines was normal, as shown in a representative karyogram in c). 
 
4.2.1 Stemness and pluripotency assessment 
The hiPSC lines could grow for many passages (>40), and they were thoroughly 
characterized to assess their identity (see Appendix III.b for detailed protocols). 
First, alkaline phosphatase (AP) activity was assessed, as a typical feature of 
pluripotent stem cells (Fig. 4.3, a).  
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Notwithstanding, also parental non-reprogrammed LL-CBMSCs showed strong 
AP activity, in line with the literature [180], suggesting that it is not a useful 
parameter to consider in the context of MSC reprogramming, unlike the 
immunophenotype panel previously proposed (paragraph 4.2).  
 
Figure 4.3. Stemness properties of human induced pluripotent stem cells (hiPSCs). In a), 
alkaline phosphatase (AP)-live staining detected AP activity in hiPSC colonies (dashed line), but also in 
parental non-reprogrammed cells, indicated by the arrow. In b), Real Time qRT-PCR revealed strong 
expression of pluripotency network-related genes, normalized to human embryonic stem cells (hESCs), as 
pluripotent positive control. Mean (n=3) with standard deviation is presented; ne, not expressed. In c), 
protein expression of typical pluripotency markers was assessed by immunofluorescence. Complete 
modification of the epigenetic landscape of NANOG and OCT4 regulatory regions after reprogramming was 
investigated by pyrosequencing of bisulfite-treated DNA (d); POS, position; PE, proximal enhancer; Pr, 
promoter. 
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Second, the expression of key pluripotency network-related genes was 
investigated by Real Time qRT-PCR, compared to parental LL-CBMSCs as 
negative control, and to a pluripotent stem cell line as positive control (Fig. 3.4, 
b). The established hiPSC lines showed increased gene expression for OCT4 
(absent in parental cells) and SOX2 (absent in parental cells), two well-known 
pluripotency markers; KLF4 was more expressed in parental cells (5-fold 
change), consistently with other reports [181], while cMYC was expressed at 
similar levels. More importantly, also NANOG (absent in parental cells) and 
LIN28A (absent in parental cells), not present in the cocktail of exogenously 
encoded reprogramming factors, showed a gene expression similar to that of the 
pluripotent control. This clearly indicates that the expression of exclusive 
pluripotency-associated genes was switched on at the endogenous level. 
Third, to detect expression of pluripotency-associated markers at the protein 
level, immunofluorescence analyses were performed on undifferentiated hiPSC 
colonies (Fig. 4.3, c). Both OCT4/SSEA4 and SOX2/TRA1-60 double stainings 
revealed strong protein expression. Finally, the epigenetic state of crucial gene 
regulatory regions was addressed on hiPSC bisulfite-treated DNA by 
pyrosequencing (Fig. 4.3, d), compared to LL-CBMSCs as negative control, and 
to a pluripotent stem cell line as positive control. The results showed complete 
methylation remodeling for CpG islands in various positions along OCT4 
promoter and proximal enhancer sequences. The same was found for NANOG 
promoter (Fig. 4.3, d), further confirming fully acquisition of pluripotent features 
for LL-CBMSCs following reprogramming. 
Finally, hiPSC differentiation properties were investigated to complete the 
characterization of the cell lines generated. Protein marker expression for 
derivatives of the three germ layers was assessed by immunofluorescence, after 
in vitro differentiation protocols were applied (Fig. 4.4). The hiPSCs could 
generate neural cell adhesion molecule (NCAM)-positive neurectodermal cells 
(Fig. 4.4, a), ?-smooth muscle actin (?-SMA)-positive mesodermal cells (Fig. 4.4, 
b), and ?-fetoprotein (AFP)-positive endodermal cells (Fig. 4.4, c). 
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Figure 4.4. Differentiation of induced pluripotent stem cells into derivatives of the three 
germ layers. The induced pluripotent stem cells underwent in vitro differentiation into derivatives of the 
three germ layers. Protein expression of typical ectodermal (a), mesodermal (b) and endodermal (c) markers 
was assessed by immunofluorescence. DAPI, 4',6-diamidin-2-fenilindolo; NCAM, neural cell adhesion 
molecule; ?-SMA, ?-smooth muscle actin; AFP, ?-fetoprotein. 
 
4.2.2 Extracellular vesicles as a new feature of pluripotent stem 
cell biology 
To investigate if hiPSCs still preserved the capacity to produce extracellular 
vesicles (EVs), the same characterization workflow used for LL-CBMSC-EVs in 
Chapter 3 was implemented. Thanks to scanning electron microscopy, the 
production of EVs by hiPSCs was confirmed. Also for hiPSCs, EVs were detected 
as outward structures protruding from the cell surface (Fig. 4.5, a). Concerning 
EV secretion, it was located at peripheral protrusions of the plasma membrane, 
indicating that hiPSCs, as well as LL-CBMSCs, need space to outgrow and 
release EVs (Fig. 4.5, b). Afterwards, EV size was assessed by nanoparticle 
tracking analysis (NTA), which detected a mean size of 256 nm (n=5; standard 
deviation (SD)=66). Again, this particle size range indicates absence of apoptotic 
bodies (1-5 ?m). 
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Figure 4.5. Characterization of extracellular vesicles (EVs) from induced pluripotent stem cells. EVs 
were recognized by scanning electron microscopy as outward structures protruding from the cell surface (a); 
representative EVs are indicated by arrows. In b), an entire induced pluripotent stem cell (hiPSC) colony is 
shown; representative EVs are indicated by arrows. Flow cytometry analysis (c) revealed positivity for 
carboxyfluorescein ester (CFSE), which produced fluorescence in the fluorescein isothiocyanate channel 
(FITC-A) (P2), demonstrating that hiPSC-EVs are intact cytoplasm containing membrane-enclosed particles; 
SSC-A, side scatter. Transmission electron microscopy (d) visualized the ultrastructural morphology of 
isolated EVs; the intact membrane of a representative EV is indicated by the arrow. 
 
Quantification of EVs by NTA revealed that hiPSCs produced a mean of 28 billion 
EVs per Petri dish (100mm) per day (n=5; SD=12). Integrity of EVs was 
investigated by carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) 
staining, whose principle was explained in paragraph 3.2. Flow cytometry 
analysis revealed that >70% of the detected events were carboxyfluorescein 
succinimidyl ester (CFSE) positive, which indicated that they were intact EVs 
(Fig. 4.5, c); in addition, 50% of CFSE-positive EVs also expressed CD63 and 
CD81 surface markers. Lastly, transmission electron microscopy images showed 
a morphology consistent with pure EV preparations (Fig. 4.5, d). Importantly, very 
recently, other laboratories reported the generation of EVs by pluripotent stem 
cells [182-187]. 
48 
 
4.3 Stem cell extracellular vesicle miRNome load 
In the recent literature, extracellular vesicles (EVs) were shown to shuttle 
preferentially small RNA species (see paragraph 1.3.1). Nevertheless, no 
complete miRNome analysis has been attempted so far for EVs generated by 
long living (LL)-cord blood (CB) multipotent mesenchymal stromal cells (MSCs) 
and human induced pluripotent stem cells (hiPSCs). This is of crucial importance, 
as the few reports trying to elucidate EV molecular mechanisms of action 
underlined the pivotal role of miRNAs. To address this point, a complete 
miRNome analysis was performed on EVs harvested from hiPSCs, LL-CBMSCs 
and a pluripotent stem cell control. The profiling was performed exploiting a Real 
Time PCR-array system covering 754 human miRNAs, whose sequences were 
derived from miRBase version 14 database (see Appendix III.b for complete 
protocols). First, an analysis of stem cell source-unique EV miRNAs was 
performed on raw PCR amplification data, selecting the 150 sequences (top 150) 
with the highest output signal (Fig. 4.6, a). Interestingly, the majority of miRNAs 
present in LL-CBMSC-EVs were also found in hiPSC-EVs (87 common miRNAs), 
consistently with the pluripotent control. Only 16 miRNAs were found to be 
exclusively incorporated into hiPSC-EVs, while LL-CBMSC-EVs showed 53 
specific miRNA sequences. Focusing on the ten most incorporated miRNAs, 
hiPSC-EVs showed a pattern identical to that of the pluripotent control EVs (Fig. 
4.6, b). This can be considered a further confirmation of a successful 
reprogramming, as these miRNAs belonged to miRNA families known to have a 
role in the maintenance of pluripotency. For instance, the miRNA302/367 cluster 
(miR-367,-302a, b, c and d) is essential for OCT4 expression and it supports 
reprogramming [188-191]. The other miRNAs belonged to the miRNA17/92 (miR-
17, -18, -19a, -20a, -19b1 and -92a-1) and 106a/363 (miR-106a, -18b, -20b, -
19b-2 -92a-2, and -363) clusters, which are implicated in control of cell 
proliferation and embryonic development [192-194]. On the other hand, LL-
CBMSC-EV miR-125b and -21 were recently shown to be shuttled in mouse EVs, 
which exerted wound healing properties [195]. Furthermore, miR-125b and -24 
were demonstrated to have a role in differentiation and self-renewal of MSCs 
[196, 197]. Intriguingly, miR-221 was detected in rat MSC-EVs, through which it 
contributed to cardioprotection during hypoxia in vitro [198]. 
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Figure 4.6. Stem cell extracellular vesicle (EV) miRNome. EVs were characterized for their miRNome 
load. In a), a Venn diagram shows the distribution of common and unique miRNAs among the three EV stem 
cell sources. In table b) the first ten most incorporated miRNAs for each EV stem cell source are listed. The 
heatmap in c) represent the fold changes in miRNA EV incorporation; the horizontal dendrogram clusters 
miRNAs for similar amplification patterns, the vertical dendrogram clusters EV stem cell source for similar 
miRNA incorporation; the legend (color key) shows the fold change range (red for less incorporated miRNAs, 
green for more incorporated miRNAs). The miRPath version 3 bioinformatic tool was used to identify 
significantly enriched cellular pathways of the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
database for the differentially expressed miRNA classes (d); only Tarbase database of experimentally 
validated miRNAs was considered. Statistics: pathway union by Fisher’s exact test (hypergeometric 
distribution) enrichment analysis method with false discovery rate correction; the class-specific disease-
unrelated top 5 ranked pathways are reported. 
 
Second, the miRNA fold change data plotted in a heatmap, by R statistical 
software, revealed two classes of more incorporated (UP) and two classes of less 
incorporated (DOWN) hiPSC-EV miRNAs (Fig. 4.6, c). The cellular pathways 
targeted by UP and DOWN classes of differentially expressed miRNAs were 
addressed by interrogation of the miRTarBase database, which uses only 
experimentally validated miRNAs (Fig. 4.6, d). The UP classes were involved, 
among others, in regulation of pluripotency in stem cells and in Wnt signaling 
pathway, also important for pluripotent stem cell specification and proliferation 
[199]. The DOWN classes revealed major associations with fatty acid metabolism 
and with adherence features. This result was consistent with the stemness 
properties of hiPSCs and LL-CBMSCs, since pluripotent stem cell metabolism 
relies more on glycolysis than fatty acid oxidation [200], while mesenchymal 
stromal cells are known to express a wide range of adhesion molecules [201]. 
To conclude, even though the heatmap-associated hierarchical clustering 
analysis grouped hiPSC-EVs and the pluripotent control together, this was due to 
differences in the EV incorporation relative amount. Notably, the EV miRNome 
load was largely maintained following reprogramming, since the majority of the 
top 150 miRNAs were common between the hiPSC-EVs and LL-CBMSC-EVs. 
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4.4 Conclusions 
The reprogramming of long living (LL)-cord blood (CB) multipotent mesenchymal 
stromal cells (MSCs) was proved feasible. Interestingly, no feeder cells were 
used, guaranteeing a more straightforward and unbiased xeno-free process. This 
was due to the feeder properties of non-reprogrammed LL-CBMSCs in culture. 
Moreover, a minimal immunophenotype panel composed of HLA-ABC and CD73 
was proposed in order to assess successful MSC reprogramming. The induced 
pluripotent stem cell (hiPSC) lines generated were characterized successfully for 
stemness and pluripotency features, indicating that a complete reprogramming 
process was achieved. 
Importantly for this research and for a possible therapeutic application of hiPSC-
EVs, reprogramming preserved secretion of extracellular vesicles (EVs) with 
physical properties similar to those of parental LL-CBMSCs. Noteworthy, the EV 
miRNome load was largely maintained, which represents a prerequisite to 
envision a switch from LL-CBMSC-EV to hiPSC-EV use. 
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Chapter 5 
 
Stem cell extracellular vesicles 
for neuroprotection 
 
 
5.1 Motivations for an ex vivo model of brain ischemia 
In Chapter 3, the anti-apoptotic and anti-inflammatory properties of LL-CBMSC 
secretome were presented, and the potential of extracellular vesicles (EVs) as 
therapeutic agents was also explored in an in vitro model of acute damage. 
Focusing on the development of EV-based therapies, pathological conditions for 
which ready-to-use therapeutics and a rapid administration is essential appeared 
the most suitable areas of clinical application. In this context, acute brain 
ischemia has a very limited therapeutic window of 3-6 hours for tissue 
plasminogen activator treatment [202]. Moreover, it is the second leading cause 
of death and dementia, and the first cause of disability in adult humans, with a 
global incidence of 76-119 cases per 100,000 inhabitants per year [203, 204]. 
This pathological condition occurs when blood is not flowing sufficiently to the 
brain to meet its metabolic demand, causing hypoxia, lack of nutrients, and, as a 
consequence, death of neural cells. Importantly, a successful therapy for acute 
brain ischemia could be beneficial also for other organs subject to the same risk, 
such as kidney, skeletal muscles, heart and lungs. 
In order to study EV potential in acute brain ischemia treatment, an ex vivo model 
was exploited. This kind of model has the advantage of higher control over the 
experimental conditions and less variability. In addition, it is more suitable to 
study the mechanism of action of a therapeutic approach, compared to in vivo 
models of sensorimotor and cognitive deficits, because molecular and cellular 
events may be investigated at the tissue and cellular level (e.g.: signaling 
pathways, cell viability, tissue secretion in response to damage). 
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5.2 Extracellular vesicle-driven damage recovery 
Ischemic damage was induced in organotypic mouse brain slices by a standard 
oxygen and glucose deprivation (OGD) culture condition (complete experimental 
schematic in figure 5.1; see Appendix III.c for detailed protocols). This kind of 
insult mimics the sudden lack of oxygen and nutrients in the ischemic brain, 
which leads to metabolic and oxidative stress, and eventually to inflammation and 
tissue necrosis. Hence, all these different aspects of ischemia-driven injury were 
addressed to investigate if EV-based treatments could be of any therapeutic use. 
Briefly, the experimental conditions were: 
 
• Undamaged brain slices (positive control, n=12); 
• OGD-damaged brain slices (negative control, n=12); 
• LL-CBMSCs in co-culture with damaged brain slices (co-culture, n=12); 
• LL-CBMSC-EV treated damaged brain slices, one-fold dose (CB-EV[1], 
n=12); 
• hiPSC-EV treated damaged brain slices, one-fold dose (hiPSC-EV[1], 
n=12); 
• hiPSC-EV treated damaged brain slices, two-fold dose (hiPSC-EV[2], 
n=12); 
• PKH26-labelled LL-CBMSC-EV treated damaged brain slices (n=2); 
• PKH26-labelled hiPSC-EV treated damaged brain slices (n=2). 
 
The one-fold dose consisted in 2.4 billion EVs per brain slice and it was 
determined based on an estimation of EV production by LL-CBMSCs in co-
culture. A direct comparison between LL-CBMSC- and hiPSC-EVs was planned 
in order to assess if and how much reprogramming had affected EV protective 
properties; to detect any dose-response phenomenon, the two-fold dose was also 
used. EV administration was repeated for two subsequent days, based on the 
assumption that LL-CBMSCs in co-culture would constantly generate new EVs. 
In addition, EV membranes were labelled with PKH26 to investigate if fusion with 
the target tissue had taken place during the treatments. 
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Figure 5.1. Experimental schematic. In a), the experimental protocol is summarized. Mouse brain slices 
were prepared 1 week before the injury induction and they were maintained in culture in 6-well plates. Each 
well contained a transwell permeable to particles <400 nm in size; n=2 brain slices were used per transwell 
(b). Ischemic-like oxygen and glucose deprivation (OGD) insult consisted in a 2 hour incubation at 0.1% O2, 
0% glucose, followed by 1 hour of reoxygenation and nutrient availability. Then, LL-CBMSC co-culture or 
extracellular vesicle (EV) administrations were performed; EVs were administered also 24 hours post-OGD. 
At 48 hours post-OGD, tissue necrosis rescue and EV fusion with the target tissue were assessed, and 
samples for gene expression and secretion analysis were collected. PI, propidium iodide; CB-EV[1], one-fold 
dose LL-CBMSC-EV treatment; hiPSC-EV[1], one-fold dose hiPSC-EV treatment; hiPSC-EV[2], two-fold 
dose hiPSC-EV treatment; PKH26, PHK26-labelled EVs. 
 
At 48 hours post-OGD insult, the effectiveness of the applied treatments was 
addressed by the evaluation of cell necrosis, which is one endpoint of the 
ischemic cascade. Necrotic cells in the brain tissue were quantified by propidium 
iodide (PI) incorporation. Strikingly, all the treatments rescued cell mortality, 
showing statistically significant reductions in PI signal, measured by fluorescence 
microscopy. In particular, all stem cell EV-based treatments demonstrated a 
neuroprotective effect equal to that of LL-CBMSC co-culture. Yet, the most 
effective treatment among them was CB-EV[1], which resulted in a statistically 
significant lower PI incorporation only if compared to hiPSC-EV[1]. Nonetheless, 
also hiPSC-EVs possessed relevant neuroprotective properties, which were more 
evident for hiPSC-EV[2]. 
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Figure 5.2. Necrosis upon oxygen and glucose deprivation (OGD)-driven injury. Necrotic cells were 
quantified by propidium iodide (PI) staining. The results are presented as percentage of untreated OGD 
negative control (% of OGD). Statistical analysis: one-way ANOVA, followed by Tukey post-test, after 
normality was assessed by Kolmogorov-Smirnov test; ***p<0.001, *p<0.05, for all experimental conditions 
compared to OGD group; °°°p<0.001, for CB-EV[1] compared to hiPSC-EV[1] conditions; n=12 for each 
experimental group. CTR, undamaged positive control; OGD, damaged untreated negative control; co-
culture, damaged brain slices in co-culture with LL-CBMSCs; CB-EV[1], damaged brain slices treated with 
one-fold dose LL-CBMSC-EVs; hiPSC-EV[1], damaged brain slices treated with one-fold dose hiPSC-EVs; 
hiPSC-EV[2], damaged brain slices treated with two-fold dose hiPSC-EVs. 
 
At 48 hours post-OGD, PKH26-labelled EV presence within the brain slices was 
addressed by fluorescence microscopy (Fig 5.2, a, b and b). The EV signals were 
detected as bright fluorescent spots, located especially at tissue slice borders. 
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Figure 5.3. Fusion of extracellular vesicles (EVs) with brain tissue cells. In a), a representative brain 
slice which did not receive PKH26-labelled EVs is shown. PKH26-labelled LL-CBMSC- (b) or hiPSC- (c) EV 
treated brain slices show positivity for fluorescence, clearly higher than the autofluorescence background; 
the arrows indicate representative PKH26-positive spots. 
57 
 
 
The next step was to evaluate which cell type was damaged by the OGD insult 
and if the treatments could have a beneficial effect on them. The presence of 
specific neural cell types was assessed at the transcriptional level by Real Time 
qRT-PCR analysis performed on markers typical of neurons (Map2), endothelial 
cells (Cd31), microglia (Cd11b), and astrocytes (Gfap). Neurons and astrocytes 
were affected by the OGD insult, as shown by a statistically significant reduction 
of the respective marker mRNA transcripts, whereas endothelial cells and 
microglia did not (Fig. 5.4, a, b, c and d). Importantly, astrocyte marker mRNA 
level was rescued in all treatments, indicating that this cell type is the main 
therapeutic target of stem cells and stem cell-EVs. Notably, the co-culture 
treatment showed only a partial and not significant rescue. 
The expression of anti-apoptotic (Bcl2) and pro-apoptotic (Bax) genes was also 
investigated to evaluate if a modulation of apoptosis by the treatments had 
played a role in the observed neuroprotection. Unfortunately, no treatment 
revealed increased expression of Bcl2 or decreased expression of Bax, 
compared to untreated control (Fig. 5.4, e and f). The same approach was used 
to address if the treatments promoted proliferation, but, also in this case, no 
significant fluctuations in Mki67 and Pcna gene expression was observed, 
compared to OGD negative control (Fig. 5.4, g and h). Instead, undamaged 
positive control brain slices showed statistically significant lower Mki67 and Pcna 
mRNA levels, compared to the other experimental conditions. This suggested 
that in this ex vivo model the OGD insult per se, followed by reoxygenation and 
glucose availability, induced transcription of these genes, maybe as an 
endogenous response to injury. Yet, a significant difference was identified 
between the co-culture condition, compared to hiPSC-EV[2], hinting at a higher 
stimulation of proliferation by the latter treatment. The gene expression of growth 
factors crucial for ischemia-triggered injury recovery was also assessed: brain-
derived neurotrophic factor (Bdnf) [205] and vascular endothelial growth factor A 
(Vegfa) [206]. The transcript levels were significantly lower than those of the 
undamaged positive control were. Notwithstanding, both hiPSC-EV[1] and [2] 
treatments demonstrated significantly higher Vegfa mRNA levels, compared to 
the co-culture condition (Fig. 5.4, i and j). 
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Figure 5.4. Effects on apoptosis, proliferation and production of growth factors. Cell type marker- (a, 
b, c and d), apoptosis- (e and f), proliferation- (g and h) and growth factor- (i and j) related gene mRNA levels 
are presented as log2 of the fold change, normalized to undamaged positive control (CTR). Statistical 
analysis: one-way ANOVA, followed by Tukey post-test, after normality was assessed by Kolmogorov-
Smirnov test; n=6 for each experimental group; °°°p<0.001, °°p<0.01, °p<0.05, compared to CTR; **p<0.01, 
*p<0.05, compared to oxygen and glucose deprivation (OGD) damaged untreated negative control; ^p<0.05, 
compared to damaged brain slices in co-culture with LL-CBMSC (co-culture) condition. CB-EV[1], damaged 
brain slices treated with one-fold LL-CBMSC-EVs; hiPSC-EV[1], damaged brain slices treated with one-fold 
hiPSC-EVs; hiPSC-EV[2], damaged brain slices treated with two-fold hiPSC-EVs. 
 
Finally, the metabolic and oxidative stress consequences of the OGD insult were 
investigated. To this purpose, the culture medium levels of ATP, adenosine and 
glutamate metabolites (mediators of ischemic damage), malondialdehyde (lipid 
peroxidation marker), superoxide dismutase and glutathione (anti-oxidant 
molecules) were measured, by colorimetric or fluorescence reaction-based 
assays. Unfortunately, none of the aforementioned molecules were detected. It is 
likely that to appreciate, if any, a modulation of these parameters, a technique 
allowing a lower detection limit should have been used (e.g.: mass spectrometry). 
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5.3 Tissue modulation as stem cell extracellular vesicle 
mechanism of action 
 
Based on the previously assessed anti-inflammatory properties of LL-CBMSCs, 
which could be relevant in the context of brain ischemia, modulation of 
inflammatory cytokines secreted by brain slices in the culture medium was 
investigated by multiplexed ELISA. The levels of INF?, IL1?, IL2, IL6, IL10, 
IL12p70, IL17 and TNF? were simultaneously measured for positive and negative 
controls, and for co-culture, CB-EV[1] and hiPSC-EV[2] treatments. Intriguingly, 
detectable levels of secreted protein were found for TNF? and IFN?. This was a 
very relevant result, because microglia-produced TNF? is one major mediator of 
post-ischemic early phase inflammation and it is responsible for many aspects of 
it [207, 208]. Furthermore, CD4+ Th1 lymphocyte-produced IFN? is involved in 
late phase ischemic events [209], and it is a potent inducer of TNF?, thus 
promoting amplification and maintenance of neuroinflammation [210, 211]. Going 
into details, TNF? and INF? secreted protein levels underwent statistically 
significant increases in OGD condition, compared to undamaged control (Fig. 5.5, 
a and b). Surprisingly, all treatment conditions showed a statistically significant 
reduction of TNF?, compared to OGD condition. The effect was so dramatic as to 
significantly decrease the protein levels below the undamaged control condition 
by a two-fold change. In addition, CB-EV[1] treatment showed a significant lower 
reduction of TNF?, compared to the co-culture condition. Concerning INF?, 
decreased levels of secreted protein were observed in all treatments, compared 
to the negative control; statistically significant results were obtained for CB-EV[1] 
and for hiPSC-EV[2], with the latter demonstrating a stronger action, but not for 
the co-culture condition. Both TNF? and INF? results indicated that complete 
rescue of these two crucial ischemia-driven injury parameters was achieved by 
the EV-based treatments. 
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Figure 5.5. Modulation of inflammatory cytokines. Tumor necrosis factor ? (TNF?) (a) or interferon ? 
(INF?) (b) protein levels are shown, normalized to undamaged positive control (CTR); mean and standard 
deviation is presented. Statistical analysis: one-way ANOVA, followed by Tukey post-test, after normality 
was assessed by Kolmogorov-Smirnov test; n=4 for CTR, n=5 for LL-CBMSC co-culture treatment (co-
culture), n=6 for all other experimental conditions; °°°p<0.001, compared to CTR; ****p<0.0001; ***p<0.001; 
*p<0.05, compared to oxygen and glucose deprivation (OGD) damaged untreated negative control; 
^^p<0.01, compared to the co-culture condition. In c), the table summarizes TNF? and INF? transcript-
targeting miRNAs; ranks among total incorporated miRNAs, and validation in human or mouse cells are 
specified; n.p., not present. CB-EV[1], one-fold dose LL-CBMSC-EV treatment; hiPSC-EV[2], two-fold dose 
hiPSC-EV treatment. 
 
Following the working hypothesis presented in paragraph 4.3, the possibility of a 
functional role for miRNAs in this context was explored. Out of the top 150 ranked 
LL-CBMSC EV-incorporated miRNAs, 15 were found to target TNF? or INF? 
mRNA transcripts, by interrogation of the miRTarBase database of 
experimentally validated miRNAs (Fig. 5.5, c). With regard to hiPSC-EVs, the 
result was 12 out of 150 top ranked miRNAs. Among them, TNF? transcript-
targeting miR-125b-5p, miR-130a-3p and miR-19a-3p were present in both stem 
cell EVs, as well as INF? transcript-targeting miR-146a-5p, miR-15a-5p, miR-15b-
5p, miR-16-5p, miR-24-3p, miR-26b-5p, miR-27a-3p and miR-29b-3p. 
Interestingly, miR-24-3p and miR-125b-5p were the two most enriched miRNAs 
in LL-CBMSC-EVs, nonetheless, they were also present in hiPSC-EVs, ranked 
25th and 60th, respectively. Thus, different stem cell-EV miRNA bioavailability 
could explain the different efficacies observed in the rescue of OGD-driven injury 
and the dose-response phenomenon verified for hiPSC-EVs. Yet, further and 
more focused experiments are needed to address these questions. 
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5.4 Conclusions 
Stem cell extracellular vesicles (EVs) were shown to exert effectively 
neuroprotection in an organotypic ex vivo model of acute brain ischemia, 
reducing considerably the entity of tissue necrosis. The mechanism unveiled in 
this context counteracts brain injury via the modulation of the damaged tissue 
environment to establish a pro-regenerative milieu. Noteworthy, the ex vivo 
model mimicked very well an acute phase brain ischemia inflammatory response. 
This confirmed its validity to assess the efficacy of the developed EV-based 
treatments in the very early stages of the pathology. Intriguingly, EVs 
demonstrated anti-inflammatory properties equal to those of LL-CBMSCs. This 
suggests that EVs are carriers of the same stem cell regenerating clues able to 
modulate inflammation. Going into detail, the action of EVs was described on 
tumor necrosis factor ? (TNF?), a pleiotropic peptide involved in inflammation- 
and immune-related activities, which plays a role not only in ischemia, but also in 
brain trauma and cerebral infection [207, 212, 213]. In addition, EV-based 
treatments targeted also interferon ?, whose capacity to activate innate and 
adaptive immune responses can act in concert with TNF? to establish chronic 
inflammation through a positive regulatory loop found in many neurological 
diseases [210, 211, 214-216]. Therefore, a larger area of application for the 
developed therapeutic approach could be considered, after the mechanism of 
action is validated also in other pathological contexts. 
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Chapter 6 
 
 
Perspectives of extracellular 
vesicle-based therapeutics 
 
 
Very recently, research on multipotent mesenchymal stromal cell (MSC) 
mechanism of action (MoA) in regenerative medicine approaches shifted its focus 
from secreted proteins to the generation of extracellular vesicles (EVs) [33, 63]. 
Consequently, an increasing amount of reports started to point at EVs as cell-
derived vehicles responsible of the transfer of regenerative and protective 
information to injured tissues [34, 109]. In this frame, EVs are becoming one of 
the central players in MSC MoA, suggesting that a cellular-to-vesicular 
therapeutic paradigm switch can be feasible and promising. EVs could be 
produced in larger amounts, compared to MSCs, and stocked in a drug-like 
ready-to-use formulation. This will guarantee feasibility of clinical application in 
pathological contexts where rapidity is essential, which is something that cell 
therapy strategies currently cannot achieve. Hence, the idea of this PhD project 
was to develop a stem cell-based albeit cell-free regenerative approach. 
Pivotal in the development of EV-based therapeutic approaches is the choice of 
the cell source. To address this issue, a mediation between the biological 
features of the cell source, the EV therapeutic properties and the scalability of the 
process at the industrial level should be done. Thus, the optimal cell source 
would allow limitless production of clinically relevant EVs able to recapitulate 
MSC regenerative potential. For this research, long living (LL)-MSCs isolated 
from a birth-associated tissue such as cord blood (CB) were chosen as EV 
source over MSCs derived from adult tissues (e.g.: bone marrow), which show 
age-related senescent features [46, 138, 139, 141, 142, 166].  
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Yet, from an industrial perspective, immortalized cell lines could be a more 
convenient EV source, compared to more heterogeneous and life span-limited 
primary cells. In this PhD work, the reprogramming technique was implemented 
as a tool to obtain LL-CBMSC-derived immortal cell lines preserving the original 
EV features. In this context, future studies assessing the safety of EV-based 
therapies will be necessary, with a focus on possible tumorigenic risks and on the 
feasibility of allogeneic clinical approaches. 
A potential drawback of EV-based therapies would be the loss of the dynamic 
stimulus-response nature of living systems, as MSCs are. This crucial issue could 
be overcome “pushing” MSCs to generate EVs enriched in specific contents. A 
variety of means could be used to reach such a goal, such as specific culture 
conditions (e.g.: hypoxia, cytokine or small molecule administration), or also 
growth substrate control (e.g.: 2D versus 3D culture systems, growth surface 
patterning/stiffness control). The modulation of these cell culture aspects was 
already proved useful to reshape MSC secretome composition [217-219], 
therefore could be effective also with regard to EV cargo.  
Another option, that is genetic engineering, could allow directed incorporation of 
specific proteins and RNA molecules into EVs, following their forced expression 
in parental cells. Essential to this highly refined control of the EV-load is the full 
comprehension of the cellular mechanisms leading to protein- and RNA-specific 
sorting into EVs. A lot of information that could be useful to this purpose is 
already available at online databases collecting data on the molecular content 
and other features of EVs, generated from different organisms, sources or under 
different culture conditions (e.g.: ExoCarta, Vesiclepedia, EVpedia, 
Microvesicles). 
In this doctoral thesis, the developed EV-based regenerative approach was 
shown to be effective in the protection of neural tissue, in an ex vivo model of 
brain ischemia. Focusing on the MoA of this therapeutic strategy, the working 
hypothesis is that EVs acted as carriers of bioactive molecules able to modulate 
the post-ischemic inflammatory environment.  
Many molecular aspects of the observed neuroprotective effect still have to be 
unveiled, yet, from the definition of the stem cell-EV miRNome, it could be 
speculated that EV-shuttled miRNAs may participate in the establishment of a 
pro-regenerative milieu.  
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Stem cell-EV miRNAs would be released into pro-inflammatory cytokine-
secreting cells (i.e.: microglia and astrocytes) of the damaged tissue, upon fusion 
of EVs with the plasma membrane. Once inside the cell, a subset of specific 
miRNAs (e.g.: miR-125b-5p and miR-24-3p) could directly repress TNF? and 
INF? transcript translation. In this way, extracellular levels of pro-inflammatory 
cytokines would be decreased, contributing to the exit from the positive regulatory 
loops leading to chronic inflammation, as depicted in figure 6.1. 
In the proposed model (modified from [209]), four pro-inflammatory loops could 
be interrupted by the EV-shuttled miRNAs. First, TNF? acts on TNF? receptor 1 
(TNF-R1) in an autocrine fashion, which leads to more TNF? secretion and 
glutamate release by microglia and astrocytes [220]; in turn, glutamate-stimulated 
group 2 metabotropic glutamate receptor (mGluR2) further induces TNF? release 
from microglia [221]. Second, TNF? increases glutamate release by astrocytes, 
too, and concomitantly reduces glutamate uptake, by the downregulation of 
astrocytic glutamate transporter (human EAAT1/murine GLAST and human 
EAAT2/murine GLT1) mRNA levels [222]. Third, INF? acts on microglia in a 
paracrine fashion, which sustains TNF? extracellular levels and promotes 
immune system cell infiltration and amplification of inflammation [210, 211]. 
Fourth, TNF? leads to increased permeability of ionotropic N-Methyl-D-aspartic 
acid (NMDA) [223] and ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) excitatory receptors [224] and to decreased membrane surface levels of 
?-aminobutyric acid inhibitory receptor A (GABAA-R) [225, 226], leading to 
increased synaptic excitatory/inhibitory ratio and excessive calcium entry, which 
induces neuronal death; in turn, dying neurons amplify the injury signals 
maintaining microglial cells in an active state [227].  
In addition, stem cell EVs may also counteract direct promotion of TNF-R1-
associated DEATH domain (TRADD)-mediated apoptosis by TNF? signaling 
[208]. It is worth noting that TNF-R1 stimulation also leads to the activation of NF-
kB protein complex, a transcription factor sequestered in an inhibited state in the 
cytoplasm. Activated NF-kB can translocate into the nucleus and there it 
regulates the cellular response to a variety of stimuli (e.g.: stress, cytokine 
signaling, free radicals, infections) [228]. The genes controlled by NF-kB can turn 
on anti-apoptotic pathways and growth factor genes, such as BDNF and NGF, 
but also increase TNF-R1 and TNF? production as well [229].  
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In conclusion, it seems that such a complex dysfunctional crosstalk, herein 
partially described in aspects related to the present PhD work, would be more 
easily corrected toward a regenerative resolution if counteracted from many 
directions at a time. In this research project, an anti-inflammatory role for stem 
cell EVs was demonstrated, and a possible role for shuttled miRNAs was 
proposed. Yet, EVs may have exerted a beneficial effect through the action of 
other biomolecules as well, such as surface-exposed proteins or receptors, which 
could interact with the plasma membrane of target tissue cells to initiate 
intracellular signal transduction pathways. In addition, EVs could shuttle also 
metabolites, which were recently demonstrated to be neuroprotective in the same 
ex vivo model of brain ischemia [230]. This is very intriguing, because the primary 
consequences of ischemia are manifested at the metabolic level, so that an EV-
based metabolic rescue appears an additional therapeutic option to investigate. 
All considered, the action of stem cell EVs could not only modulate both early-
phase innate and late-phase acquired immune mechanisms, but also other 
aspects of ischemic injury (i.e.: metabolic and oxidative stress). As a final 
consideration, the described interplay involving microglia, T lymphocytes, 
astrocytes and neurons is common to many other neural pathological conditions 
(e.g.: multiple sclerosis, Parkinson’s disease), therefore, it appears of extreme 
interest to assess if the herein presented EV-based therapeutic approach may be 
of any use in such diseases. 
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Conclusions 
 
 
 
 
The aim of this doctoral project was the development of a stem cell-based albeit 
cell-free regenerative approach. The ratio behind this choice was to meet the 
need of a therapeutic strategy matching stem cell regenerative features, without 
the disadvantages of working with living cells.  
For this purpose, multipotent mesenchymal stromal cells (MSCs), which already 
demonstrated relevant anti-inflammatory, anti-apoptotic and immunomodulatory 
paracrine properties at the clinical level, were used. Furthermore, giving the high 
interest arisen around extracellular vesicles (EVs), as cellular secretion products 
mimicking paracrine properties of parental cell sources, they were chosen as 
candidate carriers of MSC regenerative information.  
In order to isolate MSCs, different cell sources were considered. In line with other 
reports, MSCs from adult sources (i.e.: adipose tissue, bone marrow) were 
shown to possess senescent-like features (e.g.: IGF1 secretion), compared to 
MSCs from perinatal sources (i.e.: birth-associated tissues). Thus, cord blood 
(CB) was chosen as MSC source, also in reason of advantages related to the 
already existing network of banks collecting CB units for clinical purposes. From 
the dissection of the CB stromal component, a protocol for the isolation of long-
living (LL)-CBMSCs was defined, relying on the use of telomere length as 
predictive parameter of culture outcome. In addition, the feasibility of high 
efficiency CBMSC isolation rate by an improved procedure was described, 
solving one major issue in CBMSC clinical translation.  
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In vitro and in vivo anti-inflammatory and anti-apoptotic paracrine properties of 
LL-CBMSCs were shown in different models of tissue injury. This broad tissue 
protective mechanism was demonstrated to be rooted on the modulation of 
inflammation. Specifically, LL-CBMSCs were able to recruit macrophages in vivo 
in an injured tissue and to skew their phenotype to an Arg I-producing anti-
inflammatory M2 one. Furthermore, LL-CBMSCs reduced extracellular levels of 
pro-inflammatory cytokines (e.g.: TNF? and INF?), while increasing those of anti-
apoptotic growth factors (e.g.: HGF and FGF), after cell acute damage. These 
were considered crucial features of LL-CBMSCs, as reduced inflammation 
facilitates tissue regeneration in many pathological contexts. More importantly, 
LL-CBMSCs were shown to generate EVs capable to recapitulate the parental 
cell paracrine ability to rescue cell viability after acute damage.  
Then, the reprogramming technology was shown to be a feasible engineering 
solution to immortalize LL-CBMSCs, avoiding permanent modification of the 
genome caused by integration of viral DNA. In spite of the induction of 
pluripotency in LL-CBMSCs, thoroughly assessed addressing both stemness and 
pluripotency features of the generated human induced pluripotent stem cell 
(hiPSC) lines, the secretion of EVs with characteristics similar to those of the 
unreprogrammed cells was preserved. Noteworthy, LL-CBMSC-EV miRNome 
was defined for the first time and it was shown to be largely maintained in hiPSC-
EVs, as a novel feature of pluripotent stem cell biology to be further elucidated. 
Yet, this result was crucial to envision EV therapeutic approaches based on 
hiPSC-EVs, since miRNAs are, at the present knowledge, central players in EV-
mediated mechanisms of action.  
Eventually, for the first time stem cell EVs were shown to exert effectively 
neuroprotection in an organotypic ex vivo model of acute brain ischemia, used as 
a proof-of-concept to challenge the therapeutic potentiality of EVs. The EV-based 
regenerative approach reduced significantly ischemia-driven tissue necrosis. 
Remarkably, a major effect was detected for astrocytes, a glial cell type involved 
in the support of neuronal activity, but also in neural tissue regeneration following 
injury [231-234].  
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The mechanism unveiled in this context counteracts brain injury via the 
modulation of the damaged tissue environment to establish a pro-regenerative 
milieu. Noteworthy, the ex vivo model mimicked very well an early acute brain 
ischemia inflammatory response. Thus, the therapeutic potential of the developed 
EV-based treatment in the very first stage of the pathology was assessed.  
Going into detail, a previously unreported action of EVs was described on tumor 
necrosis factor ? (TNF?), a pleiotropic peptide involved in inflammation- and 
immune-related activities, which plays a role not only in ischemia, but also in 
brain trauma and cerebral infection [207, 212, 213]. In addition, the EV-based 
treatments targeted also interferon ?, whose capacity to activate innate and 
adaptive immune responses can act in concert with TNF? to establish chronic 
inflammation through a positive regulatory loop, also in many other neurological 
diseases [210, 211, 214-216]. Therefore, a larger area of application for the 
developed therapeutic approach could be considered, after the mechanism of 
action is validated also in the other pathological contexts. 
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A Chemically Defined Medium-Based Strategy to Efficiently Generate 
Clinically Relevant Cord Blood Mesenchymal Stromal Colonies
Mario Barilani,*† Cristiana Lavazza,* Valentina Boldrin,* Enrico Ragni,* Valentina Parazzi,* 
Mariacristina Crosti,‡ Elisa Montelatici,* Rosaria Giordano,* and Lorenza Lazzari*
*Cell Factory, Unit of Cell Therapy and Cryobiology, 
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy
†Department of Industrial Engineering, University of Padova, Padova, Italy
‡Istituto Nazionale di Genetica Molecolare (INGM), Milano, Italy
During the last decade it has been demonstrated that mesenchymal progenitors are present and can be isolated 
also from cord blood (CB). Recently, we managed to set up a standard protocol allowing the isolation of mesen-
chymal stromal cells (MSCs) with high proliferative potential and multiple differentiation capabilities, whereas 
the generation rate of MSC-initiating colonies could still be further improved. Herein, we strikingly succeeded 
in defining some simple and basic culture conditions based on the use of a chemically defined medium that 
increased the colony isolation efficiency up to almost 80% of processed CB units. Importantly, this result 
was achieved irrespective of CB unit white blood cell content and time elapsed from delivery, two limiting 
parameters involved with processing CB units. Thus, this high efficiency is guaranteed without strict selection 
of the starting material. In addition, since we are profoundly concerned about how different culture condi-
tions can influence cell behavior, we devoted part of this study to in-depth characterization of the established 
CB-MSC populations to confirm their stemness features in this novel isolation and culture system. Therefore, 
an extended study of their immunophenotype, including classical pericytic markers, and a detailed molecular 
analysis addressing telomere length and also stemness-related microRNA contribution were performed. In 
summary, we propose a straightforward, extremely efficient, and reliable approach to isolate and expand thor-
oughly characterized CB-MSCs, even when poor-quality CB units are the only available source, or there is no 
space for an isolation to fail.
Key words: Cord blood (CB); Cord blood-derived mesenchymal stromal cells (CB-MSCs); 
Chemically defined medium; Mesenchymal stromal cells (MSCs); Stemness potency assay
INTRODUCTION
Mesenchymal stromal cells (MSCs) are multipotent 
and represent one of the major players in cell-based clini-
cal trials, and various studies have found that they pos-
sess unique therapeutic properties1,2. Until now no single 
mechanism of action has been defined, although the pre-
vailing theory describes MSCs as living drugstores capa-
ble of secretion and delivery of numerous cytokines and 
growth factors to damaged tissues3, along with vesicular 
products implicated in many physiological processes4. 
Nonetheless, MSCs also retain the potential to differenti-
ate into mesodermal lineages and specifically into adi-
pocytes, chondrocytes, and osteocytes5, and this was the 
characteristic that first drew attention to MSCs as tools in 
regenerative medicine for tissue repair purposes.
Currently, cord blood (CB) has the undeniable advantage 
of having a completely safe and noninvasive harvesting 
procedure. Another advantage that will facil itate exten-
sive use of CB-MSCs in the clinic is the existence of 
international networks of public and private banks storing 
thousands of frozen cord blood units (CBUs) that, in the 
future, could be used for MSC isolation for therapeutic 
purposes. Like MSCs from other sources, CB-MSCs can 
also undergo adipogenesis, chondrogenesis, and osteo-
genesis upon induction6 and secrete biologically active 
molecules7. Currently, even if several attempts have been 
made and different methodological approaches have been 
implemented in order to efficiently isolate stromal cell 
colonies from CB, high-quality CBUs are often required, 
specifically with regard to time from collection to pro-
cessing, white blood cell (WBC) content, and volume8,9. 
For this reason many stem cell researchers have hesi-
tated until now to consider CB-MSCs as a real alterna-
tive to bone marrow-derived mesenchymal stromal cells 
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(BM-MSCs). Indeed, this main drawback could represent 
a huge hurdle, especially when feasibility of translation to 
the clinic has to be evaluated.
Recently, we described the existence of at least two 
stromal populations in CB, both capable of differentiation 
into mesodermal derivatives and both expressing typical 
MSC surface markers. Nonetheless, marked differences 
were found with regard to other biological features, such 
as growth properties including proliferation rate, life span 
in vitro, and ability to generate colonies under low-density 
seeding conditions. In addition, a robust statistically sig-
nificant difference was detected at the molecular level 
following the analysis of telomere length, which was pos-
itively correlated with enhanced growth properties. Thus, 
we decided to name CB-MSCs endowed with higher 
proliferation properties and longer telomeres long-living 
(LL)-CB-MSCs, while we named CB-MSCs showing 
shorter life span and shorter telomeres short-living (SL)-
CB-MSCs. We also proposed LL-CB-MSCs as the best 
choice in the context of stem cell therapy settings, on 
the basis of their biological features. For instance, the 
higher proliferation properties of LL-CB-MSCs allow for 
obtaining clinically relevant ex vivo cell expansions.
Notwithstanding the crucial advance in the knowledge 
of these important players in the regenerative medicine 
field, the establishment of such a population occurred in 
12% of total isolated colonies10. In order to improve the 
efficiency of our standard isolation protocol and at the 
same time to generate CB-MSCs showing the same or 
improved qualities of LL-CB-MSCs, the main aims of the 
present study were threefold. First of all, we investigated 
whether we could provide novel cell culture conditions to 
improve MSC colony appearance and avoid some of the 
strict CBU quality requirements. The idea was to offer the 
best environment to facilitate CB mesenchymal progenitor 
attachment to a plastic surface, which is considered essen-
tial for their survival11, and also to better support the gener-
ation and growth of stromal colonies. Second, considering 
the great influence of the medium composition on MSC 
stemness and other biological features12, we sought to fur-
ther evaluate the peculiar characteristics of the CB-MSCs 
cultured under these new conditions to provide more com-
plete information about their effect and on their properties. 
Finally, we wanted to investigate if such an optimal culture 
environment could be applied to rescue the SL-CB-MSC 
phenotype and induce them to adopt the same clinically 
relevant proliferative properties demonstrated by LL-CB-
MSCs in standard culture conditions.
MATERIALS AND METHODS
Isolation of Human CB-MSCs
Human umbilical cord blood (hUCB) was collected in 
a multiple system bag (Machopharma, Mouvaux, France) 
containing 29 ml of citrate phosphate dextrose as an anti-
coagulant. The samples were not included in the study if 
the presence of clots or hemolysis was detected before or 
after the implementation of the isolation procedure. The 
authors state that this study was performed according to 
the amended Declaration of Helsinki. In addition, written 
informed consent was obtained from all of the cord blood 
donors involved in the study, and use of human tissue and 
cells was approved by the Ethical Committee of our insti-
tute, Fondazione IRCCS Ca’ Granda Ospedale Maggiore 
Policlinico. Two standard isolation procedures routinely 
performed in our laboratory were used for CB-MSC iso-
lation under new culture conditions: a classic BM-MSC 
isolation protocol and a CB-MSC-tailored one10. In 
the first case, samples were seeded as whole blood at 
0.5 × 104 total nucleated cells (TNCs)/cm2. This protocol 
is fast and simple, but given the high number of TNCs in 
the sample, only a small CB fraction (£4 ml in this study) 
can be processed, since seeding all CB would imply the 
use of an excessive and unmanageable number of culture 
flasks (e.g., for a 20-ml CB sample with 10 × 106 TNCs/
ml, a 4,000-cm2 cell growth area corresponding to more 
than 50 75-cm2 flasks would be needed). On the other 
hand, higher seeding density cannot be applied because 
red blood cells and adherent white blood cells would 
heavily interfere with MSC attachment or colony growth. 
Alternatively, the samples were centrifuged at 680 × g for 
15 min, and the plasma was discarded, while the buffy 
coat (BC) was collected. MSC precursors were obtained 
by negative immunodepletion of CD3+, CD14+, CD38+, 
CD19+, glycophorin A, and CD66b+ cells using a commer-
cial kit (RosetteSep Mesenchymal Stem Cell, StemCell 
Technologies, Vancouver, BC, Canada) followed by den-
sity gradient separation. Briefly, for immuno depletion the 
recovered TNCs were incubated with 50 ml/ml RosetteSep 
MSC enrichment cocktail for 20 min at room temperature 
(RT). After incubation, the sample was diluted 1:3 with 
phosphate-buffered saline (PBS; Gibco, Grand Island, 
NY, USA), ethylenediaminetetraacetic acid (EDTA; 
Sigma-Aldrich, St. Louis, MO, USA), and human serum 
albumin (Kedrion, Barga, Italy) and then separated under 
standard density gradient conditions (Ficoll Paque Plus 
1.077 ± 0.001 g/L; GE Healthcare, Little Chalfont, UK). 
The ring of immunodepleted mononuclear cells (MNCs) 
was transferred to a new tube with a Pasteur pipette, 
washed, and then plated at a concentration of 1 × 106 cells/
cm2. This protocol allows the concentration of CB and 
its enrichment in MSC progenitors. Thus, all the sample 
is processed, the undesired and committed cell types are 
discarded, and a higher seeding density compared to the 
whole blood protocol can be applied.
In both cases, the sample fractions were suspended 
in culture medium composed of SPE-IV alone (ABCell-
Bio, Paris, France) or supplemented with 20% fetal 
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bovine serum (FBS; Gibco) and, when specified, with 
L-glutamine 1× (Gibco), hereafter referred to as com-
plete medium (CM). SPE-IV (ABCell-Bio) is a defined 
serum-free medium developed for optimal growth sup-
port of human MSCs containing 25 ng/ml recombinant 
human insulin-like growth factor-1 (rh-IGF-1) and 
0.33 ng/ml recombinant human-basic fibroblast growth 
factor (rh-bFGF). Other components, whose exact con-
centration is not disclosed in detail by the manufacturer, 
are clinical-grade human albumin, synthetic iron car-
rier, rh-insulin, nucleosides, L-glutamine, a-monothio-
glycerol, synthetic lipids, and aMEM. When specified, 
culture surfaces were coated with 10 mg/cm2 collagen 
I–III (ABCell-Bio) for 2 h at RT.
Cell cultures were maintained at 37°C in a humidified 
atmosphere containing 5% CO2. After 48 h, nonadherent 
cells were removed, and fresh medium was added. From 
that point, culture medium was changed every 3 days 
and cultures examined for colony appearance everyday. 
At 80% confluence, the cells were harvested with 25% 
TrypLE Select 1× (Gibco), washed with PBS (Gibco), and 
subcultured at a concentration of 1.5 × 103/cm2. LL-CB-
MSCs and SL-CB-MSCs were isolated and cultured as 
previously reported10 in the standard medium composed 
of aMEM-GlutaMAX (Gibco) supplemented with 20% 
FBS (Gibco) (standard CB-MSC culture control). To 
ensure proper culture conditions and as a routine quality 
control in our laboratory, the FBS batches used in this 
study were previously tested for optimal CB-MSC growth 
in the aforementioned standard culture conditions.
Cumulative Population Doublings
Population doublings were calculated for each estab-
lished CB-MSC population using the equation: popula-
tion doubling (PD) = log10(N)/log10(2), where N is the 
ratio between the number of cells harvested at the end of 
the culture and the number of seeded cells.
Cumulative PD (CPD) was calculated for each passage 
as the sum of the current and all the previous PD values.
Colony-Forming Unit-Fibroblast (CFU-F) Assay
Two hundred CB-MSCs were plated per 100-mm Petri 
dish (BD Biosciences, Franklin Lakes, NJ, USA) in repli-
cate (n = 2). The medium was replaced with fresh medium 
after 1 week; at day 14 the cells were washed with PBS 
(Gibco), fixed with methanol (154903; Sigma-Aldrich), 
and stained with carbolic Gentian violet solution (Ral 
Diagnostics, Cedex, France). After two washing steps 
with milliQ-grade water, colonies with diameters greater 
than 1–2 mm were counted by sight.
Morphological Analysis
The morphological parameter calculated as the ratio 
between cell major axis length and nucleus diameter was 
considered indicative of cell shape and used to distin-
guish spindle-like cells from those showing a more com-
pact shape. The two parameters were measured (n = 10 for 
each cell type) with Media Cybernetics Image-Pro Plus 
2 (Media Cybernetics, Rockville, MD, USA). Images of 
cells in culture were taken with a Nikon Eclipse TS100 
microscope (Nikon, Tokyo, Japan).
Telomere Length
Telomere length was assessed by real-time qPCR 
as previously described13. Briefly, CB-MSC DNA was 
extracted from cell pellets stored at −80°C with QIAamp 
DNA Blood Mini Kit (51104; Qiagen, Hilden, Germany). 
The telomere sequence and single-copy gene (36B4)-
specific amplification reactions were performed in trip-
licate in 96-well plates on a CFX96 machine (Bio-Rad, 
Hercules, CA, USA). The data analysis was carried out 
using CFX Manager software (Bio-Rad). In order to pres-
ent mean telomere length, the values of each CB-MSC 
population for each passage were normalized on its pas-
sage 0 value, and then the mean was calculated.
Gene Expression
Isolation of total RNA and real-time qRT-PCR assays 
were conducted in duplicate as previously reported14. The 
following primers were used.
C/EBP-b (FW 5¢-GACAAGCACAGCGACGAGT 
A-3¢, RV 5¢-AGCTGCTCCACCTTCTTCTG-3¢; COL10 
A1 (FW 5¢-ACTCCCAGCACGCAGAATCCA-3¢, RV 
5¢-TGGGCCTTTTATGCCTGTGGGC-3¢); MYOD (FW 
5¢-TGCTCCGACGGCATGATGGAC-3¢, RV 5¢-GACA 
CCGCCGCACTCTTCCC-3¢); PAX3 (FW 5¢-GCCCAA 
CCACATCCGCCACA-3¢, RV 5¢-CTTGGAGACGCAG 
CCGTGGG-3¢); ALP (FW 5¢-TACAAGGTGGTGGGC 
GGTGAACGA-3¢, RV 5¢-TGGCGCAGGGGCACAGC 
AGAC-3¢); RUNX2 (FW 5¢-AACCCACGGCCCTCCC 
TGAA-3¢, RV 5¢-CTGTGCCTGCCTGGGGTCTGTA- 
3¢); BDNF (FW 5¢-AGGTGAGAAGAGTGATGA-3¢, RV 
5¢-CGGATGTTTGCTTCTTTC-3¢); MUSASHI (FW 5¢- 
GCGGCTGTTCGTGTTTTGGG-3¢, RV 5¢-AATGAGG 
GAGAGGGAAGCTAAGTG-3¢); SOX2 (FW 5¢-GGG 
GGAAAGTAGTTTGCTGCCTCT-3¢, RV 5¢-TGCCGCC 
GCCGATGATTGTT-3¢); ANGPT1 (FW 5¢-AGCAGCC 
TGATCTTACACGGTGC-3¢, RV 5¢-GCATCAAACCA 
CCATCCTCCTGT-3¢); ICAM-1 (FW 5¢-AAGGTGACC 
GTGAATGTG-3¢, RV 5¢-GCCTGTTGTAGTCTGTAT 
T-3¢); VCAM-1 (FW 5¢-TGTCATTGAGGATATTGGA 
A-3¢, RV 5¢-TAACTGTATTCTTGGGTGAT-3¢); RPLP0 
(FW 5¢-TGTGGGCTCCAAGCAGATGCA-3¢, RV 5¢-GC 
AGCAGTTTCTCCAGAGCTGGG-3¢).
Gene expression levels were normalized on RPLP0 
“housekeeping” gene expression, following the 2DDCt 
method. For each CB-MSC population and each analyzed 
gene, passage 3 expression level was used as baseline.
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Flow Cytometry
CB-MSCs were extensively characterized by flow 
cytometry at passages 3 and 5. Cells were washed with 
PBS (Gibco), centrifuged at 270 × g for 8 min and resus-
pended in PBS (Gibco) plus 2% FBS (Gibco), and then 
incubated for 20 min in the dark with the following com-
binations of directly coupled mouse anti-human fluoro-
chrome-conjugated antibodies: CD45-FITC (21270453X2; 
ImmunoTools, Friesoythe, Germany), CD73-PE (550257; 
BD), CD90-PE-Cy5 (PNIM3703; Beckman Coulter, 
Brea, CA, USA), CD117-PE-Cy7 (PNIM3698; Beckman 
Coulter), CD105-APC (130-094-926; Miltenyi Biotec, 
Bergisch Gladbach, Germany), CD146-biotin (5050-
B100T; BioCytex, Marseille, France) revealed with 
streptavidin APC-Cy7 (BD) for the first tube; CD31-FITC 
(555445; BD), CD144-PE (PNA07481; Beckman Coulter), 
CD34-PE-Cy5 (A07777; Beckman Coulter), CD133-APC 
(130-092-880; Miltenyi Biotec), CD146-biotin (BioCytex) 
revealed with streptavidin APC-Cy7 (BD) for the second 
tube; alphaSMA-FITC (F3777; Sigma-Aldrich), PDGFR-
beta-PE (FAB1263P; R&D Systems, Minneapolis, MN, 
USA), CD146-biotin (BioCytex) revealed with streptavidin 
APC-Cy7 (BD) for the third tube; NG2-PE (PNIM3454U; 
Beckman Coulter), CD56-PE-Cy5 (555517; BD) for the 
fourth tube; SSEA4-FITC (560126; BD), CD271-PE 
(557196; BD), CD105-APC (Miltenyi Biotec) for the fifth 
tube. After staining, the cells were washed once with PBS 
(Gibco) containing 0.1% BSA (Kedrion). Fifty thousand 
events per sample were acquired with a FACSCanto II (BD) 
running FACSDiva 6.1.3 software, and isotype-matched 
mouse immunoglobulins were used as controls under the 
same conditions. Histograms and plots were generated 
using FlowJo analysis software v8.8.7 (Tree Star, Ashland, 
OR, USA). Mean fluorescence intensity (MFI) ratio was 
calculated as the ratio between sample and control MFI for 
each marker under analysis. Only MFI ratios greater than 2 
were taken into consideration.
Cell Lineage Differentiation
CB-MSCs were induced to differentiate into adipo-
genic, osteogenic, and chondrogenic cell types. Commer-
cial media (Lonza, Basel, Switzerland) were used following 
manufacturer’s protocols. Adipogenesis was promoted with 
human MSC adipogenesis induction medium (PT-3102B; 
Lonza) and human MSC adipogenesis maintenance 
medium (PT-3102A; Lonza). Lipid vacuoles were stained 
with Oil red O solution (O0625; Sigma-Aldrich), following 
manufacturer’s instructions. Osteogenic differentiation was 
induced with human MSC Osteogenic Medium (PT-3002; 
Lonza). Calcium deposits were stained with Alizarin red S 
(A5533; Sigma-Aldrich), following manufacturer’s instruc-
tions. Chondrogenesis was induced with human MSC 
chondrocyte differentiation medium (PT-3003; Lonza), 
and the presence of extracellular matrix-producing cells 
was assessed with Alcian blue staining (B8438; Sigma-
Aldrich). Due to high proliferation of CB-MSCs cultured in 
SPE-IV, initial seeding densities were modified to 0.5 × 103 
cells/cm2, and the induction lasted only 2 weeks. Images 
of stained cells were taken with a Nikon Eclipse TS100 
microscope (Nikon).
MicroRNA Expression Profiling
For miRNA studies, total RNA was isolated using 
the miRNeasy Mini kit (Qiagen) following manufac-
turer’s instructions. RNA purity was determined by 
measuring the absorbance A260/A280 in a Nanodrop 
spectrophotometer. RNA integrity was assessed using 
electrophoretic techniques. MicroRNA expression pro-
filing was performed in triplicate with an RT2 miRNA 
PCR Array System (Qiagen) following the manufacturer’s 
instructions. Briefly, 4 mg of total RNA, including small 
RNAs like miRNAs, was reverse transcribed into first-
strand cDNA using the RT2 miRNA First Strand Kit. 
Then the templates were mixed with RT2 SYBR Green 
qPCR Master Mix (Qiagen), and 25 ml was aliquoted 
into each well of the eight 96-well plates containing the 
704 predispensed miRNA-specific assays based on the 
Sanger mirBASE Release 14 (University of Manchester, 
Manchester, UK). Amplifications were carried out in a 
Bio-Rad CFX96 Real-Time PCR Detection System instru-
ment (Bio-Rad Laboratories). After amplification, rela-
tive expression of each miRNA was determined with the 
DDCt method using the online software RT2 Profiler PCR 
Array Data Analysis version 3.5 (http://pcrdataanalysis.
sabiosciences.com/pcr/arrayanalysis.php) and the global 
mean normalization procedure5,15,16. To detect only the 
reliable amplifications, all the wells giving rise to ambig-
uous double or flattened amplified product melt curve 
peaks were removed. In addition, following manufac-
turer’s instructions, an absolute Ct value of 35 was set 
as the maximum threshold, since low-expressed miRNAs 
giving rise to high Ct values might be PCR amplifica-
tion artifacts or miRNA machinery by-products17. Then 
array data of two small RNAs (miR-16 and miR-29b) 
were confirmed by qPCR using the miScript II RT Kit 
for cDNA synthesis (Qiagen) and miScript SYBR Green 
PCR Kit (Qiagen) as per the manufacturer’s instructions. 
Briefly, 1 μg of total RNA was first polyadenylated and 
then reverse transcribed to generate first-strand cDNA. 
cDNA was diluted in RNAse-free water and prepared for 
qPCR with miRNA-specific forward primers (miScript 
Primer Assay, Qiagen), a universal qPCR primer included 
in the miScript SYBR Green PCR mix, and SYBR Green 
reference dye. All reactions were run in a Bio-Rad CFX96 
Real-Time PCR Detection System instrument (Bio-Rad 
Laboratories). Relative miRNA levels were normalized 
to RSU snRNA, a verified endogenous control. Verified 
mRNA targets of selected miRNAs were identified using 
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the miRWalk database (http://www.umm.uni-heidelberg.
de)18. Final target lists were then uploaded to GeneCodis 
free software (Centro Nacionál de Biotecnología, Madrid, 
Spain) for functional interpretation using default filters19–21.
Statistical Analysis
Nonparametric Kruskal–Wallis tests followed by 
Dunn’s multiple comparisons tests were performed to 
evaluate CBU characteristics. One-way analysis of vari-
ance (ANOVA) followed by Newman–Keuls (mean nor-
malized telomere length) (Fig. 3A) or Tukey’s (relative 
telomere length) (Fig. 3B) multiple comparisons tests 
were performed to evaluate CB-MSC telomere length 
after normal distribution of the datasets was verified by a 
D’Agostino–Pearson omnibus normality test. GraphPad 
Prism version 6.00 for Windows (www.graphpad.com; 
GraphPad Software, San Diego, CA, USA) was used to 
perform all of the previously described statistical analy-
ses. Concerning the miRNA target study, the GeneCodis 
free software (Centro Nacionál de Biotecnología, Madrid, 
Spain) was run to find statistically miRNA-dependent 
enriched biological processes with respect to the entries 
of the whole human genome19–21. A value of p < 0.05 was 
used to determine statistical significance.
RESULTS
Chemically Defined Medium-Based Culture Conditions 
for the Isolation of Cord Blood Stromal Colonies
A total number of 100 CBUs were processed for this 
study, and different standard experimental approaches 
were investigated. The aim was to determine which isola-
tion procedure best supported the generation of stromal 
colonies from CB under new culture conditions, taking 
into account efficiency but also feasibility of the proce-
dure (for the complete schematic, see Fig. 1).
In a first series of isolations the importance of the col-
lagen I–III coating was investigated for the optimal use 
of a chemically defined medium containing, among other 
bioactive molecules, two important growth factors: IGF-I 
and bFGF. Whole blood samples versus immunodepleted 
fractions were compared, and the appearance of the first 
fibroblastic colony was considered as a positive event. 
Positive events on coated surfaces were obtained from 
five whole blood samples (14 total units) and from two 
immunodepleted fractions (5 total units). On the contrary, 
without the coating no positive event was observed (5 
whole blood samples and 11 immunodepleted fractions) 
(Fig. 1A).
In a second set of experiments, the addition of a stan-
dard percentage of serum was investigated as a possible 
replacement of the collagen I–III coating, based on the 
common practice of coating plastic surfaces with serum. 
In this way, positive events were obtained from three 
whole blood samples (6 total units) and from 17 immu-
nodepleted fractions (30 total units), representing the 
most efficient isolation strategy for the experimental con-
ditions reported herein.
The analysis of CBU characteristics demonstrated that 
the observed results were not biased by major differences 
between the experimental groups in terms of time elapsed 
from CB collection to processing (Fig. 1C) or WBC content 
(Fig. 1D), two crucial parameters for CB-MSC isolation8,9. 
The evaluation of processed sample volume revealed that 
no statistically significant differences were present within 
whole blood (WB, WB coating, and WB serum condi-
tions; Fig. 1E) and immunodepleted (ID, ID coating, and 
ID serum conditions; Fig. 1F) experimental groups.
Following this experimental design, the use of serum 
as a substitute for collagen I–III coating to culture the CB 
immunodepleted fraction appeared as the most promising 
approach to further ameliorate the generation of stromal 
cell colonies, due to its higher isolation efficiency. Thus, 
in order to further improve this already relatively high 
rate of positive events, L-glutamine supplementation as 
a major energy source for cultured cells was tested in 
immunodepleted fraction isolation experiments (com-
plete medium) to offer a more favorable environment for 
colony generation, along with a preference for signifi-
cantly richer-in-volume (³20 ml threshold) CBUs com-
pared to the other immunodepleted samples (ID serum 
and L-glutamine condition; Fig. 1F). Under these condi-
tions, positive events were observed in 79% of the pro-
cessed samples (23 out of 29 units) (Fig. 1B). Due to this 
high efficiency, we focused on this method for the isola-
tion and expansion of CB-MSC populations for all of the 
subsequent studies.
CB-MSC Proliferative Properties
Following the most efficient isolation conditions 
(n = 23 units with positive events), the first colonies of 
plastic adherent cells appeared reasonably soon [a median 
of 13 days after seeding (min 5, max 22 days)], with a 
colony number per processed unit ranging from 1 to 5. 
Interestingly, there were almost no other “contaminant” 
adherent cell types, like osteoclast-like or nonprolifera-
tive fibroblast-like cells. The first trypsinization occurred 
with a median of 24 days after seeding (min 7, max 41) 
and the median number of cells harvested from passage 0 
was 0.37 × 106 cells (min 0.05, max 2.59 × 106 cells).
Three CB-MSC populations were established, which 
were named CB-MSC 1, 2, and 3, each starting from a 
single colony derived from a distinct CBU (unrelated 
donors). All three CB-MSC populations were extensively 
characterized along long-term culture for growth kinetics, 
immunophenotype, and molecular profile. The CB-MSC 
growth curves are shown in Figure 2A. For all of the pas-
sages, 1,500 cells/cm2 was the optimal seeding density, 
Delivered by Ingenta to: Guest User
IP: 193.204.172.140 On: Mon, 14 Nov 2016 13:39:06
Article(s) and/or figure(s) cannot be used for resale. Please use proper citation format when citing this article including the DOI,
1506 BARILANI ET AL.
Figure 1. Complete experimental schematic. The two graphs represent isolations performed without (A) or with (B) serum supple-
mentation, and they specify further experimental conditions (diagram branches) and isolation success as percentage (dotted line rect-
angles). The following CB unit parameters were evaluated for the different whole blood (WB) and immunodepleted fraction (ID) 
isolation experiments: time from collection to processing (C), WBC content (D), and processed volume (E, F). Box and whisker graphs 
show 25th and 75th percentiles (plot hinges), median, minimum, and maximum values (C, D) or 10th and 90th percentiles with outside 
values (E, F). **p < 0.01; ***p < 0.005; ****p < 0.001; ns = statistically nonsignificant difference.
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which allowed us to trypsinize the cells once a week with 
medium changes every 3–4 days. In two cases (CB-MSC 
2 and 3) growth arrest occurred only after reaching a 
CPD of 75, and only after passage 13, while CB-MSC 1 
reached a CPD of 45 and arrested its growth at passage 9. 
We also noted that the cells proliferated with a constant 
rate without high fluctuation in terms of population dou-
blings (CB-MSC 1, P1–P9: mean (m)PD = 5.1, standard 
deviation (SD) = 1.6; CB-MSC 2, P1–P15: mPD = 5.1, 
SD = 0.7; CB-MSC 3, P1–P13: mPD = 5.8, SD = 1.3), or 
of days between two subsequent trypsinizations during 
almost all the culture (a mean of 7 days from P1 to P7 for 
the three populations; SD = 1.3). If we consider the three 
CB-MSC populations together from passage 1 to passage 
9, the result is a mean growth curve that approximates 
almost perfectly a linear function, constantly increasing 
the CPD of 5.6 after every passage (Fig. 2B).
At passage 1, the CFU-F assay was performed, and all 
the three CB-MSC populations could generate colonies 
under low-density seeding conditions (a mean of 76 colo-
nies; SD = 35) (Fig. 2C).
CB-MSC Morphology
In order to give quantitative information about cell mor-
phology, two parameters were measured by image analyzer 
software: diameter of the nucleus and cell major axis. The 
morphology of CB-MSC 1 (Fig. 2D) was compared with that 
of LL-CB-MSCs cultured in the standard medium (Fig. 2E). 
The results are summarized in Figure 2F. Although no statis-
tical significance was observed, the ratio seemed to be lower 
for CB-MSC 1, as shown by both the mean and median, but 
concomitantly also presented the greatest degree of varia-
tion, as shown by SD and minimum and maximum values. 
This was consistent with previously reported data12, com-
paring CB-MSC morphology of the same population in two 
different media. No significant differences in cell morphol-
ogy were observed among CB-MSC 1, 2, and 3 or between 
LL-CB-MSCs and CB-MSC 2 or 3 (data not shown).
Figure 2. Biological characterization of established CB-MSC populations. Proliferation rate (A) and mean proliferation rate (B) of the 
three CB-MSC populations. The error bars in (B) represent standard deviation. A representative image of CB-MSC CFU-F is shown 
(C). (D–F) Morphology study: images of CB-MSCs cultured under standard conditions (D) or relying on the complete medium (E); 
(F) summarizes the results.
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Telomere Length Assessment
To further characterize the CB-MSC populations, 
telomere length was assessed (Fig. 3A and B). Evaluating 
the established CB-MSC populations together, a dramatic 
and significant decrease in mean telomere length was 
observed from passage 0 to passage 1 (Fig. 3A), after 
which telomere length was maintained at a constant (sta-
tistically nonsignificant differences between P1 and P9 
samples). Intriguingly, the CB-MSC populations evalu-
ated separately at passage 0 showed a similar relative telo- 
mere length for CB-MSC 2 and 3, while CB-MSC 1 had a 
telomere length significantly shorter (three times).
Steady-State Gene Expression Profile Along 
Prolonged Culture
The genes analyzed included typical MSC differen-
tiation markers: C/EBP-b for adipogenesis, COL10A1 
for chondrogenesis, and ALP and OSTERIX for osteo-
genesis. Additionally, genes typically expressed by cells 
from other lineages, such as neural cells [brain-derived 
neurotrophic factor (BDNF), MUSASHI, sex-determining 
region y-box 2 (SOX2)], or implicated in the angiogenic 
[angiopoietin 1 (ANGPT1), intercellular adhesion mol-
ecule 1 (ICAM-1), vascular cell adhesion molecule 1 
(VCAM-1)] and myogenic (MYOD, PAX3) processes 
were considered. The mean gene expression levels of the 
CB-MSC populations evaluated together revealed stable 
and mostly unchanged expression along prolonged cul-
ture of the majority of the genes taken into consideration 
(Fig. 3C). The only genes that showed a steady increas-
ing trend in their transcription levels, albeit not signifi-
cant, were chondrocytic COL10A1 and ANGPT-1, whose 
expression lead to a threefold difference between P3 and 
P7 samples.
Figure 3. Telomere length. For telomere length analysis, passages 0, 1, 3, 5, 7, and 9 were studied. The histogram in (A) shows the mean 
value for each passage of the three analyzed CB-MSC populations with the standard deviation. The data are presented as percentage 
relative to P0 telomere length value. The histograms in (B) show mean value from triplicates of real-time qPCR analysis, again associ-
ated with standard deviation. ***p £ 0.005; *p £ 0.05. (C) Steady-state transcription profile. The mRNA levels (P3-5-7) of genes involved 
in adipogenesis, chondrogenesis, myogenesis, and osteogenesis were taken into consideration. Also the expression of neurotrophic and 
angiogenetic growth factors as well as neural and endothelial markers was analyzed. The histograms represent mean gene expression of 
the three CB-MSC populations analyzed, while the error bars show the corresponding standard error of the mean (SEM) values.
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Immunophenotype of CB-MSC Populations
All CB-MSCs stained positively for canonical MSC 
surface markers CD90, CD105, and CD73, whereas they 
were negative for CD45 and CD34 (Fig. 4A) (data not 
shown for CB-MSC 3). A deeper analysis with a more 
extensive surface marker panel was applied to investigate 
if the observed differences among CB-MSCs in growth 
properties and passage 0 relative telomere length could 
correlate with a specific immunophenotype. With this in 
mind, CB-MSC 1 was compared to CB-MSC 2 at pas-
sages 3 and 5. CB-MSC 2 was considered representative 
of both CB-MSC 2 and 3 behavior, since they shared the 
same growth characteristics and telomere length. Both 
populations were strongly positive for CD146. In addition, 
CB-MSCs were completely negative for CD31, CD133, 
CD117, and CD144, and almost completely negative 
for a-smooth muscle actin (a-SMA) and stage-specific 
embryonic antigen-4 (SSEA4) (Fig. 4A). Concerning 
platelet-derived growth factor receptor (PDGFR)-b, 
nerve/glial antigen 2 (NG2), CD56, and CD271 some 
marked differences were observed (Fig. 4B). PDGFR-b, 
NG2, and CD56 were more expressed in CB-MSC 2. 
Mean fluorescence intensity (MFI) ratios summarized in 
Figure 4C showed a marked difference along passages for 
PDGFR-b in both populations. The case of CD271 was 
peculiar since CB-MSC 1 did not express CD271 at pas-
sages 3 nor 5, whereas CB-MSC 2 at passage 3 showed a 
portion of CD271+ cells (MFI ratio = 5.0) corresponding 
clearly to a distinct subpopulation, as shown in the den-
sity plot in Figure 4D. However, this subpopulation was 
absent at passage 5 (MFI ratio = 1.8).
Maintenance of Differentiation Potential
To evaluate the differentiation potential some changes 
in the standard protocols were developed. Mostly 
because the proliferation potential of these CB-MSCs 
was too high, it was difficult to keep the standard 
induction protocols without an earlier cell detachment. 
CB-MSCs were differentiated toward the adipogenic, 
osteogenic, and chondrogenic lineages. Adipogenesis 
was confirmed by Oil red O staining of lipid vacuoles 
(Fig. 4E). Osteogenesis was assessed by Alizarin red S 
staining, which evidenced the conspicuous production of 
calcium deposits (Fig. 4F). Chondrogenesis was detected 
by presence of Alcian blue-positive cells (Fig. 4G). No 
macroscopic differences in the differentiation capacity 
toward the adipogenic, osteogenic, and chondrogenic 
lineages were observed for the three CB-MSC popula-
tions at the analyzed passage.
Identification of miRNA Expression Profiles
To unravel whether molecular differences could also 
be found between CB-MSC 2 and 3, which demonstrated 
homogenous cell growth, clonogenic properties, telomere 
length, and molecular signature, a whole-genome com-
parative gene expression profiling analysis was performed 
using arrays able to monitor the expression of 704 miRNA 
sequences. After a quality control procedure, 243 and 244 
miRNAs out of the total 704 available sequences were 
detected in CB-MSC 2 and CB-MSC 3, respectively. In 
order to exclude potential erroneous miRNA expression 
changes introduced by handling or technical pitfalls, ran-
dom individual real-time qRT-PCR reactions on cDNA 
obtained from two biological replicates of CB-MSC 2 and 
3 were performed. Thus, the expression of two miRNAs 
belonging to unrelated families (miR-16 and -29b), both 
normalized with the small nuclear RNA RNU6-2 used as a 
housekeeper, was analyzed, and then the values were com-
pared with those obtained in the arrays (also normalized 
with RNU6-2). As shown in Figure 5A and B, the inde-
pendent samples showed consistent values (within twofold 
modulation) with the array data. We also checked whether 
the ratios between CB-MSC 2 and CB-MSC 3 in the single 
PCR amplifications for these two miRNAs were consis-
tent in comparison with the array data and again such 
values did not show modulations higher than twofold units 
(Fig. 5C). All of these tests on independently processed 
and assayed samples confirmed the validity of the pro-
posed array results, although the design of the arrays with 
single probes leaves open the possibility of few potential 
technical-dependent miRNA expression variations.
To compare miRNA expression patterns between 
CB-MSC 2 and 3, a pairwise comparison of the two 
expression profiles was performed generating a distri-
bution of normalized intensity with a correlation coeffi-
cient of 0.96 (Fig. 5D). This finding demonstrates that 
the two CB-MSCs share a strikingly similar miRNA 
expression pattern, thus accounting for possible phe-
notypic and functional overlap. Nevertheless, a deeper 
characterization was undertaken selecting miRNAs with 
fourfold or higher differential expression, corresponding 
to a difference of at least two normalized Ct value units. 
Distinct molecular signatures were extracted consist-
ing of increased expression of four miRNAs (miR-450a 
+10.4, miR-369-3p +4.5, miR-10a +4.1, miR-10b +4.1) 
and downregulation of one miRNA (miR-27a* −4.3) in 
CB-MSC 2 compared to CB-MSC 3. Notably, none of 
the differentially expressed miRNAs is among the most 
expressed ones. In fact, the five most expressed miRNAs 
are conserved and constant between the two CB-MSCs 
(miR-21, miR-125b, miR-16, miR-1260, and miR-199-
a-3p) with the two most expressed (miR-21 and miR-
125b) recently proposed as stem cell markers22–24. Next, a 
gene target identification for the five more differentially 
modulated miRNAs was performed using miRWalk, a 
database that presents literature information on experi-
mentally validated miRNA interactions with genes18. 
Mining the miRWalk database, 239 validated targets were 
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shown to be regulated by these miRNAs. Then, on the 
identified genes, the GeneCodis software showed that the 
two most statistically enriched biological processes were 
connected with regulation of transcription [from RNA 
polymerase II promoter—Gene Ontology (GO): 0045944, 
p < 0.001; DNA-dependent—GO: 0045893, p < 0.001], a 
result in agreement with the most enriched cellular com-
ponent of the submitted gene products that resulted to 
be the nucleus (GO: 0005634, p < 0.001). Finally, such 
a relationship with gene regulation was supported by the 
molecular functions uncovered by these regulated genes 
that appeared to be directly linked with an enrichment in 
the protein-binding category (GO: 0005515, p < 0.001), 
especially associated with DNA-binding transcription 
factor activity (GO: 0003700, p < 0.001) and DNA-
binding properties (GO: 0043565, p < 0.001).
Rescue of SL-CB-MSC Short-Living Phenotype
Two SL-CB-MSC populations previously obtained in 
the standard medium were thawed at passage 2 and cul-
tured in the complete medium to observe whether their 
short-living phenotype could be rescued. From a mor-
phological point of view the cells grown in the standard 
medium seemed to possess a more spindle-like versus a 
more compact morphology, compared to the same cells 
grown in the complete medium (Fig. 5E). Strikingly, both 
SL-CB-MSC populations showed an increased life span 
and higher CPD peaks (from a value of 5.4-10.8 to 20.2-
21.3), doubling the maximum number of passages (from 
P2–3 to P7) in the complete medium compared to the 
standard one (Fig. 5F). Notwithstanding this ameliorated 
growth kinetic, they did not reach the same high perfor-
mances of CB-MSC 2 and 3 of the present study.
DISCUSSION
Over the last years, the clinical use of allogenic CB 
for hematopoietic stem cell (HSC) transplantation has 
increased dramatically, and more recently CB was also 
used as a source of MSCs25. Unfortunately, the low fre-
quency of these MSCs in CB and the consequent low 
isolation efficiency still is a major problem, which keeps 
this source far from being widely recognized for its pos-
sible role in regenerative medicine. In this regard, several 
attempts and different methodological approaches have 
been implemented in order to more efficiently isolate 
MSCs from CB. Notwithstanding, this source still offers 
some advantages in comparison to the more classical ones, 
including the easy procurement, the absence of risks to 
donors, and the reduced risk of transmitting infections26. 
Up until now, one of the crucial CB characteristics that 
makes CB-MSC isolation feasible is the “freshness” of 
the CBU (£2 h from CB collection to processing)27.
In our laboratory we set up a standard strategy10 allow-
ing the isolation of long-living (P > 7), high proliferative 
CB-MSCs with multipotent differentiation capabilities 
(LL-CB-MSCs). Yet, the efficiency of this process should 
be further improved, especially if clinical application is 
the final goal. In the last years several commercially avail-
able media have been proposed on the market for MSC 
culture; however, they are mainly developed and tested 
for MSCs from bone marrow and adipose tissue, whose 
isolation efficiency is close to 100%. In this context, with 
respect to the first goal of our work, we succeeded in 
defining some culture conditions for obtaining CB-MSC 
colonies at high efficiency, overcoming a major draw-
back, which hampers a widespread availability of this 
kind of therapeutic cell. The adopted strategy combines 
an immunodepletion treatment of CBUs and a chemically 
defined medium specifically developed for optimal MSC 
isolation and culture. In this way we also skipped the 
use of a collagen I–III coating that could possibly make 
the translation of this system in a clinical-grade setting 
in some countries more difficult. With this approach and 
a preference for rich-in-volume samples, the successful 
rate of CB-MSC colony generation was dramatically 
improved up to 79%, avoiding strict quality selection of 
the starting material in terms of cellularity and “fresh-
ness.” In addition, no osteoclast-like cell contamination, 
which badly affects the newly born stromal colonies28, 
was observed. This could be due to the presence of IGF-1 
in the defined medium, which has been demonstrated to 
reduce monocyte adhesion properties29. The same effect 
was reported also for bFGF, the other growth factor pres-
ent in the chemically defined medium30.
The second goal of this work was to investigate the bio-
logical features of CB-MSCs obtained in this new isolation 
and culture system, focusing on growth properties, on the 
molecular pattern, and also on the protein level. The pro-
liferation curves of the expanded CB-MSCs reached higher 
CPD peaks in comparison with CB-MSCs isolated and cul-
tured under standard conditions10, and they showed a stable, 
linear, and homogeneous growth. Based on the International 
Society for Cellular Therapy (ISCT) classification31, the 
CB-MSCs obtained expressed the classical MSC markers 
and maintained them during passages and possess multipo-
tent differentiation abilities. The cells were also able to gen-
erate colonies under low-density seeding conditions, even 
if their morphology differed from that of colonies obtained 
from CB-MSC cultured in standard conditions10, being more 
compact and presenting a higher cell density. This again 
could be ascribed to the synergic action of IGF-1 and bFGF, 
which add their effect to that of serum growth factors.
Telomere length was dramatically decreased from pas-
sage 0 to passage 1, but then was maintained at the same 
level along culture, suggesting that the medium tested is 
not sufficient to prevent repetitive telomere sequence loss 
at the initial phases of the culture establishment, but none-
theless it could play some role in stabilizing its decrease. 
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Unfortunately, the extreme difficulty to have more than 
one colony able to give rise to a CB-MSC population 
from the same CBU has hampered, until now, the abil-
ity to perform proper experiments to address this issue, 
in which standard and novel media effects on telomere 
length could be compared. Some minor differences were 
found between the CB-MSC populations. In particular, 
telomere length dissimilarities correlated with different 
replicative potentials: CB-MSC 1 presented the short-
est telomere and arrested its growth at passage 9, while 
CB-MSC 2 and 3 showed higher telomere length and 
could be cultured at least until passage 13.
Moving to an extensive immunophenotype profiling, 
some noncanonical surface markers were found to be 
expressed. These surface markers were all classic pericytic 
markers such as CD146, NG2, CD56, and even the more 
relevant PDGFR-b32. Intriguingly, pericytes have been 
proposed as the precursors and sort of in vivo counterpart 
of MSCs33, so that such an immunophenotype could mirror 
a CB-MSC state reminiscent of its pericytic precursor.
In addition, CB-MSCs showed very homogenous gene 
expression profiles. The study revealed stable expression 
of key genes involved in distinct differentiation path-
ways, suggesting that the tested medium succeeded in 
maintaining the CB-MSC cultures in an undifferentiated 
state. To confirm the homogeneity found at the molecular 
level between the CB-MSCs endowed with the longest 
telomeres, we addressed their miRNA signatures using 
a miRNA array. Interestingly, we observed that in these 
CB-MSCs the most expressed miRNAs were stemness-
related miR-21 and miR-125b22–24.
Based on our recent report10 describing two CB-MSC 
populations distinguished by telomere length and life span, 
we wondered if the analyzed populations were bona fide 
SL- and LL-CB-MSCs, even if characterized by growth 
properties enhanced by a culture medium much richer than 
the standard one. This hypothesis was substantiated by the 
“rescue” experiments, as SL-CB-MSCs previously isolated 
following the standard methodology increased the number 
of total passages and of population doublings in response 
to this novel culture system. Nevertheless, the “rescued” 
SL-CB-MSCs still possessed a shorter life span compared 
to LL-CB-MSCs, confirming that two distinct stromal popu-
lations exist in cord blood irrespective of the culture condi-
tions adopted to isolate or maintain them. It is also true that 
even the observed partial rescue of the SL-CB-MSC short-
living phenotype could represent a relevant effect to take 
into account when such a population is the only one isolated 
from a specific CB unit. This is of paramount importance, 
most of all in the context of private CB banking, where clini-
cally relevant CB-MSC numbers must be obtained necessar-
ily from related or autologous CBUs.
In conclusion, we assessed how medium composition 
can exert a heavy influence on cell behavior, so that our last 
message in the bottle is that new media with more complex 
composition than the standard ones can have advantages 
on cell culture, although a deep characterization is strongly 
encouraged to really define how the new culture system 
may modulate the cells you are dealing with.
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a b s t r a c t
Stem cell therapy with human mesenchymal stem cells (hMSCs) represents a promising strategy in
spinal cord injury (SCI). However, both systemic and parenchymal hMSCs administrations show signif-
icant drawbacks as a limited number and viability of stem cells in situ. Biomaterials able to encapsulate
and sustain hMSCs represent a viable approach to overcome these limitations potentially improving the
stem cell therapy. In this study, we evaluate a new agarose/carbomer based hydrogel which combines
different strategies to optimize hMSCs viability, density and delivery of paracrine factors. Speciﬁcally, we
evaluate a new loading procedure on a lyophilized scaffold (soaked up effect) that reduces mechanical
stress in encapsulating hMSCs into the hydrogel. In addition, we combine arginineeglycineeaspartic acid
(RGD) tripeptide and 3D extracellular matrix deposition to increase the capacity to attach and maintain
healthy hMSCs within the hydrogel over time. Furthermore, the ﬂuidic diffusion from the hydrogel to-
ward the injury site is improved by using a cling ﬁlm that oriented efﬁcaciously the delivery of paracrine
factors in vivo. Finally, we demonstrate that an improved combination as here proposed of hMSCs and
biomimetic hydrogel is able to immunomodulate signiﬁcantly the pro-inﬂammatory environment in a
SCI mouse model, increasing M2 macrophagic population and promoting a pro-regenerative environ-
ment in situ.
© 2015 Elsevier Ltd. All rights reserved.
1. Introduction
Many treatments (neuroprotective and/or neuroregenerative)
have been proposed to counteract the neuropathological evolution
of spinal cord injury (SCI) [1e5]. Among these, stem cell therapy
represents a promising strategy [6e8] and accumulating data show
that human mesenchymal stem cells (hMSCs) could be a real
therapeutic approach in tissue repair after SCI [9e11]. Indeed,
coherently with a multi-faceted SCI neuropathology, hMSCs are
potentially able to counteract many harmful events and to sustain
regeneration through several processes [10]. Different therapeutic
effects have been proposed for hMSCs, but it is now well known
that a paracrine effect [12], instead of a potential differentiation or
transdifferentiation into neuronal or glial cells [13,14], is the most
promising approach to exploit the therapeutic efﬁcacy of the
hMSCs [12,15,16]. In fact, hMSCs can act therapeutically by releasing
exogenous trophic factors [17,18] and/or by modulating, through
several factors, the immune system response [19e21]. However,
different limitations are still to be overcome in using hMSCs as
therapeutic opportunity in SCI. Speciﬁcally, cell therapy delivered
systemically (intravenous injections) could lead to a limited efﬁcacy
due to the unfeasibility of the cells to cross the blood brain barrier
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(BBB) and reach the injured site where they could be more useful
[22e24]. Furthermore, a cellular systemic administration may give
rise to potential side effects (pulmonary embolus) [25] that should
not be underestimated. On the other side, an intrathecal injection
could cause the loss of many cells in the intrathecal space or in the
cerebrospinal ﬂuid [24,26] or could stress and damage cells through
mechanical forces [27], thwarting the effort to treat directly the
injured site. Another proposed approach is a direct injection in the
parenchyma, however, this could lead to a limited viability of stem
cells due to both ischemia [28,29] and adverse environment in the
injured site that follow SCI [29,30]. In order to overcome these
drawbacks, new delivery strategies have been proposed by using
original biomaterials [30e32]. Particularly, hydrogels offer the
possibility to load and sustain both in vitro and in vivo hMSCs
creating an optimal niche close to the injured site, but preserving
them from the hostile tissue [30,33]. A variety of hydrogels (natural
or synthetic) has been proposed as scaffolds able to allocate
different stem cells [32,34e36]. Nevertheless, these scaffolds have
been evaluated only for their own capacity to maintain the cell
viability for a short time in vitro [37,38] and very few attempts have
been proposed for an in vivo treatment [39,40]. However, an opti-
mized scaffold able to act as a reservoir of neuroprotective factors
secreted by hMSCs has not been developed and investigated yet.
There are some concerns in using these scaffolds as potential
reservoir in vivo. One relevant limit in themaintenance of stem cells
allocated in a scaffold is the loss of adhesion due to the scaffold
structural properties that do not represent appropriately a biolog-
ical niche. In particular, a speciﬁc cell death (anoikis) occurred
when hMSCs are not able to adhere to a biologic supportive niche
such as an appropriate extracellular matrix (ECM) [6,41]. ECM has
been demonstrated to be a crucial element to sustain hMSCs
adhesion, trophic support and survival [42e44], maintaining and
preserving also their stemness [45]. So far, only a few studies have
been performed to mimic a sustainable ECM for hMSCs in 3D
scaffolds. But just one single molecule at time (e.g. ﬁbrin, laminin,
collagen, ﬁbronectin or arginineeglycineeaspartic acid (RGD)
peptide) has been proposed and characterized [35,46e48]. How-
ever, these approaches could not be able to favor appropriately
hMSCs adhesion to the scaffold since they do notmimic native ECM
that is a combination of several proteins, cytokines and growth
factors [49]. Thus, an alternative supporting strategy able to
improve the adhesion and viability of the stem cells into the
hydrogel is needed. In this study, we propose a new biomaterial
coatedwith 3D ECM, with the aim to create a more optimized niche
able to better sustain hMSCs viability and healthy.
2. Materials and methods
2.1. Hydrogels synthesis
Hydrogels were prepared by batch reaction in a phosphate
buffered saline solution (PBS, SigmaeAldrich) at about 80 C in
which a polymeric solution was achieved by stirring polymers:
carbomer 974p (branched polyacrylic acid, MW ¼ 1 MDa, Fagron),
agarose (MW ¼ 300 kDa, Invitrogen) and polyethylene glycol (PEG,
MW ¼ 2000 Da, SigmaeAldrich). The composition is: 9 mL PBS,
50 mg carbomer 974p, 300 mg PEG and 50 mg agarose [50]. The
reaction pH was indeed kept neutral with NaOH 1 N. The effective
gelation and reticulation were achieved by means of electromag-
netic stimulation (500 W power irradiated) for 15 s per 5 mL of
polymeric solution. Themixing reactor was kept closed to avoid any
eventual loss of solvent vapors, and the gelation was then achieved
in a 48 multiwell cell culture plate (0.25 mL each with the cylinder
diameter of 1.1 cm) inwhich the gelling solutionwas poured during
cooling.
2.2. RGD hydrogel synthesis
RGD functionalized hydrogels (HG RGD) were prepared as pre-
sented in previous work [51]. Brieﬂy, the peptide was synthesized
manually using the stepwise solid phase Fmoc method and then
functionalized with azide group (RGD-azide). Polyacrylic acid (PAA,
MW ¼ 130 kDa) with propargyl group was synthesized and dia-
lyzed (PAA-propargyl). RGD-azide (25 mg) was suspended in THF
(5 mL) and PAA-propargyl (78 mg) was dissolved in distilled water
(10 mL). Two solutions were blended together and added copper
iodide (2.2 mg, 0.0116 mmol) and sodium ascorbate (2.2 mg,
0.0111 mmol). The reaction mixture was allowed to stir for 24 h at
60 C. Subsequently, it was cooled at 25 C and dialyzed against acid
solution consisting of distilled water (2000 mL), sodium chloride
(11.2 g) and HCl 37% w/w to reach pH ¼ 5; dialysis occurred for
three days, with daily replacement of dialysis solution. Finally, the
mixture was frozen at 20 C and then lyophilized and stored for
further use. PAA functionalized is blended in PBS at room temper-
ature, until complete dissolution together with branched PAA
(carbomer 974p). PEG is subsequently added and the system kept
stirred for 45 min; then the mixing is left to settle. The composition
is: 9 mL PBS, 40 mg carbomer 974p, 10 mg PAA-RGD, 300 mg PEG,
50mg agarose. NaOH 1 N is then added to adjust pH to 7.4 and then,
after the addition of agarose powder which is not soluble at room
temperature, the system is subjected to electromagnetic stimula-
tion (500 W irradiated power), heating up to 70e80 C to induce
condensation reactions, through interconnections of hydroxyl
groups. PAA carboxyl groups constitute crosslinking sites to be
reacted with hydroxyl groups from agarose and PEG, forming ester
bonds and altogether giving rise to the three dimensional matrix.
Mixing reactor was kept closed to avoid any eventual loss of solvent
vapors and the gelation was then achieved in a 48 multiwell cell
culture plate (0.25 mL each and with the cylinder diameter of
1.1 cm) where the gelling solution was poured during cooling. In
order to obtain lyophilized scaffolds, hydrogels were frozen on dry
ice for 5 min, transferred at80 C over night and then dried in the
following conditions: 1 mbar and45 C. The lyophilized gels were
sterilized for at least 3 h by UV illumination before cells seeding.
Obtained freeze-dried hydrogels resemble a sponge and for this
reason here after they are indicated as sponge-like hydrogels.
2.3. Cord blood human mesenchymal stem cells culture
Umbilical cord blood was collected from normal deliveries, after
written informed consent, in a multiple system bag (Macho-
pharma) containing 29 mL of citrate phosphate dextrose as anti-
coagulant. Brieﬂy, whole blood was centrifuged at 1900 rpm for
15 min, the plasma subsequently discarded and the buffy coat with
a portion of red blood cells collected was immunodepleted of
CD3þ, CD14þ, CD38þ, CD19þ, glycophorin A and CD66bþ using a
commercial kit RosetteSep® (StemCell Technologies), according to
manufacturer's instructions. In summary, the sample was incu-
bated with 50 mL/mL RosetteSep MSC enrichment cocktail for
20 min at room temperature to isolate MSC precursors.
The buffy coat was then diluted 1:2 with phosphate buffered
saline (PBS; Gibco), ethylenediaminetetraacetic acid (EDTA; Sig-
maeAldrich) and human serum albumin (HAS; Kedrion), and
separated under standard density gradient conditions (Ficoll Paque
Plus 1.077 ± 0.001 g/L; GE Healthcare). After, mononuclear cells
were then plated at 1  106 cells/cm2 in standard medium:
alphaMEM-GlutaMAX (Invitrogen) supplemented with 20% fetal
bovine serum (FBS, Life Technologies).
Cultures were maintained at 37 C in a humidiﬁed atmosphere
containing 5% CO2. After 48 h, non-adherent cells were removed
and fresh medium was added. At 80% conﬂuence, the cells were
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harvested using 25% TrypLE Select 1 (Gibco) and subcultured at a
concentration of 4  103 cells/cm2 until passage 3 [52]. From pas-
sage 3, when the cell population was homogenous with no he-
matopoietic contamination, human mesenchymal stem cells
(hMSCs) were used for in vitro and in vivo experiments. hMSCs
populations derived from ten umbilical cord blood unit, already
established and fully characterized for optimal growth properties
and deﬁned as long living (LL)-CBMSCs [52], were used for this
study. hMSCs identity deﬁnition is presented as supplementary
information (Fig. S1). All experiments have been conducted ac-
cording to the principles expressed in the declaration of Helsinki.
2.4. Classic loading
hMSCs were harvested and suspended at a density of
5  106 cells/mL in growth medium supplemented with 2 FBS.
Hydrogels were prepared as described above by mixing polymer
powders in PBS. The hydrogel was heated at 80 C to start gelation.
When hydrogel solution temperature fell below 40 C, a 1:1 solution
of cells and hydrogel was prepared (20 mL cells and 20 mL hydrogel).
Cells and hydrogel were mixed together and the ﬁnal solution was
pipetted into polystyrene cylinders (5 mm diameter) and let it
polymerize for 30 min in incubator at 37 C. After polymerization,
growth medium was added to polymerized hydrogels containing
cells. Each hydrogel contained approximately 100,000 cells.
2.5. Sponge-like loading
hMSCs were harvested and suspended at a density of
1.25  106 cells/mL in growth medium. 80 mL of cells were added
directly onto the sponge-like hydrogel (40 mL for each side).
Hydrogels were let to swell for 30 min in incubator at 37 C and
then 1 mL of growth medium was added. Each hydrogel contained
approximately 100,000 cells.
2.6. ECM quantiﬁcation
After 1, 7, 14 and 21 days after hMSCs seeding on sponge-like HG
RGD, the ECM deposition was quantiﬁed by Sirius Red staining.
Sirius Red is a method for collagen staining and it allows the
evaluation of the ECM deposition overtime [53,54]. In particular,
hydrogels were decellularized with an ammonium hydroxide
buffer containing Triton X-100, in order to remove cells but pre-
serving ECM deposition, as reported by Prewitz et al. [55] Brieﬂy,
hydrogels were immersed in a warm solution containing 0.5% of
Triton X-100 and 20 mM of ammonium hydroxide in PBS in fast
agitation for 10 min. After 3 washes in PBS, the ECMwas stained by
picro Sirius Red solution composed of 1% of Sirius Red (Direct Red
80, SigmaeAldrich) in a saturated aqueous solution of picric acid
(SigmaeAldrich) that was added to the hydrogels and maintained
for 30 min at room temperature. Then the excess of staining was
eliminated by 3 washes with acidiﬁed water (0.5% of acetic acid in
distilled water). To quantify the ECM staining, the Sirius Red dye
was extracted from the hydrogel through a solution of 0.05MNaOH
andmethanol [1:1], inwhich hydrogels were immersed for 1 h. The
obtained solution was evaluated by a spectrophotometer (Inﬁnite
M200, TECAN) at an absorbance of 540 nm.
2.7. Extracellular matrix (ECM) deposition
hMSCs were let to grow for 14 days on sponge-like HG RGD.
Then all the liquids around hydrogel were removed and the
hydrogels were frozen on dry ice for 5 min and then transferred
at80 C overnight. The lyophilization procedurewas conducted as
reported above.
2.8. Cellular density and viability analyses in vitro
hMSC density and survival were determined by analyzing
confocal images of live cells stained with calcein AM (1:1000,
Invitrogen). Calcein AM is a non-ﬂuorescent cell-permeant dye that
is converted to a green-ﬂuorescent calcein after acetoxymethyl
ester hydrolysis by intracellular esterases. It was added to the well
containing hydrogels for 30 min at 37 C. Then the medium was
removed and substituted with fresh growth medium. hMSCs
within the scaffold were stained with Calcein AM and acquired by
confocal microscope (Olympus Fv1000) equipped with Laser 488.
Three optical sections of the hydrogels spaced of 80 mm were ac-
quired at 10 magniﬁcation. The number of calcein AM positive
cells was measured using a “surface detection” tool of Imaris soft-
ware (Bitplane). The number of cells was evaluated as cellular
density (cells/mm2).
2.9. Scanning Electron Microscopy (SEM)
SEM analysis was performed in sponge-like HG RGD and HG
RGD þ ECM after 1 day from hMSCs seeding. Each hydrogel was
ﬁxed overnight in a buffer containing 1.5% of glutaraldehyde in
0.1 M of sodium cacodylate. Then hydrogels were dehydrated in an
increasing scale of alcohols and frozen at 80 C overnight. Before
SEM analysis hydrogels were dried and gold coated and then
analyzed at 10 kV with Evo 50 EP Instrumentation (Zeiss).
2.10. Cellular differentiation assays
hMSC differentiation after encapsulation in HG RGD þ ECM was
assessed by Real Time PCR. The gene expression for the three main
mesodermal lineage differentiation (osteogenic, chondrogenic and
adipogenic) was performed. Sponge-like HG RGDþ ECM containing
hMSCs cultured for 21 days in growth medium were analyzed. As
positive control, hMSCs cultured in HG RGD for 21 days and treated
with differentiation media were analyzed. In particular, to promote
adipogenesis, osteogenesis and chondrogenesis, commercial media
(Lonza S.p.A.) were used, and the manufacturer's protocols were
followed or slightly modiﬁed [52]. For information about differen-
tiation media full composition please refer to www.lonza.com. Data
are expressed as fold change compared to steady-state undifferen-
tiated hMSCs (negative control). Hydrogels were homogenized and
RNA was extracted using RNeasy mini kit (Qiagen), according to
manufacturer's instructions. Brieﬂy, hydrogels containing cells were
suspended in QIAzol Lysis Reagent and homogenized with a tissue
grinder. Chloroform was added to the homogenate and a phase
extraction performed. 0.3 mL of the aqueous phase were added to
450 mL of ethanol and loaded onto an RNeasy column. The column
was washed and RNA eluted in 50 mL of RNAse free water. RNA was
quantiﬁed by a spectrophotometer (Inﬁnite M200, TECAN) at
260 nm for all samples, frozen at 20 C and stored until use.
Reverse transcription was carried out using iScriptTM cDNA
Synthesis Kit (Bio-Rad Laboratories Ltd). Real time PCR was per-
formed on a CFX96 Real Time Systemusing Sso FastEva Green Super
mix (Bio-Rad), according to the manufacturer's instructions. The
expression of the following genes was evaluated: alkaline phos-
phatase (ALP), runt-related transcription factor 2 (RUNX2) and
osterix are genes involved in various stages of osteogenic differ-
entiation [56]; aggrecan (ACAN) and type 10 collagen alpha 1
(COLLX) are genes correlated to the late phase of chondrogenic
differentiation [57]; adipsin and fatty acid binding-protein 4
(FABP4) are genes actively expressed during the late phase of adi-
pogenic differentiation [58]. Ribosomal protein large P0 (RPLP0)
gene expression was used as control [59]. Speciﬁc primers used are
listed below:
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 adipsin (Fw: GACACCATCGACCACGA; Rev: CACGTCGCAGAGA
GTTC);
 FABP4 (Fw: AAAGAGAAAACGAGAGGATGA; Rev: AACGTCCCTTG
GCTTATG);
 RUNX2 (Fw: AAGGCTGCAAGCAGTATTTACAA; Rev: CTCGGATCCC
AAAAGAAGTTTTGCT);
 osterix (Fw: CCTGCTTGAGGAGGAAGTTCA; Rev: AGAGTTGTTGA
GTCCCGCAG);
 ALP (Fw: TACAAGGTGGTGGGCGGTGAACGA; Rev: TGGCGCAGGG
GCACAGCAGAC);
 ACAN (Fw: TCGCCAGGTGTGTGGGACTGA; Rev: ACTCAGCGAGT
TGTCATGGTCTGA);
 COLLX (Fw: ACTCCCAGCACGCAGAATCCA; Rev: TGGGCCTTTTAT
GCCTGTGGGC);
 RPLP0 (Fw: TGTGGGCTCCAAGCAGATGCA; Rev: GCAGCAGTTTC
TCCAGAGCTGGG).
2.11. Surgery
Procedures involving animals and their care were conducted in
accordance with institutional guidelines at the IRCCS d Institute
for Pharmacological Research “Mario Negri” in compliance with
national (Decreto Legge nr.116/92, Gazzetta Ufﬁciale, supplement
40, February 18, 1992; Circolare nr. 8, Gazzetta Ufﬁciale, July 14,
1994) and international laws and policies (EEC Council Directive 86/
609, OJL 358, 1, Dec. 12, 1987; Guide for the Care and Use of Labo-
ratory Animals, US National Research Council, 8th edition, 2011).
Adult C57BL/6J female mice (23e30 g) were anesthetized by
intraperitoneal injection of ketamine hydrochloride (IMALGENE,
100 mg/kg) and medetomidine hydrochloride (DOMITOR, 1 mg/kg).
Before surgery, animals received an antibiotic and analgesic subcu-
taneous treatment with Ampicillin (50 mg/kg) and Buprenorﬁn
(0.15mg/kg), respectively. The back of the animals was shaved at the
dorsal level and a cutaneous incision was made to expose the
backbone.Animalswereplaced onaCunningamSpinal CordAdaptor
(Stoelting) mounted on a stereotaxic frame. A laminectomy at the
T12 level was done to uncover the lumbar spinal cord. A moderate
compression of the spinal cord was obtained using an aneurysm clip
(30 g compressive force for 60 s) as described previously [50].
2.12. Cellular staining for in vivo tracking
Before the seeding in the scaffold, hMSCs were stained with the
marker of cellular viability 5-6-Carboxyﬂuorescein diacetate N-
succinimidyl ester (CFDA-SE, SigmaeAldrich), a cell-permeant
ﬂuorescent based tracer for long-term viable cell labeling. In
particular, suspended cells were incubated for 30 min at 37 C with
pre-warmed CFDA-SE solution in PBS (ﬁnal concentration 5 mM).
Then, 5 times the original staining volume of mediumwas added in
order to remove any free dye remaining in the solution. Cells were
then incubated for 5 min at 37 C. Finally, cells were centrifuged at
300 g for 10 min, resuspended in pre-warmed complete culture
medium and deposited in sponge-like HG RGD þ ECM.
2.13. In vivo positioning of hMSC in HG RGD þ ECM
hMSCs were encapsulated for 1 day in sponge-like HG
RGD þ ECM. Then, hMSCs loaded HG RGD þ ECM (a total of
25,000 cells/animal) was positioned in correspondence to the
injury level. The hMSC loaded hydrogel was secured by applying a
cling ﬁlm on the top, sealed at the edges with a tissue adhesive (3M
Vetbond). Dorsal muscles were then juxtaposed using absorbable
sutures and the skin was sutured. After the surgery, the animals
were kept on a warm pad for 30 min and then placed in separated
cages with facilitated access to food and water for recovery.
As controls for subsequent analyses, other groups of animals
were taken into consideration: animals treatedwith hMSCs directly
injected in the parenchyma, animals treated with conditioned
medium (CM) directly injected in the parenchyma, animals treated
with HG RGD þ ECM loaded only with CM. hMSCs and CM were
injected as follows: hMSCs were suspended at a concentration of
50,000 cells/mL and, using a 30G needle associated to the stereo-
taxic, they were injected (0.5 mL/site) very close to the epicenter of
the lesion (rostral edge) with a ﬂow rate of 0.25 mL/min. The needle
was positioned at the midline, then it was deepened into the pa-
renchyma to 0.6 mm below the pia mater. For the other groups, CM
was obtained after 1 day culture of hMSCs in culture plates. Using
the same protocol adopted for hMSCs seeding, CM was loaded into
the HG RGD þ ECM. Brieﬂy, 80 mL of CM were added directly onto
the sponge-like hydrogel (40 mL for each side). Then, hydrogels
were let to swell for 30 min in incubator at 37 C.
2.14. hMSCs in vivo tracking
In vivo tracking of viable hMSCs stained with CFDA-SE was ob-
tained using a stereomicroscope (Olympus SZX10). Animals with
the backbone and the hydrogel exposed were evaluated by a ste-
reomicroscope and a series of images of the entire hydrogel were
acquired at 1.6. Hydrogels acquisitions were made the same day
of the positioning (day 0) and at 3 or 9 days after the positioning.
CFDA-SE positive cells were counted using the “spots detection”
tool of Imaris software (Bitplane). The number of stem cells
detected in each hydrogel at day 0 was considered as 100% of sur-
vival. The number of cells detected in the same hydrogels at 3 or 9
days was then reported as a percentage of survival in respect to the
same hydrogel at day 0.
2.15. In vivo positioning of Hoechst hydrogels
After the spinal cord compression, sponge-like HG RGD was
loaded with 20 mL of 0.7 mg/mL Hoechst 33258 pentahydrate (bis-
benzimide) (Life technologies) and positioned at the injury level.
The animals were then divided in 2 groups, one with only the
positioning of Hoechst-loaded hydrogels onto the injury site, the
other where Hoechst-loaded hydrogel was secured by applying a
cling ﬁlm on the top, sealed at the edges with a tissue adhesive (3M
Vetbond). Dorsal muscles were then juxtaposed and the skin was
sutured. After the surgery, the animals were kept on awarm pad for
30min and then placed in separated cages with facilitated access to
food and water for recovery.
2.16. Spinal cord transcardiac perfusion
For histological evaluations, after 9 days from the Hoechst
hydrogels positioning, mice were deeply anesthetized with keta-
mine hydrochloride (IMALGENE, 100 mg/kg) and medetomidine
hydrochloride (DOMITOR, 1 mg/kg) and transcardially perfused
with 40 mL of sodium phosphate buffered (PBS) 0.1 M, pH 7.4,
followed by 50 mL of 4% paraformaldehyde solution in PBS. Spinal
cords were then removed, postﬁxed overnight in the same ﬁxative
and then transferred to 30% sucrose in PBS at 4 C overnight for
cryopreservation and stored at 4 C until use. The spinal cord was
embedded in OCT compound, frozen by immersion in N pentane at
45 C for 3 min and then stored at 80 C. Frozen tissues were
sectioned at 50 mmon a cryostat at20 C. Starting from the rostral
edge (about 6 mm rostral to the epicenter), one section every 10
was mounted on slides for a total of 24 sections (about 12 mm
sectioned) and coverslipped with a 50% glycerol solution in PBS
before to proceed with acquisition at 10magniﬁcation by confocal
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microscopy (Olympus Fv1000, Laser 405).
2.17. Hoechst distribution analysis
The quantiﬁcation of the Hoechst distribution and penetration
into tissue was performed using the free software ImageJ, making a
threshold based on signal intensity. The thresholded area was then
quantiﬁed and showed as total Hoechst delivery area evaluated in
the tissue. Furthermore, an evaluation of the Hoechst signal in each
slice sampled (each 10 sections) in a spinal cord region of 12 mm
was performed. Four animals per group were analyzed.
2.18. Flow cytometry
After 9 days of treatment by hMSCs loaded HD RGD þ ECM,
animals were decapitated and spinal cords were rapidly ﬂushed out
by the column. The region around the epicenter of the lesion was
put on a cell strainer (40 mm nylon mesh) and a cell suspensionwas
obtained by pressing with the plunger of a 10 mL syringe. Then the
cell strainer was washed with 5 mL of GKN solution pH 7.4 (8.00 g/L
NaCl, 0.40 g/L KCl, 0.93 g/L NaH2PO4, 1.42 g/L Na2HPO4, 2.00 g/L D-
glucose, 0.02% BSA). For each sample, 1.5 mL of the cell suspension
obtained was centrifuged at 2000 rpm for 5 min and pellet cells
were resuspended in 500 mL of FACS blocking (1% BSA, 5% FBS in
PBS). After 20 min of incubation in FACS blocking at 4 C, primary
antibodies CD11b-APC780 (ebioscience [1:100]) and CD45-PE
(BDbioscience [1:100]) were added and incubated for 20 min at
4 C in the dark. Then, 1 mL of PBS was added and samples were
centrifuged at 2000 rpm for 5 min. Pellet cells were resuspended in
1mL of FACS blocking before proceeding to FACS analysis. A speciﬁc
isotype antibody staining was performed as negative control.
Immunophenotyping analyses were performed on at least
1,500,000 cells for each sample by using MoFlo Astrios instruments
(Beckman Coulter) equipped with 488, 546 and 640 nm lasers.
Fluorescence pulses were detected using a band pass ﬁlter 671/20
for CD45, 795/70 for CD11b. Results were analyzed using Kaluza
software (Beckman Coulter). Data are expressed as percentage of
positive cells per gated event.
2.19. RNA analysis
After 9 days of treatment by hMSCs loaded HD RGD þ ECM,
animals were decapitated and spinal cords were rapidly ﬂushed out
by the column. The region around the epicenter of the lesion was
rapidly frozen on dry ice and stored at 80 C until use. Total RNA
was obtained from tissues using RNeasy Mini Kit (Qiagen), as
already reported above. Samples of total RNA were treated with
DNAse (Applied Biosystems) and reverse-transcribed with random
hexamer primers using Multi-Scribe Reverse Transcriptase (Taq-
Man Reverse transcription reagents; Applied Biosystems). Real-
time RT-PCR was performed according to the manufacturer's in-
structions using 2 ng of cDNA, 200 nmol of each primer and SYBR
Green master mix (Applied Biosystems) in a total volume of 20 mL.
Levels of PCR product were measured using SYBR Green ﬂuores-
cence collected during Real-Time RT-PCR on an Applied Biosystems
7300 system. The expression of the following genes was analyzed:
 YM1 (Fw: TCTGGTGAAGGAAATGCGTAAA; Rev: GCAGCCTTGGA
ATGTCTTTCTC);
 Arginase I (Fw: CATGGGCAACCTGTGTCCTT; Rev: TCCTGGTACAT
CTGGGAACTTTC);
 IL-1b (Fw: AGTTGACGGACCCCAAAAGA; Rev: GGACAGCCCAG
GTCAAAGG);
 TNFa (Fw: AGACCCTCACACTCAGATCATCTTC; Rev: TTGCTACGAC
GTGGGCTACA);
 b-Actin (Fw: CGCGAGCACAGCTTCTTT; Rev: GCAGCGATATCGT
CATCCAT).
b-Actinwas used as reference gene and relative gene expression
levels were determined according to the manufacturer's DDCt
method (Applied Biosystems). Data are expressed as fold change
from untreated injured mice spinal cord samples.
2.20. Statistical analyses
Statistical analyses were performed by Prism software (Graph-
pad). Statistical tests applied were ManneWhitney test, one-way
ANOVA or two-way ANOVA followed by Bonferroni's post hoc test,
as reported in ﬁgure legends. Data are presented as mean ± SEM.
3. Results
3.1. Extracellular matrix improves hMSCs adhesion and survival in
biomimetic hydrogels
In order to optimize and evaluate the hMSCs adhesion and
viability several hydrogel compositions and different loading pro-
tocols were developed and tested. Speciﬁcally, we synthesized and
functionalized the following scaffolds: carbomer/agarose/poly-
ethylene glycol (PEG) based hydrogel incorporating RGD adhesive
peptide (HG RGD) or HG RGD with a 3D ECM deposition (HG
RGD þ ECM) (Fig. 1 A). Furthermore, different loading protocols
have been tested: hMSCs were mixed with the hydrogel during its
polymerization (hereafter termed classic loading, Fig. 1 B a) or
ﬂuidically loaded into lyophilized HG, the latter acting like a sponge
able to soak up cells together with the medium solution (hereafter
termed sponge-like loading, Fig. 1 B b). Cell survival, adhesion and
density within the scaffolds were evaluated by labeling live cells
with Calcein AM over time and expressed as number of positive
cells per mm2. To evaluate the different loading protocols proposed
we used a HD RGD scaffold demonstrating a signiﬁcant increase of
hMSCs survival at both 14 and 21 days after a sponge-like loading
compared to the classic loading (Fig. S2 A, B). Moreover, a partial
spindle shapemorphology was detected only in the sponge-like HG
RGD, but not in the classic loading HG RGD (Fig. S2 A, B), suggesting
that a reduced stress and a better adhesion were obtained when
hMSCs were loaded by ﬂuidic diffusion into the hydrogel. In order
to further increase cell density and adhesion in the scaffold, we
developed a HG RGD containing a 3D deposition of ECM potentially
able to provide more anchorage for hMSCs and a better supporting
environment. We ﬁrst seeded hMSCs into HG RGD and we
measured the ECM deposited over time. A progressive ECM depo-
sition was observed from 1 up to 14 days, where ECM deposition
reaches a “plateau” (Fig. S3). Thus, for a second hMSCs seeding, we
decided to deposit ECM up to 14 days and then we lyophilized the
HG RGD þ ECM to allow a new encapsulation of hMSCs by a
sponge-like loading (see the Materials and methods section and
Fig. 1 A and B). Noteworthy, analyzing hMSCs within HG
RGD þ ECM, we found a markedly increased cell adhesion to the
biomimetic substrate. Indeed, already at the ﬁrst day after seeding,
HG RGD þ ECM provided an anchorage for hMSCs. The almost to-
tality of hMSCs showed a healthy spindle shape morphology 1 day
after the encapsulation with a signiﬁcantly higher long lasting cell
density (3 fold higher) compared to HG RGD (Fig. 2 a).
3.2. SEM analysis shows a high hMSC density with a spindle shape
morphology in HG RGD þ ECM
In order to further characterize hMSC adhesion, morphology
and density within both HG RGD and HG RGD þ ECM, we
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performed Scanning Electron Microscopy (SEM). SEM evaluation
showed an irregular surface among the network mesh, varying
from rough, in HG RGD, to smooth, in HG RGD þ ECM, the latter
revealing the ECM deposition (Fig. 3). Furthermore, we observed
more clusterized and spindle shape hMSCs attached to the HG
RGDþ ECM biomimetic scaffold compared to HG RGD, conﬁrming a
healthy state and a higher cell adhesion within HG RGD þ ECM
(Fig. 3).
3.3. HG RGD þ ECM preserves hMSC stemness
In order to demonstrate that HG-RGD þ ECM did not sponta-
neously induce any typical MSC differentiation thus preserving the
hMSC stemness for a long time, even when encapsulated, we
compared the gene expression proﬁle of hMSCs encapsulated in
HG-RGD þ ECM with the same hMSCs but differentiated towards
osteocytes, chondrocytes and adipocytes (Fig. 4 D). Genes evaluated
were alkaline phosphatase (ALP), Runt-related transcription factor
2 (RUNX2) and Osterix for osteocytes, Aggrecan (ACAN) and
collagen type X (COLLX) for chondrocytes, whereas Adipsin and
Fatty acid binding-protein 4 (FABP4) for adipocytes. The analysis
was conducted on hMSCs encapsulated within HG RGD þ ECM for
21 days and subsequently isolated for PCR analysis. As positive
control we used hMSCs loaded within HG RGD and treated with
differentiating media up to 21 days. We observed a signiﬁcantly
higher gene expression in positive controls compared to untreated
hMSCs loaded in HG-RGD þ ECM for all genes tested (Fig. 4 A, 4 B
and 4 C) demonstrating that HG-RGD þ ECM per se was not able to
stimulate any classical mesodermal differentiation preserving
stemness for a long time.
Fig. 1. Schematic representation of different hydrogel compositions and loading protocols tested. (A) Hydrogel compositions tested were: RGD (arginineeglycineeaspartic
acid) adhesive peptide incorporated into HG (HG RGD, a) or HG RGD with a 3D-ECM deposition (HG RGD þ ECM, b). The latter was obtained by different steps such as represented in
panel b. (B) Cartoons represent the different loading protocols tested: a classic loading way in which hMSCs were mixed with HG RGD during its polymerization (a, inset) or sponge
like loading in which hMSCs were loaded with a soaked up effect into lyophilized HG RGD (b, inset).
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3.4. hMSCs loaded within HG RGD þ ECM preserve viability up to 9
days in vivo
Since HG RGD þ ECM showed an optimized viability, a higher
cellular adhesion and a preserved stemness of hMSCs after a
sponge-like loading in vitro, we decided to evaluate the behavior of
hMCSs loaded in HG RGD þ ECM also in vivo. To do that, after the
implantation in the injured site, we performed a longitudinal study
by means of intravital microscopy. Cell survival was evaluated over
time by labeling live stem cells with CFDA-SE (a vital ﬂuorescent
staining) (Fig. 5 A and B a). Cell density within the hydrogel was
evaluated by counting the number of CFDA-SE positive cells that we
expressed as percentage, considering 100% of survival immediately
after the implantation. Analyzing intravital microscopy at 3 days
following positioning, the number of hMSCs in the HG RGD þ ECM
decreased to about 40% of the initial number, that became 15% at 9
days after the positioning (Fig. 5 B b).
3.5. Oriented delivery optimizes the ﬂuidic release of factors from
HG RGD þ ECM in vivo
In order to demonstrate that a ﬂuidic diffusion occurs from the
hydrogel after implantation in the injury site in vivo, we evaluated
the release proﬁle of a ﬂuorescent solution (Hoechst 33258)
delivered by HG RGD þ ECM. After 9 days from the HG RGD þ ECM
positioning in the lesion site, Hoechst 33258 ﬂuorescence showed
an evident intense signal mostly distributed in the epicenter of the
injured site, whereas only few sections were stained outside the
epicenter of the lesion (Fig. 6 a). This was conﬁrmed by examining
quantitatively the distribution of Hoechst 33258 staining in a
portion of the spinal cord encompassing 12 mm around the
epicenter of the injury (Fig. 6 a, d). In order to increase the ﬂuidic
diffusion from the hydrogel toward the injury site, we applied and
tested an impermeable cling ﬁlm that, sealing the hydrogel to the
spinal cord, optimizes the ﬂuidic diffusion toward the injury site
(Fig. 6 b). Analyzing the Hoechst 33258 staining in spinal cord tis-
sue after an oriented delivery (Fig. 6 b), we found a dramatic in-
crease of ﬂuorescent staining in both the epicenter and in regions
outside the lesion, compared to unsealed hydrogel (Fig. 6 a). This
was conﬁrmed by evaluating quantitatively the distribution of the
Hoechst 33258 staining in the spinal cord segments around the
traumatized spinal cord (Fig. 6 c, d). These analyses demonstrated
that a more oriented diffusion from the hydrogel, obtained by using
a cling ﬁlm, can potentially optimize a paracrine release of trophic
factors toward the injured site, potentially increasing the thera-
peutic effect.
Fig. 2. HG RGD þ ECM shows a high hMSC viability with a spindle-shape morphology in vitro. (a) Graph representing viability of hMSCs loaded in sponge-like HG RGD or
sponge-like HG RGD þ ECM scaffolds. Cell viability was evaluated over time by labeling live cells with Calcein AM. Already at the ﬁrst day after seeding, HG RGD þ ECM displays a
signiﬁcantly higher viability and density of hMSCs compared to HG RGD. This high cellular density is preserved over time. In the graph the cell density within the hydrogels is
reported as number of calcein AM positive cells per mm2. Statistical analysis: Mann Whitney test for each time point. Mean ± SEM is reported. (*) p < 0.05. (**) p < 0.01. n ¼ 8 per
group. (b) Representative images showing hMSCs stained with Calcein AM in sponge-like HG RGD and sponge-like HG RGD þ ECM scaffolds. Already at the ﬁrst day after seeding
here represented, the almost totality of hMSCs within HG RGD þ ECM shows a healthy spindle shape morphology. Differently, only a very few hMSCs in HG RGD show a partial
adhesion to the scaffold and a spindle shape morphology. Scale bar represents 200 mm.
Fig. 3. Morphological analysis of HG scaffolds by SEM. Representative SEM images of both sponge-like HG RGD (a) and sponge-like HG RGD þ ECM (b) scaffolds. The ECM
deposition is represented by irregular surface among the networks mesh in HG RGD þ ECM (arrowhead). A higher cellular density and a higher cell attachment to the substrate can
be observed in HG RGD þ ECM. Scale bar represents 10 mm. 3000.
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Fig. 4. mRNA analysis of hMSCs encapsulated within biomimetic scaffold. (A, B, C) Graphs representing the expression of speciﬁc genes related to three differentiation lineages:
alkaline phosphatase (ALP), runt-related transcription factor 2 (RUNX2) and osterix for osteogenic differentiation; aggrecan (ACAN) and collagen type X (COLLX) for chondrogenic
differentiation and adipsin and fatty acid binding-protein 4 (FABP4) for adipogenic differentiation. hMSCs encapsulated whithin HG RGD þ ECM for 21 days are compared to the
positive control represented by hMSCs loaded in HG RGD and treated with speciﬁc differentiating media for 21 days. Data are expressed as fold change compared to steady-state
undifferentiated hMSCs (negative control). Statistical analysis: Mann Whitney test. Mean ± SEM is reported. (*) p < 0.05. n ¼ 3 per group. (D) A representative cartoon of the three
lineage commitments of hMSCs (osteocytes, chondrocytes and adipocytes) with respective principal pro-differentiating stimuli: ascorbic acid, b-glycerophosphate and dexa-
methasone to induce osteogenic differentiation; ascorbic acid, dexamethasone, pyruvate and TGF-b 3 to induce chondrogenic differentiation; insulin, 3-isobutyl-1-methylxanthine
(IBMX), dexamethasone and indomethacin to induce adipogenic differentiation.
Fig. 5. hMSCs viability within HG RGD þ ECM is revealed up to 9 days in vivo. (A) (aec) Representative images of intravital acquisition of CFDA-SE positive hMSCs within HG
RGD þ ECM positioned in the injury site in vivo. Analysis has been performed immediately after the positioning (day 0, a and d) and at 3 (b and e) or 9 days (c and f) after the
positioning. (def) The isosurfaces represent CFDA-SE positive cells considered for quantiﬁcation of respective hydrogels. Scale bar represents 0.2 mm. (B) (a) Cartoon represents
intravital acquisition of CFDA-SE positive hMSCs within HG RGD þ ECM in the injury site. (b) Quantitative evaluation of viable hMSCs within HG RGD þ ECM over time. Mean ± SEM
is reported. n ¼ 8.
I. Caron et al. / Biomaterials 75 (2016) 135e147142
3.6. hMSCs loaded in HG RGD þ ECM modulate inﬂammatory
response in vivo
We assessed by FACS analysis whether hMSCs loaded in HG
RGDþ ECM sealed with cling ﬁlm and implanted in the injured site
were able to modulate, through a paracrine effect, resident
microglia and recruited macrophages in the traumatized site, one
therapeutic effect proposed in literature [60]. To distinguish be-
tween the two cell populations we performed, according to the
literature [61e63], a double labeling with both CD11b and CD45
antibodies, identifying microglia by a CD11bpos/CD45low signal and
recruited macrophages by a CD11bpos/CD45high signal (see Fig. S4
for gating). The amount of CD11b/CD45 positive labeled cells was
evaluated in the injury epicenter. In response to SCI, resident
microglia and recruited macrophages increased very early, even at
1 day post injury (DPI), reaching a peak of microglia activation and
recruited macrophages migration in the damaged site at 7e9 DPI
(data not shown). Mice treated with hMSCs loaded in HG
RGD þ ECM and analyzed at 9 DPI showed a signiﬁcantly increased
amount of recruited macrophages in the injured site (hMSCs, Fig. 7
A, b) compared to untreated mice (injury, Fig. 7 A, a), as demon-
strated by dot plots (Fig. 7 A) and by quantitative analysis of
microglia/macrophages ratio (Fig. 7 B). No changes were detected
comparing FACS analysis of untreated injured mice (INJ) to injured
mice treated with conditioned medium loaded within HG
RGD þ ECM (HG RGD þ ECM þ CM) or conditioned medium or
hMSCs injected into the parenchyma (CM injected and hMSCs
injected, respectively) (Fig. S5, A). These data demonstrated that
only hMSCs loaded within HG RGD þ ECM recruit more macro-
phages in the injured site via a paracrine effect. Furthermore, to
investigate whether the proposed treatment was able to modulate
M1 and/or M2 phenotypes in the injured site we performed a gene
expression analysis to detect bothM1 (IL-1b and TNFa) or M2 (Arg-I
and YM1) phenotypes [60]. Analyzing both IL-1b and TNFa mRNA
in the epicenter of the lesion in hMSCs loaded HG
RGD þ ECM þ cling ﬁlm treated mice at 9 DPI (Fig. 7C; a, b), only
TNFamRNAwas detected signiﬁcantly increased in treated injured
mice (fold change of about 1.5) compared to the untreated injured
mice (Fig. 7C; a). However, evaluating M2 mRNA markers in hMSCs
loaded HG RGD þ ECM þ cling ﬁlm treated mice, we demonstrated
a signiﬁcant increase of Arginase I M2-related transcript (Fig. 7C; d),
but not of YM1 (Fig. 7C; c), compared to untreated injured mice.
Noteworthy, Arginase I showed a mean fold change of about 10
compared to the untreated injured mice (Fig. 7C; d). No changes
were detected bymRNA analysis comparing untreated injuredmice
(injury) to injured mice treated with either conditioned medium
(CM injected) or hMSCs (hMSCs injected) injected in the paren-
chyma (Fig. S5, B). However, the analysis of IL-1b expression
revealed higher levels of transcription in mice treated with condi-
tioned medium loaded in HG RGD þ ECM (HG RGD þ ECM þ CM,
Fig. S4 B, b) compared to untreated mice (fold change of about 2.5),
suggesting a partial effect of HG RGD þ ECM scaffold in eliciting a
polarization toward a pro-inﬂammatory M1 phenotype. Never-
theless, the treatment of mice with hMSCs loaded HG RGD þ ECM
Fig. 6. Hoechst delivery from HG RGD þ ECM in vivo. Release proﬁle study of a ﬂuorescent solution (Hoechst 33258) delivered by HG RGD þ ECM in the injured site of the spinal
cord. In a and b, representative images of Hoechst staining are shown in a portion of the spinal cord encompassing 12 mm around the epicenter of the injury. Cartoons show HG
RGD þ ECM positioning in both not oriented (a) and oriented delivery (b). Spinal cord after an oriented delivery shows a higher Hoechst staining as both total signal (c) and
distribution around the epicenter (d) compared to unsealed hydrogel. Statistical analysis: Mann Whitney test for total Hoechst delivery (c), Two-way ANOVA followed by Bon-
ferroni's post hoc test for Hoechst staining distribution (d). Mean ± SEM is reported. (*) p < 0.05, (**) p < 0.01, ($) p < 0.0001. n ¼ 4 per group.
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was able to revert the increased IL-1b expression, suggesting a
further anti-inﬂammatory paracrine effect of hMSCs in vivo (Fig. 7C;
b).
4. Discussion
Engineered scaffolds are considered a promising approach to
create an optimal environment able to sustain a long lasting cell
viability of stem cells in situ with the ability to help the tissue in
terms of neuroprotection and neuroregeneration. These scaffolds
offer the opportunity to deliver cells appropriately into the injured
site optimizing the therapeutic effect of the treatment proposed.
However, different limits have been revealed when these hMSCs
have been encapsulated into biomaterials hampering their viability
and a long lasting effect of the treatment. This was mostly due to
the lack of an optimal combination of hMSCs, scaffold design and
supporting environment that has limited the capability to support
appropriate cell viability in vitro and in vivo [49]. It is well known
that stem cell viability, phenotype and stemness are modulated by
the interaction with the complex physicochemical composition of
the natural niche mostly composed of ECM [43,55,64,65]. There-
fore, the ECM could be considered a building block in sustaining
hMSCs within biomaterial for maintaining a high viability and a
high cellular density over time. In line with this idea, we here
demonstrate and conﬁrm that an optimal combination of an orig-
inal hydrogel with a pre-constituted ECM deposited by hMSCs,
together with an efﬁcient stem cell loading (sponge-like effect), is
an effective strategy to increase the viability and the cellular
Fig. 7. hMSCs loaded in HG RGD þ ECM modulate inﬂammatory response increasing M2 macrophages in vivo. (A) Representative FACS dot plots of microglial cells (CD11bpos/
CD45low) and macrophages (CD11bpos/CD45high) present in SCI epicenter of untreated injured (injury, a) or hMSCs loaded within HG RGD þ ECM treated injured mice (hMSCs, b)
evaluated at 9 DPI (days post injury). An increased macrophages recruitment in hMSCs treated mice was found (b) compared to untreated mice (a). (B) Quantiﬁcation of the ratio
between microglia (CD11bpos/CD45low) and recruited macrophages (CD11bpos/CD45high) evaluated in untreated injured (injury) or hMSCs loaded within HG RGD þ ECM treated
injured mice (hMSCs) at 9 DPI. Graph shows a lower microglia/macrophages ratio in hMSCs group, demonstrating an increase of macrophages recruitment. Mean ± SEM is reported.
Statistical analysis: Mann Whitney test. (*) p < 0.05. n ¼ 5e7 mice per group. (C) Quantitative evaluation of mRNA expression of both M1 (TNFa, a and IL-1b, b) and M2 (YM1, c and
Arginase I, d) markers of microglia/macrophages polarization in untreated injured (injury) or hMSCs loaded HG RGD þ ECM treated injured mice (hMSCs) at 9 DPI. A signiﬁcant
increase of TNFa (about 1.5 folds) and Arginase I (about 10 folds) can be observed in mice treated with hMSCs compared to untreated injured mice, suggesting a skew toward an M2
pro-regenerative environment in hMSCs group. Mean ± SEM is reported. Statistical analysis: Mann Whitney test. (**) p < 0.01. n ¼ 10e14 mice per group.
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density within an hydrogel for at least 21 days after seeding. In
particular, in this study we establish that a lyophilized gel could be
loaded through a soaked up effect preserving a higher cell viability
compared to hMSCs loaded during the solution/gel transition.
Reduced cell viability detected after a conventional loading pro-
cedure is likely due to the mechanical stress to which the cells are
exposed [66], that is dramatically reduced loading hMSCs by a
sponge-like effect. Furthermore, we demonstrate that RGD motif
together with the pre-deposited 3D ECM has increased strongly the
density of these cells within the hydrogel already at the ﬁrst day
after seeding. Furthermore, the 3D RGD ECM scaffold as here pro-
posed signiﬁcantly improves hMSCs maintenance showing a very
high cell density up to 21 days in vitro. This time of survival is quite
striking compared to other scaffolds proposed in literature where
cells viability was observed only up to 7e14 days [48,67,68].
Furthermore, we demonstrate that a 3D ECM optimizes a healthy
environment by converting hMSCs from a round shape to a spindle-
like morphology, representing healthy cells indistinguishable from
cells grownwithin a culture well. Differently, other groups reported
a lower stem cells survival with a round shape morphology of
hMSCs in the scaffold [48,67,68], suggesting that a spindle shape
morphology is indicative of a cellular wellness that can contribute
to the long term survival. We demonstrate also a preserved stem-
ness of hMSCs during the time of analysis, conﬁrming that a po-
tential pleiotropic effect is maintained in this condition for a multi-
therapeutic approach in SCI. Altogether, these data conﬁrm that a
3D ECM is a relevant support for the maintenance of hMSCs in this
scaffold. So far, only few attempts have been made to mimic the
physiological ECM directly within a biomaterial with the aim to
optimize hMSCs viability [46e48,55,68e72]. Several studies used
reconstituted monotypic ECM preparations in two dimensions to
examine cell-matrix interactions and survival of the cells [55,71,72].
However, this represents a platform that does not constitute an
optimal 3D native conﬁguration, but only a 2D interactive structure
[55,71,72]. It is well known that cell is affected by the physical
environment in which it is grown. Indeed, in living tissue, cells
reside in 3D microenvironments and establish many interactions
with the surrounding matrix [73e75]. Moreover, cells in 3D culture
exhibit different gene expression compared to cells in 2D [73] and
provide different cell polarization, such as demonstrated in litera-
ture [73] and in our study. Indeed, a 3D framework provides more
contact for cell adhesion, which is necessary for proteineprotein
ligation and cell-matrix signaling [73e75]. In addition, the archi-
tecture and conformation of the niche determines the mechanical
properties of the ECM which in turn control cell adhesion, prolif-
eration and differentiation [76]. For this reason, our 3D approach
represents an optimal condition for cell culture where ECM is
widely distributed in a 3D scaffold permitting a more appropriate
environment for cellecell interaction and polarization, and creates
a more permissive environment similar to natural niche in which
hMSCs can survive properly. Our approach is different also from
previous studies whose attempts were to functionalize the scaffold
with one single ECM peptide, as laminin, ﬁbrin or RGD peptide
[46e48,68,69], or to use a powdered ECM from porcine urinary
bladder [70]. Indeed, ECM is composed of proteins, proteoglycans
and factors able to establish a dynamic interaction with stem cells.
Simultaneously, stem cells remodel actively the ECM in relation to
their deﬁnite needs. Thus, only a few bioactive peptide sequences
incorporated in synthetic hydrogels could represent only a partial
support, but not an optimized environment to sustain hMSCs
[46e48,68,69]. Therefore, to the best of our knowledge, this is the
ﬁrst study presenting a 3D natural ECM deposition able to increase
adherence and viability of loaded hMSCs. In vivo experiments
further demonstrate that a HG-RGD þ ECM loaded with a ﬂuores-
cent compound (Hoechst 33258) is efﬁciently implanted in the
spinal cord and is able to release efﬁciently this molecule showing a
sustainable delivery from the scaffold toward the injured site. To
improve this delivery, we propose the use of an impermeable cling
ﬁlm that dramatically increases an oriented delivery toward the
damaged site. Thus, we expect that, once implanted, hMSCs loaded
HG-RGD þ ECM þ cling ﬁlm will be able to release a higher con-
centration of factors in the injured spinal cord without any
obstruction to their paracrine effect. This is conﬁrmed by FACS and
mRNA analyses demonstrating that a paracrine effect sustained by
viable hMSCs loaded within HG RGD þ ECM in just a few days is
able to increase and/or convert efﬁcaciously M2 macrophages
(immunomodulation) in the injured site, promoting a pro-
regenerative environment that represents a relevant outcome in
treating SCI [26,50,77,78]. Noteworthy, injecting the same number
of hMSCs directly in the parenchyma, a lack of efﬁcacy is found in
terms of macrophages recruitment or M1/M2 polarization. So far,
the direct injection of hMSCs has been frequently proposed as pre-
clinical SCI treatment, sometimes demonstrating a protective effect
on histological or behavioral outcomes [13,79,80]. However,
although a direct injection of stem cells may represent an attractive
approach as clinical protocol, it shows deep concerns because very
often stem cells leave the zone of injection, as they are not conﬁned
by any support. On the other hand, if injected stem cells remain in
situ, they could be exposed to a hostile environment due to the
tissue degeneration. Thus, a biomimetic scaffold, as proposed in
this study, able to maintain MSCs viable, undifferentiated and
conﬁned within a 3D structure out of the degenerative environ-
ment is a forefront application. Moreover, the original scaffold
material here proposed maximizes hMSCs paracrine protective
effects, offering the possibility to reduce dramatically the cellular
efﬁcacious dose. Indeed, a consistent higher number of hMSCs is
required when a direct injection is performed in situ to overcome
mechanical forces that could damage stem cells passing from the
needle [27] and concomitantly to preserve a sufﬁcient number of
them to counteract an inﬂamed and adverse environment present
in the injured site [29,30].
In conclusion, we propose a new sustainable stem cell therapy
by using HG RGD þ ECM derived from the combination of different
promising strategies such as: 1) a new loading procedure on a
lyophilized scaffold (soaked up effect) that reduces mechanical
stress and preserves hMSC viability when encapsulated into the
hydrogel, 2) a RGD motif that increases the capacity to entrap
hMSCs within the hydrogel after the seeding, 3) a 3D ECM depo-
sition able to maintain over time healthy hMSCs with an high
viability and density and 4) an oriented delivery of paracrine factors
for treating efﬁcaciously the injured site. We believe that the
optimized scaffold as here proposed results to be a promising and
innovative approach that may represent a breakthrough in using
stem cells therapy supported by biomaterial with potential bene-
ﬁcial impact on SCI.
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Figure S1: hMSCs identity definition. (A) Representative immunoprofile of hMSCs. (B) Staining 
data assessing MSC identity: (a) Oil Red O-positive adipocytes, scale bar represents 50 μm; (b) 
Alizarin Red S-positive osteocytes, scale bar represents 100 μm; (c) Alcian blue-positive 
chondrocytes. Scale bar represents 100 μm. 
  
  
 
Figure. S2 hMSCs viability in vitro. (a) Graph representing hMSC viability after a classic or sponge-
like loading within HG RGD scaffolds. Cell viability was evaluated over time by labeling live cells 
with Calcein AM. In the graph the cell density within the hydrogels is reported, as the number of 
calcein AM positive cells per mm2. hMSCs after a classic loading display a viability that decreases 
dramatically already at 7 days post seeding and no viable cells could be observed 21 days after 
seeding. Contrarily, hMSCs after a sponge-like loading preserve a viability that results to be 
significant at both 14 and 21 days after seeding compared to classic loading. Statistical analysis: 
One way Anova for each time point. Mean±SEM is reported. (°°) p<0.01 n=8 per group. (b) 
Representative images show hMSCs stained with Calcein AM within HG RGD scaffolds after a 
classic or sponge-like loading. Some hMSCs with spindle shape morphology are detected in the 
sponge-like HG RGD, but not in the HG RGD after a classic loading. Scale bar represents 200 μm. 
  
  
 
 
Figure. S3 Quantification of extracellular matrix (ECM) deposition. (a) Graph representing Sirius 
Red quantification of ECM deposited by hMSCs seeded in sponge-like HG RGD scaffold. An increase 
of ECM deposition could be observed from 1 up to 14 days, where ECM deposition reaches a 
“plateau”. (b) Images representing Sirius Red staining of HG RGD scaffold after 1 (a), 7 (b), 14 (c) 
and 21 (d) days after hMSCs seeding. Scale bar represents 500μm. 
  
  
Figure. S4 Gating strategy in FACS analysis for CD11b and CD45 staining. Representative gating 
strategy for CD11b (b, e, h) and CD45 (c, f, i) staining in injury (d-f) and hMSCs loaded in HG 
RGD+ECM (g-i) treated mice evaluated at 9 DPI. Gating performed on the isotype (a-c). 
 
  
  
Figure. S5 FACS and mRNA analysis. . (A) Quantification of the ratio between microglia 
(CD11bpos/CD45low) and recruited macrophages (CD11bpos/CD45high) evaluated in untreated injured 
mice (injury), injured mice treated with conditioned medium (CM injected) or hMSCs injected in the 
parenchyma (hMSCs injected) and injured mice treated with conditioned medium loaded in HG 
RGD+ECM (HG RGD+ECM+CM) at 9 DPI. No differences are detected among groups analyzed. 
Mean±SEM is reported. Statistical analysis: One-way ANOVA. n= 5-4 mice per group. (B) 
Quantitative evaluation of mRNA expression of M1 (TNFα, a and IL-1β, b) and M2 (YM1, c and 
Arginase I, d) markers for microglia/macrophages. No differences are detected among untreated 
injured mice (injury) and injured mice treated with conditioned medium (CM injected) or hMSCs 
injected in the parenchyma (hMSCs injected). However, mice treated with conditioned medium 
loaded within HG RGD+ECM (HG RGD+ECM+CM) show a significant higher IL-1β expression 
compared to untreated injured mice, suggesting an effect of HG RGD+ECM scaffold in eliciting a 
pro-inflammatory response. Mean±SEM is reported. Statistical analysis: One-way ANOVA followed 
by Bonferroni’s post hoc test comparing groups to the injury condition. (**) p<0.01. n= 5-4 mice per 
group. 
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a b s t r a c t
In a recent work, our group showed the existence of two distinct mesenchymal stem cell (MSC)
subsets within human umbilical cord blood. One less proliferative and short-living (SL-CBMSC), the
other with higher growth rate and long-living (LL-CBMSC), and therefore better suited for regenera-
tive medicine applications. We examined whether LL-CBMSC possess peculiar paracrine properties able
to affect angiogenesis or inﬂammatory processes. It was shown for the ﬁrst time that pro-angiogenic,
proliferation—stimulating and tissue repairing factors were released at high level not only as soluble
cytokines, but also as mRNA precursors embedded in membrane vesicles. The combination of this pri-
mary (proteic factors interacting with surface receptors) and delayed (mRNA transferred and translated
via vesicle fusion and cargo release) interaction in endothelial target cells resulted in strong blood vessel
induction with the development of capillary-like structures. In addition, LL-CBMSC dynamically modu-
lated their release of pro-angiogenic and anti-inﬂammatory factors in an in vitro model of damage. In
conclusion, LL-CBMSC synthesize and secrete multiple factors that may be attuned in response to the
status of the target cell, a crucial requisite when paracrine mechanisms are needed at onset of tissue
regeneration.
© 2016 Elsevier GmbH. All rights reserved.
1. Introduction
A great interest has recently arisen in the ﬁeld of mesenchymal
stem cells (MSC) because of their high potential for multi-lineage
differentiation and proliferation, characteristics that make these
cells useful for clinical applications in tissue engineering, regener-
ative medicine, cell and gene therapy (Phinney and Prockop, 2007;
Murphy et al., 2013; Das et al., 2013). Elective tissues for MSC iso-
lation are bone marrow (BMMSC) and adipose tissue (ADMSC),
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although their use has disadvantages, including the necessity of
invasive harvest from patients or donors. Therefore, alternate
sources of MSC have been intensively sought and umbilical cord
blood resulted to be an interesting candidate because it is usually
discarded at the time of birth after a painless and non-invasive col-
lection process (Bieback et al., 2004; Erices et al., 2000; Gang et al.,
2004; Lee et al., 2004). Umbilical cord blood-derived MSC (CBMSC)
rapidly gained importance in the regenerative medicine ﬁeld since,
due to their low immunogenicity, theydonot elicit the proliferative
response of allogeneic lymphocytes (Le Blanc et al., 2003).
In the last few years researchers afﬁliated with cord blood bank
networks provided more and more details in order to improve
CBMSC isolation efﬁciency and identity deﬁnition (characteristic
and potentialities), essential prerequisites for supporting new clin-
ical concepts in cellular therapy (Kögler et al., 2004; Zhang et al.,
2011). In a previous work we clearly showed the existence of at
http://dx.doi.org/10.1016/j.ejcb.2016.04.003
0171-9335/© 2016 Elsevier GmbH. All rights reserved.
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least two distinctMSC subsetswithin the umbilical cord blood: one
mainly short-living and less proliferative (SL-CBMSCs), the other
long-living, with higher growth rate, and, very importantly, with
signiﬁcantly longer telomere (LL-CBMSCs) (Barilani et al., 2015).
Notably, LL-CBMSC retained a higher clonogenic potential together
with a high osteogenic commitment, both parameters commonly
used to deﬁne effective MSC populations.
In thiswork,wecharacterized thismultipotent LL-CBMSC (here-
after named for simplicity CBMSC) population with respect to
several factors related to their practical utility as therapeutic MSC.
These include proliferation kinetics, extensive immunophenotyp-
ization, gene expression and differentiation capabilities, cytokine
secretion, paracrine properties and angiogenesis potential. In this
frame, for the ﬁrst time the presence of mRNA coding for pro-
angiogenic and anti-inﬂammatory factors was investigated in the
fraction of secreted extracellular vesicles. These data are therefore
intended to be a milestone when working with MSC isolated from
umbilical cord blood and intended for clinical applications.
2. Materials and methods
2.1. Isolation of MSC from cord blood (CBMSC)
Humanumbilical cord blood (CB, n =264 samples)was collected
from full-term newborns after written informed consent of the
mother. After vaginal or cesarean delivery of the baby, the umbil-
ical cord was clamped and disinfected; CB was recovered from
umbilical cord veins into sterile collection bag containing 29mL of
citrate-phosphate dextrose (CPD) as anticoagulant (MacoPharma,
France). CBMSC isolation was performed as described in Barilani
et al., 2015. Complete culture medium consisting of aMEM (Life
Technologies, Carlsbad, CA, USA) supplemented with 20% FBS (Life
Technologies) was changed every 3days. At 80% conﬂuence, the
cells were harvested using 25% TrypLE Select 1X (Gibco) and were
washed with PBS (Gibco) and subcultured at a concentration of
4×103 cells/cm2 till reaching a plateau in the growth curve.
2.2. Cumulative population doublings
Population doubling was calculated for each CBMSC lin-
eage using the following equation: population doubling
(PD) = log10(N)/log10(2); where N is the number of cells har-
vested at the end of the culture/the number of seeded cells. To
calculate the expansion potential of cells, cumulative population
doublings (CPD) was calculated by recording the cell counts and
the cellular dilution factor at each passage (P). Cell counting
was performed using Trypan Blue (Fluka, Buchs, Switzerland) to
discriminate dead cells.
2.3. Clonogenic potential
The clonogenic potential of CBMSC (n=7) was tested by
ﬁbroblastic-colony-forming unit (CFU-F) assay. For optimal count-
ing of colonies, 200 cells were seeded in duplicate in complete
medium 100-mm dishes (Corning) from culture at P2, P4, P6 and
P8. The medium was changed weekly and after two weeks the cells
were washed with PBS (Life Technologies), ﬁxed with methanol
(Sigma-Aldrich), and stained with carbolic gentian violet solution
(Ral diagnostics, Cedex, France). After 2 washing steps with milliQ-
grade water, colonies with diameter bigger than 1–2mm were
counted.
2.4. Flow cytometric analysis
CBMSC were extensively characterized by ﬂow cytometry at
p3 and p5 (n=7). Cells were washed in PBS for 20min at RT and
incubated in the dark with the following mouse anti-human anti-
bodies: CD3–APC (Beckman Coulter – BC, Brea, CA, USA), CD13–PE
(BC), CD14–PE (BC), CD34–APC (Becton Dickinson—BD, San Jose,
CA, USA), CD40–FITC (BD), CD44–APC (Miltenyi Biotec, Bergisch
Gladbach, Germany), CD45–PC7 (BC), CD56–APC (BC), CD90–FITC
(BD), CD73–APC (Miltenyi Biotec), CD105–PE (BC), CD133–PE
(Miltenyi Biotec), CD146–PC5 (BC), alpha-SMA–FITC (Sigma-
Aldrich), HLA-ABC–FITC (BC), HLA-DR–PE (BC), NG2–PE (BC),
NGFR–PE(BD), PDGFR-beta–PE (BD), VE-Cadherin–FITC (Bender
Medsystem, Vienna, Austria). The isotype-matched immunoglob-
ulins IgG1–FITC (BC), IgG1–PE (BC), IgG1–PC7 (BC) and IgG1–APC
(BC) were used as negative controls under the same conditions.
After staining, the cells werewashed oncewith PBS. At least 10,000
events were acquired with a Cytomics FC500 ﬂow cytometer (BC)
and data were analyzed using the CXP analysis software.
2.5. Immunoﬂuorescence
CBMSC at p3 were ﬁrst ﬁxed with cold methanol/acetone (1:1)
for 2min. When necessary, cells were permeabilized with 0.1%
Triton X-100 (10min), then washed in PBS. Non-speciﬁc binding
sites were blocked with PBS containing 2% bovine serum albumin
(Sigma-Aldrich) for 20min at RT. Cellswere incubatedwith directly
conjugated anti-human antibodies against: CD34–FITC (DAKO,
Glostrup,Denmark, 1:50), CD144–FITC (BenderMedSystems, 1:25),
CD146–PE (ByoCytex, Marseille, France, 1:20), alpha-SMA–FITC
(Sigma-Aldrich, 1:100), PDGFR-beta–PE (BD, 1:20), for 1h at RT.
Puriﬁed mouse anti-human antibodies were against: CD133 (Mil-
tenyi Biotec, 1:50),Nanog (AbCam,Cambridge,UK, 1:200), Oct-4AB
(Millipore, Billerica, MA, USA, 1:50), SSEA-4 (Chemicon, Temecula,
CA, USA, 1:25), Signal Transducers and Activators of Transcrip-
tion (STAT) 3 (AbCam, 1:10), STAT5 (AbCam, 1:50), STAT6 (AbCam,
1:10) and von Willebrand factor (vWF; DAKO, 1:40). After stain-
ing with primary puriﬁed antibodies, cells were ﬁrst incubated
with Fluorescence Enhancement Probe (Biocare Medical Inc, Con-
cord, CA, USA) for 30min at RT and then with DyLight 488 or
549 detection component (Biocare Medical Inc 1:100) for 30min
at RT. Nuclear counterstaining with DAPI (Roche Diagnostic Cor-
poration, Indianapolis, IN, USA) was performed for 15min at RT.
An isotype-matched negative control was performed for each
immunostaining. All slides were mounted with DakoCytomation
FluorescentMountingMedium (DAKO) and the cellswere analyzed
using a video confocal microscope (ViCo-Eclipse 80i, Nikon, Tokyo,
Japan) equippedwith Plan Fluor 40x1.30 DICH/N2 and Plan Apo VC
60x/1.40 DIC N2 oil objectives (Nikon). Photographs were acquired
with a CCD cooled interline-transfer FireWire camera (Nikon) and
processed using Media Cybernetics Image Pro Plus (Media Cyber-
netics Inc., Rockville, MD, USA).
Negative controls were performed using a species-speciﬁc
labelled secondary antibody for indirect immunoﬂuorescence
while isotype-matched controls were used for direct staining.
2.6. RNA and microRNA isolation, qRT-PCR analysis
Total RNA including small RNAs as microRNA (miRNA) was iso-
lated with miRNeasy Mini Kit (Qiagen, Hilden, Germany) following
manufacturer’s instructions from 0.5×106 CBMSC (n=5 at p4) or
1×1010 puriﬁed extracellular vesicles (EV) (n =3 at p4). RNA purity
wasdeterminedbymeasuringA260/A280 ratio inaNanodropspec-
trophotometer. RNA integrity was assessed using electrophoretic
techniques.
FormiRNAdetection,miR-302b andmiR-335 levels, normalized
against housekeeping miR-191 and miR-214 (Bargaje et al., 2010),
were assayed by qRT-PCR using the miScript II RT Kit for cDNA syn-
thesis (Qiagen) and miScript SYBR Green PCR Kit (Qiagen) as per
manufacturer’s instructions. Brieﬂy, RNA was ﬁrst polyadenylated
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and then reverse-transcribed to generate ﬁrst-strand cDNA that
was prepared for qRT-PCR with miRNA-speciﬁc forward primers
(miScript Primer Assay, Qiagen) and a universal qRT-PCR primer
included in the miScript SYBR Green PCR mix, and SYBR Green ref-
erence dye. All reactions were run in triplicate in a BioRad CFX96
Real-Time PCR Detection System instrument.
For qRT-PCR assays on mRNA, ﬁrst strand cDNA synthesis and
PCR analysis were performed as described in Ragni et al., 2013a
using the CFX96TM Real- Time PCR detection system (Biorad, Rich-
mond, CA, USA).
For cell differentiation analyses, differences in expression of
Osterix (OSX), Osteopontin (OPN), Collagen type II alpha 1 (COL2A1),
Collagen type X alpha 1 (COL10A1), Peroxisome proliferator-
activated receptor gamma (PPARG), Glucose transporter type 4
(GLUT4), ADIPSIN genes were evaluated by comparing differenti-
ated CBMSC with non-differentiated control CBMSC. TATA-binding
protein (TBP) and Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta polypeptide (YWHAZ)
wereused as reference genes, according to our previouswork about
stability of different reference genes in MSC (Ragni et al., 2013a).
For mRNA embedded in secreted EV, expression of connec-
tive tissue growth factor (CTGF), ﬁbroblast growth factor (FGF),
interleukin-6 (IL-6), transforming growth factor beta 1 (TGFB1),
vascular endothelial growth factor (VEGF) and hepatocyte growth
factor (HGF) was evaluated.
For all genes, primers will be provided upon request.
2.7. qRT-PCR array expression proﬁling
Mesenchymal-related gene expression proﬁling was performed
with Human Mesenchymal Stem Cells RT2 Proﬁler PCR Array Sys-
tem (http://www.sabiosciences.com/rt pcr product/HTML/PAHS-
082D.html, Qiagen) following manufacturer’s instructions and
relative expression of each mRNA was determined using the soft-
ware RT2 Proﬁler PCR Array Data Analysis (http://pcrdataanalysis.
sabiosciences.com/pcr/arrayanalysis.php). All reactions were run
in a BioRad CFX96 Real-Time PCR Detection System instru-
ment (Bio-Rad Laboratories). Results were interpreted with
GeneCodis (National Center of Biotechnology—CNB-CSIC, Univer-
sidad Complutense de Madrid), a web-based tool for the biologic
interpretation of high-throughput experiments.
2.8. Cell lineage differentiation
CBMSC (n=5 at p4) were differentiated into adipogenic,
osteogenic and chondrogenic cell lineages, as previously described
(Ragni et al., 2013a). Completion of the differentiation processes
were conﬁrmed by qRT-PCR assaying the differentiation-speciﬁc
mRNA levels in induced and non-induced cultures.
2.9. Hematopoietic support assay
CD34+ hematopoietic progenitors were immunoselected (CD34
Microbead Kit, Miltenyi Biotec) from full term CB units (CB
CD34+ cells, n =3) and were seeded at 5.0×103 cells/cm2 in trip-
licate on conﬂuent layers of irradiated (10Gy) CBMSC (n=3 at
p4). As a positive control, MS5 BM stromal cells, which allow
the proliferation of very primitive human progenitor cells and
allow having reproducible and standardized culture conditions
(Issaad et al., 1993), were used. Hematopoietic and mesenchy-
mal cells were co-cultured for 5 weeks in a classical extended
long-term culture-initiating cell (LTC-IC) assay in a complete
medium (MyeloCult H5100, Stem Cell Technologies) containing
freshly prepared hydrocortisone (ﬁnal concentration 10−6 M), but
no cytokines. Half of the medium was collected, immediately
stored at −80 ◦C and replaced once a week, and cultures were
observed daily for the presence of cobblestone areas (CA). After 5
weeks, 2500 cells were seeded in methylcellulose (H4435, Stem-
Cell Technologies) and CFU-granulocyte, erythroid, macrophage,
megakaryocyte (GEMM), CFU- granulocyte-macrophage (GM) and
high-proliferative-potential colony precursors (HPPC) were scored
after 14-day incubation (37 ◦C, 5% CO2) (Corselli et al., 2013). In
addition, cells in the supernatants and adherent fractions were
characterized by ﬂowcytometry for the expression of the following
hematopoietic cell markers: CD34, CD38, CD133 and CD45.
2.10. ELISA
The release of stem cell factor (SCF) was measured using a sin-
gle proteome assay (Human Quantikine ELISA kit, R&D Systems,
Minneapolis, MN, USA) in the supernatants of hematopoietic sup-
port cultures at different time points (1 to 5weeks). The collected
supernatants were thawed and centrifuged to remove the par-
ticulate. The assay was performed following the manufacturer’s
instructions. The optical density of each sample was determined,
until half an hour, using a microplate reader set to 450nm with
wavelength correction set to 570nm(Genios Plus, TECAN, Salzburg,
Austria). Datawere analyzed usingMagellan Software (TECAN) and
expressed as mean concentration (pg/mL) of the secreted factor.
A multiplex sandwich ELISA was performed to quantify some
humanangiogenesis factors releasedbyCBMSC (n=5at p3), such as
heparin-binding epidermal growth factor (HB-EGF, lowerdetection
limit: 1.8 pg/mL), hepatocyte growth factor (HGF, lower detection
limit: 3.1 pg/mL), ﬁbroblast growth factor (FGF, lower detection
limit: 2.0 pg/mL) and vascular endothelial growth factor (VEGF,
lower detection limit: 4.9 pg/mL). These evaluations were per-
formed on steady-state MSC supernatants and on supernatants
collected from the cell damage assay at different time points (24,
48, 72, 192h after injury). In addition, on the supernatants col-
lected from the cell damage assay some inﬂammatory factors
tested were tested such as interleukin-10 (IL10, lower detection
limit: 0.2 pg/mL), interleukin-12 (IL12 p70, lower detection limit:
0.4 pg/mL), interferongamma(IFNg,0.2pg/mL), tumornecrosis fac-
tor (TNFalpha, lower detection limit: 1.6 pg/mL). Brieﬂy, each well
of themicroplatewas pre-spottedwith target protein-speciﬁc anti-
bodies and 50L of standards, and sampleswere added to the plate
for one hour at RT with shaking (200 rpm). After washing away
unbound proteins, 50L of biotinylated antibodies were added to
the plate (30min, RT, with shaking). Excess of biotinylated anti-
bodies was washed away, and 50L of Streptavidin-Horseradish
Peroxidase (SA-HRP)was added to the plate (30min, RT,with shak-
ing). In order to identify the signal, we used SuperSignal ELISA
femto chemiluminescent substrate (Pierce, Rockford, IL, USA); the
luminescent signal was recorded within 10min using a cooled CCD
camera and amount of each target protein was analyzed using
Microsoft Excel 2003 (Microsoft Corporation) as recommended by
the manufacturers. Complete medium was also tested as a blank
and the value obtained was subtracted from values recorded in
cell-conditioned media.
2.11. Response to cell damage
Co-culture assay was set up using a conﬂuent proximal tubular
cell line (HK2; ATCC, CRL-2190) cultured with aMEM-GlutaMaxTM
supplemented with 5% FBS. The damage was induced in HK2 cells
by adding 8M cisplatin for 6h (Morigi et al., 2010). After that,
cisplatin was removed and, in some wells, CBMSC were added to
the culture at a concentration of 5.0×104 cells/well. Media were
collected from cisplatin-damaged HK-2 cells alone, from CBMSC
alone and from co-cultures at 24, 72, 192h after injury. Angiogenic
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Fig. 1. Morphology, CPD and clonogenic potential of CBMSC. (A) A representative image displaying morphology of CBMSC at passage 3. (B) Growth kinetics of different
CBMSC batches expressed as CPD (mean± SD). (C) A representative CFU-F picture. (D) Absolute number of clonogenic cells during culture.
and inﬂammatory factors released in the media were quantiﬁed by
a multiplexed sandwich ELISA, as described above.
2.12. Tube formation assay
Seventy-two hours after addition of complete medium, CBMSC-
conditionedmedia (CM)wereharvested from80%conﬂuentCBMSC
cultures (n =3 at p4) and they were stored at −20 ◦C until used for
the angiogenic assay. The angiogenic potential of CBMSCwas inves-
tigated using the AngioKit assay (TCS CellWorks Ltd., Buckingham,
UK) according to the manufacturer’s instructions. In this assay, the
CBMSC-CM were tested on co-cultures of human endothelial cells
with human interstitial cells at the earliest stages of tubule for-
mation in a 24 well plate format. The angiogenic stimulator VEGF
(5ng/mL) and the well-known inhibitor suramin (10g/mL) were
included as positive and negative controls, respectively. Complete
medium was also used as negative control. Media were changed
every 72h; after 11days, cells were ﬁxed, stained with blood ves-
sel markers such as CD31 and vWF antibodies and then revealed
with diaminobenzidine (DAB) staining. Vascular tubular structures
were visualized by an optical microscope. All experiments were
performed in triplicate.
2.13. EV preparation
CBMSC(n=3atp4)weregrownto80%conﬂuenceand then fresh
medium without FBS was added. After 24h, conditioned culture
medium was collected and serially centrifuged to remove ﬂoating
cells and cellular debris (400g for 10min, 600g for 10minand3000g
for 15min) and ultracentrifuged at 100,000g for 1h at 4 ◦C. The
pellet was suspended in PBS or dissolved in lysis buffer for RNA
extraction.
2.14. Measurement of particle number and size distribution by
nanoparticle tracking analysis (NTA)
NTA was carried out using the Nanosight system (NanoSight,
Wiltshire, UK) on EV suspended in PBS. NTA related the rate of
brownian motion to particle size. Vesicles were visualized by light
scattering using a conventional opticalmicroscope aligned perpen-
dicularly to thebeamaxis.After avideowas taken, theNTAsoftware
trackedbetween frames theBrownianmotionof individual vesicles
and calculated total concentration and their size through applica-
tion of the Stokes-Einstein equation.
2.15. Statistical analysis
Results were analyzed by unpaired Student’s t-test and the sta-
tistical signiﬁcances were accepted for p-values≤0.05.
3. Results and discussion
3.1. Isolation, culture and growth of human CBMSC
After the processing of umbilical cord blood samples, themono-
nucleated cell fraction was seeded. The appearance of the ﬁrst
ﬁbroblastic adherent cells occurred a median of 16days after
seeding, with a minimum of 4days to a maximum of 64. These
isolated adherent cells presented diamond-like morphological fea-
tures, with a homogeneous spindle-shaped morphology (Fig. 1A).
In order not to cause stress or early senescence to the “newly
born” cells, the ﬁrst trypsinization was set a median of 22days
after seeding, accordingly with our previous data showing consis-
tent and non-senescent phenotype until high passages (10-13) for
long-living CBMSC isolated following this protocol (Barilani et al.,
2015). To examine the proliferation capacity of the CBMSC in vitro,
the cumulative population doubling (CPD) was measured (Fig. 1B).
Notably, CBMSC reached veryhighCPDvalues (between28 and42).
These data are similar to those previously published for foetal MSC
(Guillot et al., 2007; Sung et al., 2010), where CPD values (30-40)
resulted to be consistently higher than for adult MSC as BMMSC
(CPD between 20 and 25).
Finally, another major breakthrough for MSC deﬁnition is
that seeding cell suspensions at clonal density results in the
establishment of discrete colonies initiated by single cells (the
colony-forming unit ﬁbroblastic, CFU-Fs; Friedenstein et al., 1970)
and their number and concentration was reported to positively
correlate with effective clinical outcomes (Hernigou et al., 2005).
Fig. 1C and 1D clearly show that in CBMSC the total number of
clonogenic cells continues to rise along timeup topassages6-8 that,
for clinical purposes using adult MSC, are generally avoided (6%
of reported clinical trials for BMMSC; Ikebe and Suzuki, 2014). All
these data conﬁrm both CBMSC “young” features and their intrigu-
ing potentialities for prolonged expansion leading to higher cell
amount, often a bottleneck for clinical preparations.
3.2. Immunophenotype proﬁling
MSC: immunophenotyping by ﬂow cytometry is a routinely
used approach to characterize purity and homogeneity of clinical
preparations (Nery et al., 2013). Stem cell community established
that a minimal phenotypic pattern for the identiﬁcation of MSC
requires them to be immunopositive for CD73, CD90, and CD105
expression, while being negative for CD34, CD45, and HLA-DR
(Dominici et al., 2006). Furthermore, in the last years many other
markershavebeenassociatedwithstemnessalthoughcaveatsneed
to be taken into consideration when designing or interpreting MSC
immunophenotype panels (Lv et al., 2014; Lin et al., 2013). To have
a comprehensive CBMSC characterization, the expression of many
veriﬁed and postulated MSC cell-surface antigens was evaluated
by ﬂow cytometry on cultured cell lines at p3 and p5. As shown
in Fig. 2, CBMSC expressed CD13, CD44, CD73, CD90, CD105, HLA
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Fig. 2. Flowcytometry analysis of expandedCBMSC. (A) Percentages of cells positive
formarkers assayedboth in single anddouble staining (meanandstandarddeviation
of 7 replicates) are reported and statistical analysiswas performed between passage
3and5. ** forp-value≤0.01 (B) representativedotplot panel showing co-expression
of CBMSC at p5 for perivascular/pericyte-like markers such as alphaSMA and NG2
and alphaSMA and CD146.
ABC, NGFR and PDGFR-beta. CBMSCwere negative forHLADR, CD3,
CD14, CD34, CD40, CD45, CD56, CD133 and VE-Cadherin. These
cells also expressed CD146, alpha-SMA and NG2 (Fig. 2A and B),
which altogether characterize a multipotent adult stem cell popu-
lation consistent with a perivascular/pericyte-like phenotype and
origin (Crisan et al., 2009). No relevant differences were observed
between the two passages and by different batches, except for
alpha-SMA (p-value ≤0.01) and alpha-SMA/NG2 positive cells (p-
value≤0.01) that increased at passage 5. Altogether, these data
conﬁrm that CBMSC possess all the stemness markers commonly
used to deﬁne effectiveMSC populations and that extensive cultur-
ing does not affect their immunophenotype, again suggesting high
cell stability during expansion.
3.3. Immunoﬂuorescence
To reinforce ﬂow cytometry data, some crucial stemness mark-
ers were visualized by immunoﬂuorescence techniques. Fig. 3A
conﬁrms high CBMSC positivity for CD146 and alpha-SMA that,
by ﬂow cytometry, resulted to be present in 95% and 97% of ana-
lyzed cells at passage 5, respectively. CD146 showed a surface
localization, more abundant in the area of cell body, conﬁrming
data previously presented in BMMSC (Tormin et al., 2011), whereas
alpha-SMA distributed in typical intracellular ﬁbers-resembling
structures along the cell longitudinal axis and becoming more
tightly associated in the cellular protrusions. Fig. 3B conﬁrms both
alpha-SMA localization and high positivity for PDGFRB (96% at pas-
sage 5 by ﬂow cytometry), that distributes throughout the cell
surface as observed in endothelial progenitor cells (Wang et al.,
2012).
Few reports have shown that umbilical cord blood-derived pro-
genitors can express pluripotent/multi-lineage markers, as Oct3/4,
Sox2, Nanog and SSEA4 (Habich et al., 2006; Peters et al., 2010;
van de Ven et al., 2007). Fig. 3C shows high positivity for the tran-
scription factor Oct4 which is distributed in a punctuate pattern
both in the nucleus and in the perinuclear area of the cytoplasm,
accordingly with its phosphorylation-dependent nucleocytoplas-
mic redistribution and its trafﬁcking through nuclear pores (Yang
et al., 2014). This localization pattern may be of functional rele-
vance since it was recently demonstrated that transient retention
of Oct4 in the nucleus was sufﬁcient to maintain an undifferen-
tiated state in embryonic stem cells (Oka et al., 2013). Fig. 3D
shows positivity for cell surface SSEA4 that is seen in the cyto-
plasm and on the cell surface, both in punctuate patterns and in
ﬁbers-resembling aggregates, as shown in periodontal ligament-
derived MSC (Trubiani et al., 2010). Finally, we also analyzed the
expression of members of the STAT family, which are required for
embryonic stem cellmaintenance and self-renewal (Bausek, 2013).
Notably, CBMSC were positive for STAT-5, -6 and most importantly
STAT-3, a key transcriptional determinant for the maintenance of
an undifferentiated phenotype in embryonic stem cell and directly
regulating the expression of pluripotency-related genes Oct4 and
Nanog (Raz et al., 1999; Chih-I et al., 2012) (Fig. 3E–G). Taken alto-
gether, these results suggest thatCBMSC, often considerate as foetal
MSC, are primitive cells, somewhere between embryonic stemcells
and mature adult stem cells.
3.4. Molecular proﬁling
Among molecular factors discriminating between various stem
cell types, microRNA (miRNA) were recently identiﬁed (Huang
and Lin, 2012). miRNA are non-coding RNAs able to regulate gene
expression at a post-transcriptional level, with each miRNA being
able to target a number of different mRNA species and to establish
complex networks of interactions to coordinate cellular responses.
Also, miRNAs are involved in stem cell self-renewal and differen-
tiation by targeting components that determine stem cell fate (Yu
et al., 2012). Therefore, to characterize at molecular level the stem-
ness properties of CBMSC, the expression of “stemness” miR-302b
andmiR-335 (Tomé et al., 2011; Lee et al., 2008)was assessed. Such
analysiswas performed in comparisonwith standard and validated
BMMSC populations routinely used in our laboratory and using
miR-191/miR-214ashousekeepers (Bargaje et al., 2010), since their
stability and thus suitability tobeusedasmiRNAreferencebetween
CBMSC and BMMSC was conﬁrmed in a recent publication of our
group (Ragni et al., 2013b). Notably, both markers were signif-
icantly (p-value≤0.05) more expressed in CBMSC than in bone
marrow MSC, with miR-302b being 17 times upregulated (Fig. 4A).
These data are a further conﬁrmation for CBMSC primitive identity
since miR-302b was shown to play an important role in maintain-
ing pluripotency in embryonic stem cells and in maintaining cell
self-renewal (Lee et al., 2008).
Further, speciﬁc gene expression signatures were also demon-
strated to be correlated with stemness properties of mesenchymal
stem cells (Wang et al., 2011; Jansen et al., 2010). Thus, we proﬁled
the expression of key genes involved in maintaining pluripo-
tency and self-renewal status and encompassing several functions
T. Montemurro et al. / European Journal of Cell Biology 95 (2016) 228–238 233
Fig. 3. Immunoﬂuorescence analysis. Cultured CBMSC were positive for perivascular markers (A and B) and for embryonic markers such as Oct-4 AB and SSEA-4 (C and D).
CBMSC were positive also for STAT-3 (E), STAT-5 (F) and STAT-6 (G). Magniﬁcation 40–60× as reported in ﬁgure. Scale bars 20m. Negative controls with a species-speciﬁc
labelled secondary antibody for indirect immunoﬂuorescence and isotype-matched controls for direct staining are shown in small boxes.
(stemness markers, MSC-speciﬁc markers, MSC-differentiation
markers and MSC-associated genes) in three independent CBMSC
isolates (see Supplementary Table 1 in theonline version atDOI: 10.
1016/j.ejcb.2016.04.003). Notably, all three CBMSC showed a con-
sistent similarity in the expression of tested genes (R value >0.9
for each couple of datasets) that allowed extracting a panel of 55
genes to be submitted to hierarchical clustering analysis (Fig. 4B).
This deﬁned a panel of 22 candidates consistently expressed at
homogeneously high levels (VIM, COL1A1, ITGB1, RHOA, ANXA5A,
CTA2, ALCAM, CD44, MMP2, ITGAV, TGFB1, SMURF2, VEGFA, JAG1,
KITLG, ENG, GTF3A, IL6, NT5E, ANPEP, FGF2 and THY1). On these
identiﬁed genes, the GeneCodis program was run to ﬁnd statis-
tically enriched biological processes with respect to the entries of
the whole human genome (Carmona-Saez et al., 2007; Nogales-
Cadenas et al., 2009; Tabas-Madrid et al., 2012). Interestingly, the
most signiﬁcant biological processes were angiogenesis (pValue
6.6e-10), positive regulation of cell proliferation (2.0e-09) and cell
adhesion (4.0e-08). Consistently, looking for enriched molecular
functions, GeneCodis identiﬁed growth factor activity (6.7e-10),
protein binding (4.3e-06) and cytokine activity (3.4e-06). Finally,
ﬁve genes, ANXA5 (coding for a calcium-dependent phospholipid
binding protein expressed in perycites with the capacity to dif-
ferentiate into multiple mesenchymal lineages; Brachvogel et al.,
2005), COL1A1 (Collagen, type I, alpha 1 expressed in bone mar-
row MSC with high osteogenic potential; Kulterer et al., 2007),
ITGB1 (Integrin, beta 1 surface antigen speciﬁcally marking MSC
populations; Salem and Thiemermann, 2010), RHOA (small GTPase
with an essential role in the migration of MSC via reorganization
Fig. 4. Molecular proﬁle and cell differentiation of CBMSC. (A) qRT-PCR analysis of miR-302b and miR-335 in CBMSC vs BMMSC with normalized BMMSC values set as 1.
Error bars represent SEM. * for p-value≤0.05. (B) Hierarchical clustering of mesenchymal stem cell-associated genes of three independent CBMSC isolates at passage 5,
obtained with Cluster 3.0 software following default settings. (C and D) The osteogenic induction was veriﬁed by alizarin red staining, which marks calcium-rich minerals
deposits and by quantiﬁcation of osteo-related genes, Osterix (OSX), and Osteopontin (OPN); ** for p-value≤0.01, *** for p-value≤0.001. (E and F) Chondrogenesis was
proved by alcian blue staining of the chondrocyte-speciﬁc glucosaminoglycan and by expression of Collagen type II and type X, alpha 1 (COL2A1, COL10A1) in induced cells
respect to control cells; * for p-value≤0.05, *** for p-value≤0.001. (G and H) Lipid droplets in the adipogenic-differentiated CBMSC stained positive for Oil red O. For this
differentiation Peroxisome proliferator-activated receptor gamma (PPARG), Glucose transporter type 4 (GLUT4) and ADIPSIN genes were evaluated; ** for p-value≤0.01, ***
for p-value≤0.001.
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Fig. 5. Hematopoietic support. (A)HSCCD34+ fromCBunitswere co-culturedwith CBMSC, according to the schemepictured. (B) Phase-contrastmicroscopic viewof adherent
cells showed the dark round cells forming a cobblestone area underneath the ﬁbroblastic cell layer. (C–E) HSC CD34+ cells were grown on CBMSC for 5 weeks, harvested, and
allowed to form colonies in semisolid media for 14days before scoring colony phenotypes (C: HPPC, D: CFU-GM, E: CFU-GEMM). Magniﬁcation B: 100×; C–E: 40×. (F) Cells
harvested at the end of LTC-IC assaywere analyzed by ﬂow cytometry for the detection of hematopoieticmarkers CD34, CD38 and CD133within the CD45+ cell compartment.
of the cytoskeleton; Raheja et al., 2011) and VIM (Vimentin, a type
III intermediate ﬁlament protein that is expressed in mesenchymal
cells;Madeira et al., 2012), were always themost expressed in each
CBMSC, thus deﬁning a subset of ﬁve highly reliable and abundant
MSCmarkers to unequivocally deﬁne umbilical cord blood-derived
mesenchymal stem cells.
3.5. Cell lineage differentiation
As a whole with a unique molecular signature, a distinguish-
ing feature of MSC is their great capacity for self-renewal while
maintaining their multipotency. MSC are capable of differentiat-
ing tomesengenic osteocytic, chondrocytic, andadipocytic lineages
when stimulated under appropriate conditions (Augello and De
Bari, 2010). We studied this potency in CBMSC by exposure to
appropriate inductive media in vitro.
In osteogenic conditions, CBMSC acquired extended area of
mineralization, as evidenced by staining with the calcium-speciﬁc
dye Alizarin red (Fig. 4C). Induced cells consistently showed ele-
vated levels of the late stage marker associated with osteogenesis
OPN (4-fold increase) (Fig. 4D). Both aspects conﬁrm the ability of
CBMSC to complete in vitro the osteogenic process.
CBMSC cultured in chondrogenic conditions demonstrated the
presence of intracellular matrix mucopolysaccharides, that are
cartilage-speciﬁc proteoglycans, as evidenced by Alcian Blue stain-
ing (Fig. 4E). Effective chondrogenesis was further corroborated
by analyzing the mRNA level increase of type II collagen (COL2A1,
8-fold increse) and type X collagen (COL10A1, 27-fold increase),
both being routinely used as marker of late-stage chondrocyte
hypertrophy (associated with endochondral ossiﬁcation) (Fig. 4F).
Again, such data indicate the full potential to differentiate in vitro
into mature chondrocytes.
Under adipogenic induction, few CBMSC generated sporadic
lipid vacuoles with very small intracellular lipid droplets stainable
by the triglyceride-speciﬁc dye Oil Red O (Fig. 4G). Poor adi-
pogenic potential detected by microscopic analysis was consistent
with the qRT-PCR results observed for late adipogenesis mark-
ers PPARG (2-fold increase), GLUT4 (2-fold increase) and ADIPSIN
(11-fold increase) (Fig. 4H) that, in ADMSC and BMMSC, after
adipogenic process were demonstrated to display much higher
increase ratios (eg, ADIPSIN increase of 110-fold for ADMSC and
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Fig. 6. Angiogenic potential of CBMSC and secretory proﬁle in response to cell damage. (A) Tube formation and the presence of capillary-like networks were induced by
CBMSC conditioned media, as highlighted by staining endothelial cells with antibodies against von Willebrand factor and CD31. VEGF was used as positive control; suramin
and complete medium were used as negative control. (B) To explore the angiogenic and anti-inﬂammatory potential, CBMSC were co-cultured for 24–48–72–192h in an in
vitro system of damage repair (cisplatin-damaged HK2 cells). Black bars: co-culture of HK2 cell line after cisplatin damage together with CBMSC; grey bars: HK2 cell line after
cisplatin damage. HK2 cell line without damage was used as steady-state: white bars. * for p-value≤0.05, ** for p-value≤0.01, *** for p-value≤0.001.
60-fold for BMMSC, as shown in a recent publication of our group,
Ragni et al., 2013a). Intriguingly, low efﬁciency of the adipogenic
in vitro differentiation remains one of the major limitations also
for embryonic stem cells (Dani et al., 1997; Schaedlich et al., 2010;
Chen et al., 2007), being this another trait connecting CBMSC with
primitive stem cell populations.
3.6. Hematopoietic support ability
Together with their multilineage potential, one of the ﬁrst fea-
tures that unequivocally characterized MSC populations isolated
from the bonemarrow stromawas their ability to providemicroen-
vironmental support for hematopoietic stem cells (HSC) (Morrison
and Scadden, 2014). Thus, in order to deeply deﬁne CBMSC
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identity in the frameof stemcell-relatedpotentialities,weexplored
umbilical cord blood-derived cells ability to sustain ex vivo HSC
expansion.
By co-culturing CBMSC with umbilical cord blood CD34+ HSC,
according to the scheme presented in Fig. 5A, we observed a robust
ability to support hematopoietic cell proliferation, also if com-
pared to standardized MS5 murine bone marrow stromal cell line
used as a feeder. Notably, already after 10days, the appearance of
typical colonies of adherent haematopoietic cells named cobble-
stone areas (tightly knit group of phase-dark, angular cells in the
stroma) was observed (Fig. 5B), conﬁrming that CBMSC could sup-
port and expand HSC. During all the long-term culture-initiating
cell assay (LTC-IC), the cobblestoneareaswere stronglymaintained.
Then, after 5 weeks, these primary stroma-supported cultures
were scored for replatable colony-forming cells (CFC) that are
released into the culture supernatant and assayed in semisolid
culture systems (Bock, 1997). Very large hematopoietic colonies
were detected as shown in Fig. 6C–E with a strong presence of
high proliferative potential cells (Fig. 5C) together with colony
forming (CFU) such as granulocyte/macrophage CFU (Fig. 5D) and
granulocyte/erythroid/macrophage/megakaryocyte CFU (Fig. 5E).
In addition, at the end of the LTC-IC, the immunophenotype of
the cells after trypsinization was analyzed by ﬂow cytometry and
conﬁrmed the presence of primitive hematopoietic cells express-
ing CD34, CD133 and CD38 within the CD45+ cell compartment
(Fig. 5F).
Finally, if compared to MS5, CBMSC secreted high levels
(83.7 +22.1pg/mL versus undetectable levels) of SCF, an essential
hematopoietic cytokine that interacts, with other cytokines, to
preserve the viability of hematopoietic stem and progenitor cells
(Hassan and Zander, 1996). Altogether, these results demonstrated
that CBMSC may provide a useful source of stromal support for
CD34+ HSC expansion and suggest the use of these cells in place of
commonly used BMMSC to positively impact ex vivo expansion and
preservation of the ‘stemness’ potential of HSC.
3.7. Secretory proﬁle
As clearly shown by the effective hematopoietic support ability,
MSC may inﬂuence surrounding cells or reconstruct a coordinat-
ing function, in particular via the secretion of factors like cytokines
and chemokines (Schinköthe et al., 2008). Molecular data sug-
gested that CBMSC may be strongly involved in angiogenesis
and promotion of cell proliferation. Thus, cytokines involved in
these processes were evaluated in the growth medium. At steady
state CBMSC spontaneously released 13.5pg/mL (range 8.7–16.7)
HB-EGF (angiogenesis and wound healing), 22.4pg/mL (range
16.3–39.1) HGF (angiogenesis and tissue regeneration), 10.6pg/mL
(range 7.1–13.5) FGF (angiogenesis and wound healing) and 471.3
(range 369.3–590.0) pg/mL VEGF (vasculogenesis and angiogene-
sis), as assessed by quantitative multiplex ELISA measurement of
angiogenic factors.
In addition to their role as biomarkers, released extracellular
vesicles (EV) have been very recently included among the play-
ers contributing to MSC regenerative potential (Teng et al., 2015;
Zhang et al., 2015; Anderson et al., 2016) although, to date, a
molecular deﬁnition of their cargo is missing. In this frame, we
deeply investigated the ability of CBMSC to secrete EV and fur-
ther characterized their nucleic acids content for mRNA promoting
angiogenesis and cell proliferation. CBMSC spontaneously secreted
4500EV/cell/day (range 3200–5300). CBMSC-EV showed a mean
size of 250nm (range 50–450nm), suggesting absence or negli-
gible contamination of apoptotic bodies that usually fall into the
size range of 1–5m. qRT-PCR analysis demonstrated the pres-
ence of several transcripts related to angiogenic and proliferative
functions. The most abundantly detected were CTGF (inductor of
vascular endothelial angiogenesis), FGF and IL-6 (inductor of VEGF
expression)mRNAs.We also clearly observed TGFB1 (angiogenesis)
and VEGF transcripts. Finally, HGF mRNA was ampliﬁed, although
at low amount.
Altogether, these data conﬁrm that CBMSC secrete crucial
proangiogenic, proliferation-stimulating and tissue repair factors,
either as soluble cytokines (fast and transitory response) or as
membrane vesicles embedded precursors (delayed and durable
support through translated mRNA), that may sequentially con-
tribute to cell recovery and regeneration.
3.8. Tube formation assay
The angiogenic potential of CBMSC was investigated by assess-
ing the effect of conditioned medium (CM), containing both
secreted factors and EV, on endothelial cell culture. CBMSC-CM
was able to signiﬁcantly induce blood vessel response with the
development of capillary-like structures resulting positive for the
endothelial markers von Willebrand Factor (glycoprotein present
in the subendothelialmatrixof thevesselwall) andCD31 (glycopro-
tein present in endothelial cells) (Fig. 6A). Also, CM augmented the
number of blood vessels crossing the delimited area and increased
the formation of new blood vessels as observed with recombi-
nant VEGF, used as positive control; conversely, the unconditioned
medium did not display any pro-angiogenic activity, analogously
to suramin (an anti-trypanosomal agent with an antiangiogenic
action). These results suggest that CBMSC could be particularly
attractive for their pro-angiogenic properties, especially in those
processes requiring new blood vessel formation.
3.9. Response to cell damage
During wound healing, angiogenic capillary sprouts invade
the ﬁbrin/ﬁbronectin-rich wound clot and within a few days
organize into a microvascular network throughout the granula-
tion tissue (Tonnesen et al., 2000). The chemotherapeutic agent
cisplatin is known to promote acute kidney injury with vasocon-
striction, detachment of tubular cells, luminal tubular obstruction
and trans-tubular back-leakage of the glomerular ﬁltrate (Ozkok
and Edelstein, 2014). Among other factors, renal function healing
is associated with an adequate blood supply and, in animal models,
MSC supplementation promoted the recovery of damaged blood
vessels, thereby contributing to themaintenanceof bloodperfusion
and to the stabilisation of the vasculature (Kucic et al., 2008; Tögel
et al., 2009). Therefore, to conﬁrm CBMSC secretome angiogenic
support, a standardized in vitro model of renal damage caused by
cisplatinwasperformed (Morigi et al., 2010). In the co-culturewells
with damaged renal HK-2 cells, angiogenic factors were strongly
released in a much higher quantity if compared to the steady state
levels (Fig. 6B). In particular, the production of HGF signiﬁcantly
increased compared to cisplatin-damaged HK-2 cells alone at dif-
ferent time points (p value≤0.05 at 24h). Consistently, the other
assayed angiogenic factors showed an increased trend, even if not
statistically signiﬁcant, in the ﬁrst 48–72h in the presence of the
damage. These results strongly suggest that CBMSC are respond-
ing dynamically in the wound bed niche promoting angiogenesis
observed in animal models.
Finally, the secretion of immunomodulatory molecules in our
renal damage model was assayed (Fig. 6B). A signiﬁcant reduc-
tion of inﬂammatory factors such as TNFalpha, IL10, IL1beta and
INFgamma was observed at all the major time points when CBMSC
were co-cultured in the presence of the damage. These results
conﬁrm the plasticity of mesenchymal stem cells in immunomod-
ulation and reinforce the idea of CBMSC as potent cellular products
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for therapeutic applications when paracrine mechanisms are
needed as it happens during tissue regeneration.
4. Conclusions
Whereas a plethora of different tissue origins for the isolation
of mesenchymal stem cells have been described, human umbil-
ical cord blood presents a large number of advantages being
devoid from any ethical controversy with non-invasive harvest-
ing procedures. Isolated CBMSC possess all the features of the
most commonly used adult MSC with striking and speciﬁc features
such as their increased proliferative and pro-angiogenic capaci-
ties. Intriguingly, this ability may be due to a two-step mechanism
involving in a ﬁrst instance fast-acting secreted soluble factors and
subsequently EV-delivered nucleic acids for a durable response.
Therefore, data herein presented support CBMSC as a very promis-
ing stemcell population for all clinical applications relyingon tissue
regenerationmost of allwhennewblood vessel formation together
with immunomodulation and paracrine support are critical com-
ponent of wound healing process.
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Supplementary Table 1 
 CBMSC 1 CBMSC 2 CBMSC 3 
ABCB1 34.36 39.39 36.64 
ALCAM 25.67 24.24 25.85 
ANPEP 29.67 26.42 26.53 
ANXA5 22.78 23.47 24.67 
BDNF 27.81 28.05 29.25 
BGLAP 32.36 31.33 32.10 
BMP2 40.00 36.46 39.12 
BMP4 40.00 40.00 40.00 
BMP6 37.10 35.02 35.21 
BMP7 40.00 40.00 40.00 
CASP3 28.69 27.84 28.85 
CD44 26.01 24.39 25.62 
COL1A1 23.31 19.63 19.85 
CSF2 37.28 37.13 37.47 
CSF3 36.76 37.94 40.00 
CTNNB1 31.43 27.84 27.78 
EGF 28.37 31.23 35.93 
ENG 28.40 25.76 26.54 
ERBB2 35.56 32.14 31.02 
FGF10 39.54 38.82 40.00 
FGF2 25.65 26.49 27.31 
FUT1 40.00 39.78 39.69 
FUT4 40.00 37.53 35.15 
FZD9 40.00 38.52 37.62 
GDF15 33.71 34.18 27.09 
GDF5 33.67 29.19 27.26 
GDF6 36.66 32.76 30.76 
GDF7 40.00 40.00 38.41 
GTF3A 24.07 25.86 28.07 
HAT1 23.88 27.85 29.02 
HDAC1 28.87 27.21 27.84 
HGF 40.00 35.76 30.60 
HNF1A 40.00 38.02 40.00 
ICAM1 32.22 29.66 28.50 
IFNG 40.00 39.06 40.00 
IGF1 40.00 39.83 40.00 
IL10 40.00 39.91 39.96 
IL1B 34.62 29.20 28.38 
IL6 24.20 26.17 28.83 
INS 38.85 40.00 40.00 
ITGA6 29.27 28.87 28.92 
ITGAV 26.85 24.95 25.78 
ITGAX 38.21 40.00 40.00 
ITGB1 22.87 21.90 22.56 
JAG1 31.31 25.63 27.19 
KDR 34.40 32.33 34.85 
KITLG 26.63 25.71 28.16 
LIF 30.33 27.89 28.73 
MCAM 28.92 27.13 27.96 
MMP2 26.36 24.46 25.26 
NES 31.17 31.07 34.09 
NGFR 39.76 39.51 40.00 
NOTCH1 36.91 33.51 33.70 
NT5E 26.49 26.19 27.12 
NUDT6 28.69 29.58 27.19 
PDGFRB 35.62 29.23 27.70 
PIGS 30.74 27.98 27.71 
POU5F1 38.05 34.58 34.68 
PPARG 34.03 33.08 31.95 
PROM1 36.74 40.00 40.00 
PTK2 29.85 27.94 28.66 
PTPRC 40.00 40.00 40.00 
RHOA 21.70 22.63 24.78 
RUNX2 32.55 27.86 30.88 
SLC17A5 30.46 29.39 29.63 
SMAD4 29.49 27.53 29.02 
SMURF1 32.17 29.16 29.82 
SMURF2 24.99 25.22 26.94 
SOX2 40.00 40.00 40.00 
SOX9 31.97 31.43 31.70 
TBX5 40.00 39.31 40.00 
TERT 39.33 38.99 40.00 
TGFB1 28.57 24.99 25.51 
TGFB3 34.21 31.81 30.41 
THY1 29.14 26.89 25.94 
TNF 40.00 39.56 40.00 
VCAM1 29.17 29.64 30.51 
VEGFA 25.61 25.25 26.56 
VIM 19.75 19.36 21.71 
VWF 38.13 38.28 37.26 
WNT3A 38.02 37.85 40.00 
ZFP42 40.00 40.00 34.63 
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Introduction 
Over the past 15 years, multipotent mesenchymal stromal cell (MSC) research 
has grown exponentially and a plethora of additional MSC sources have been 
unraveled [1], suggesting that they can be present virtually in any vascularized 
tissue of the body [2, 3].  
Nowadays, MSCs can be divided mainly into adult and perinatal stem cells, 
depending on their tissue source. Adult MSCs include those deriving from bone 
marrow [4] and adipose tissue [5], whereas perinatal MSCs are isolated from 
amniotic fluid [6], cord blood [7-9], umbilical cord perivascular compartment [10] 
and Wharton’s jelly [11, 12].  
In 2006, Dominici et al. [13] provided milestone guidelines with a minimal set of 
standard criteria to define the specific characteristics of MSCs. The properties 
that define MSC populations were classified into three categories: physical 
properties, defined by their ability to adhere to plastic culture surfaces; 
immunophenotypic properties, corresponding to the expression of specific 
surface antigens (CD105-, CD73- and CD90-positive, and CD45-, CD34-, 
CD14- or CD11b-, CD79a- or CD19- and HLA-DR-negative cells); functional 
properties, defined as the potential to differentiate into osteoblasts, adipocytes 
and chondrocytes in vitro.  
These criteria have been extremely helpful to initially provide common accepted 
parameters in the MSC field. Nonetheless, we think it is now mandatory to shed 
new light on MSC features, with a focus on adult and perinatal MSCs, 
compared to human foreskin fibroblasts (HSFs).  
With the present study we will be able to answer very relevant questions: are 
there alternative determinants able to discriminate tissue-specific MSCs? Can 
we clearly distinguish MSCs from adult and perinatal sources? Summarizing: 
are all MSCs the same? 
Materials and methods 
 
Cell isolation, growth and MSC characterization 
Each stem cell type was isolated from independent healthy donors (n=3), after 
informed consent was obtained. The isolation protocols were already described 
by Ragni et al. [14, 15] for ADMSCs and BMMSCs, Barilani et al. [8, 9] for 
CBMSCs, Bossolasco et al. [16] for AFCs, Montemurro et al. [17] for PVCs, 
Batsali et al. [10] for WJMSCs, Gioventù et al. [18] for DPMSCs, Normand et al. 
[19] for HSFs. All cells were cultured in αMEM (Thermo Fisher Scientific, 
Waltham, MA, USA) supplemented with 20% FBS (Thermo Fisher Scientific). 
AFCs were cultured in a medium specific for amniocytes (Amniomed; 
Euroclone, Pero, Italy). Stem cell identity of isolated MSCs was assessed by 
immunophenotype profiling, which confirmed high expression of typical MSC 
surface markers, such as CD90, CD73, CD44, and CD105, and negativity for 
the hematopoietic markers CD34, CD133 and CD45. Characterization of each 
MSC type was performed by adipogenic, osteogenic and chondrogenic 
differentiation protocols and subsequent histochemical staining, as previously 
described in Barilani et al. (2016) (data not shown). 
All the following analyses (flow cytometry, PCR-array, Real Time qRT-PCR, 
ELISA) were performed at passage 3-5 for each cell population, with a medium 
change 24 hours before cell harvesting or collection of conditioned media. 
 
RNA isolation 
RNA was isolated using RNeasy Plus Mini-kit (Qiagen, Hilden, Germany), 
following manufacturer’s instructions. RNA purity was determined by measuring 
absorbance A260/A280 in a Nanodrop spectrophotometer (ND-1000; Thermo 
Fisher Scientific, Waltham, MA, USA). RNA integrity was assessed using 
electrophoretic techniques. 
 
 
 
 
 
qRT-PCR array expression profiling 
mRNA expression profiling was performed with Mesenchymal Stem Cell RT2 
Profiler PCR Array System (Qiagen), following manufacturer’s instructions. 
Relative expression of each mRNA was determined with the Ct method using 
the software RT2 Profiler PCR Array Data Analysis (Qiagen) and the 
housekeeping genes of the array. 
 
cDNA synthesis and quantitative RT-PCR assays 
cDNAs were synthesized from 800 ng of total RNA in 20 μL reactions, using the 
iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA), 
according to the manufacturer's instructions. Specific primers for BMP7, CD56, 
CD146, CD271, EGF, FUT1, IGF1, NG2, PDGFR and TBX5 were designed in-
house, selecting only the primers spanning an exon-exon junction and 
producing a PCR amplificate with length between 70 and 150 base pairs. Real 
Time qRT-PCR was carried out using SsoFast EvaGreen Supermix (Bio-Rad) in 
a BioRad CFX96 Real-Time PCR Detection System instrument (Bio-Rad), using 
standard PCR conditions. All experiments were perfomed in triplicates and 
values exceeding standard deviation >10% were discarded; each assay 
included a blank. To confirm product specificity, a melting curve analysis was 
performed after each amplification. Relative gene expression was normalized to 
ACTB, B2M, GAPDH, and RPLP0 gene expression using the ΔΔCt method. For 
statistical analysis and expression data generation, the Bio-Rad CFX Manager 
software was used. Primer sequences will be provided upon request. 
 
Flow cytometry 
100,000 cells were harvested for each cell population. The cells were 
centrifuged at 350 xg for 7 minutes, after which the supernatant was discarded. 
The resuspended cell pellet was then incubated with fluorochrome-conjugated 
antibodies in a total volume of 200 μL of PBS for 20 minutes in the dark at RT. 
The following antibodies (BD, Franklin Lakes, NJ, USA) were used: CD271-PE, 
PDGFR-β-PE, CD56-PC5, CD146-PC7, SSEA4-FITC, NG2-PE, CD34-PerCP-
C5.5. Unstained samples were prepared to assess autofluorescence. A total of 
10,000 events were acquired using a BD FACSCanto II cytometer (BD) and 
analyzed by the BD FACSDiva version 7 analysis software (BD). The use of the 
application setting option for the cytometer parameter adjustment guaranteed 
consistent and unbiased analysis of samples within different experiments. 
 
ELISA 
Supernatants of MSCs and HSFs were collected at passage 3-5 after 
centrifugation at 350 xg for 10 minutes and stored at -20°C. Human MCP-1 and 
IGF1 proteins were quantified in with the human MCP-1 ELISA Kit (Thermo 
Scientific, Rockford, IL, USA) and human IGF1 ELISA Kit (Elabscience, WuHan, 
China), according to manufacturer’s instructions. The optical density (OD value) 
was detected with a plate reader (GENios Plus; TECAN, Männedorf, 
Switzerland) with a 450 nm filter set. The data were analyzed with Magellan 
software (TECAN). 
 
Statistical analysis 
All statistical analysis were performed with Prism version 6.0 (GraphPad, La 
Jolla, CA, USA), if not indicated otherwise. Single linkage clustering was 
performed with R software (https://www.r-project.org).  
Principal component analysis was performed with Multibase software 
(www.numericaldynamics.com). 
  
Results: qRT-PCR array 
               
Complete qRT-PCR array. Fold change (Magnitude of gene expression) between multipotent 
mesenchymal stromal cells (MSCs) from different sources is represented. Min, minimum; avg, average; 
max, maximum; AF, amniotic fluid; HSF, human skin fibroblasts; AD, adipose tissue; BM, bone marrow; 
CB, cord blood; WJ, Wharton’s jelly; PV, perivascular compartment.  
Bibliography 
 
1. Hass, R., et al., Different populations and sources of human 
mesenchymal stem cells (MSC): A comparison of adult and neonatal 
tissue-derived MSC. Cell Commun Signal, 2011. 9: p. 12. 
2. Crisan, M., et al., A perivascular origin for mesenchymal stem cells in 
multiple human organs. Cell Stem Cell, 2008. 3(3): p. 301-13. 
3. Corselli, M., et al., Perivascular ancestors of adult multipotent stem cells. 
Arterioscler Thromb Vasc Biol, 2010. 30(6): p. 1104-9. 
4. Pontikoglou, C., et al., Bone marrow mesenchymal stem cells: biological 
properties and their role in hematopoiesis and hematopoietic stem cell 
transplantation. Stem Cell Rev, 2011. 7(3): p. 569-89. 
5. Bunnell, B.A., et al., Adipose-derived stem cells: isolation, expansion and 
differentiation. Methods, 2008. 45(2): p. 115-20. 
6. Steigman, S.A. and D.O. Fauza, Isolation of mesenchymal stem cells 
from amniotic fluid and placenta. Curr Protoc Stem Cell Biol, 2007. 
Chapter 1: p. Unit 1E.2. 
7. Bieback, K. and H. Kluter, Mesenchymal stromal cells from umbilical cord 
blood. Curr Stem Cell Res Ther, 2007. 2(4): p. 310-23. 
8. Barilani, M., et al., A Chemically Defined Medium-Based Strategy to 
Efficiently Generate Clinically Relevant Cord Blood Mesenchymal 
Stromal Colonies. Cell Transplant, 2016. 25(8): p. 1501-14. 
9. Barilani, M., et al., Dissection of the cord blood stromal component 
reveals predictive parameters for culture outcome. Stem Cells Dev, 
2015. 24(1): p. 104-14. 
10. McElreavey, K.D., et al., Isolation, culture and characterisation of 
fibroblast-like cells derived from the Wharton's jelly portion of human 
umbilical cord. Biochem Soc Trans, 1991. 19(1): p. 29s. 
11. Batsali, A.K., et al., Mesenchymal stem cells derived from Wharton's 
Jelly of the umbilical cord: biological properties and emerging clinical 
applications. Curr Stem Cell Res Ther, 2013. 8(2): p. 144-55. 
12. Wang, H.S., et al., Mesenchymal stem cells in the Wharton's jelly of the 
human umbilical cord. Stem Cells, 2004. 22(7): p. 1330-7. 
13. Dominici, M., et al., Minimal criteria for defining multipotent mesenchymal 
stromal cells. The International Society for Cellular Therapy position 
statement. Cytotherapy, 2006. 8(4): p. 315-7. 
14. Ragni, E., et al., Differential microRNA signature of human mesenchymal 
stem cells from different sources reveals an "environmental-niche 
memory" for bone marrow stem cells. Exp Cell Res, 2013. 319(10): p. 
1562-74. 
15. Ragni, E., et al., Adipogenic potential in human mesenchymal stem cells 
strictly depends on adult or foetal tissue harvest. Int J Biochem Cell Biol, 
2013. 45(11): p. 2456-66. 
16. Bossolasco, P., et al., Molecular and phenotypic characterization of 
human amniotic fluid cells and their differentiation potential. Cell Res, 
2006. 16(4): p. 329-36. 
17. Montemurro, T., et al., Differentiation and migration properties of human 
foetal umbilical cord perivascular cells: potential for lung repair. J Cell 
Mol Med, 2011. 15(4): p. 796-808. 
18. Gioventu, S., et al., A novel method for banking dental pulp stem cells. 
Transfus Apher Sci, 2012. 47(2): p. 199-206. 
19. Normand, J. and M.A. Karasek, A method for the isolation and serial 
propagation of keratinocytes, endothelial cells, and fibroblasts from a 
single punch biopsy of human skin. In Vitro Cell Dev Biol Anim, 1995. 
31(6): p. 447-55. 
 
1 
 
II. Unpublished data 
 
b. EXTRACELLULAR VESICLE-SHUTTLED mRNA IN 
MESENCHYMAL STEM CELL COMMUNICATION 
 
Enrico Ragni1, Federica Banfi1, Mario Barilani1,2, Alessandro Cherubini1, 
Valentina Parazzi1, Paola Larghi3,4, Vincenza Dolo5, Valentina Bollati6, Lorenza 
Lazzari1* 
 
1Cell Factory, Unit of Cell Therapy and Cryobiology, Fondazione IRCCS Ca' 
Granda Ospedale Maggiore Policlinico, Milan, Italy 
2Department of Industrial Engineering, University of Padova, Padova, Italy 
3Autoimmunity Program, Istituto Nazionale di Genetica Molecolare "Romeo Ed 
Enrica Invernizzi", Milan, Italy 
4Department of Pathophysiology and Transplantation, University of Milan, Milan, 
Italy 
5Department of Life, Health and Environmental Sciences, University of L'Aquila, 
L'Aquila, Italy 
6EPIGET - Epidemiology, Epigenetics and Toxicology Lab, Department of Clinical 
Sciences and Community Health, University of Milano, Milan, Italy; Epidemiology 
Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy 
 
Author contribution:  
E.R.: conception and design, collection and assembly of data, data analysis and 
interpretation, manuscript writing, final approval of manuscript; F.B.: conception 
and design, collection and assembly of data, data analysis and interpretation, 
final approval of manuscript; M.B., V.P., A.C., P.L., V.D., V.B.: collection and 
assembly of data, final approval of manuscript; L.L.: conception and design, final 
approval of manuscript. 
 
2 
 
* Corresponding author: Lorenza Lazzari, PhD, Cell Factory, Unit of Cell Therapy 
and Cryobiology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 
Via F. Sforza 35, 20122 Milan, Italy, Tel: +390255034053, Fax: +390255032796, 
lorenza.lazzari@policlinico.mi.it 
 
Acknowledgements:  
????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????and the Italian program 
???????????????????????????????????????? ????????15 (both to L.L.). 
 
Disclosure of potential conflicts of interest:  
The authors indicate no potential conflicts of interest. 
 
Keywords:  
???????????????????????????????????????????????????????? ??; IL-10. 
3 
 
ABSTRACT 
 
Mesenchymal stem cells (MSC) are multipotent cells able to differentiate into 
several cell types, hence providing cell reservoirs for therapeutic applications. 
The absence of detectable MSC homing at injury sites suggests that paracrine 
functions could, at least in part, be mediated by extracellular vesicles (EVs); EVs 
are newly identified players that are studied mainly as predictive or diagnostic 
biomarkers. Together with their clinical interests, EVs have recently come to the 
fore for their role in cell-to-cell communication. In this context, we investigated 
gene-based communication mechanisms in EVs generated by bone marrow and 
umbilical cord blood MSC (BMMSC and CBMSC, respectively). Both MSC types 
released vesicles with similar physical properties, although CBMSC were able to 
secrete EVs with faster kinetics. A pattern of preferentially incorporated EV 
transcripts was detected with respect to random internalization from the cytosol, 
after a validated normalization procedure was established. In the paradigm where 
EVs act as bioeffectors educating target cells, we demonstrated that kidney 
tubular cells lacking IL-10 expression and exposed to BMMSC-EVs and CBMSC-
EVs acquired the IL-10 transcript, which was efficiently translated into the 
corresponding protein. These findings suggest that horizontal mRNA transfer 
through EVs is a new mechanism in the MSC restoring ability observed in vivo 
that is here further demonstrated in an in vitro rescue model after acute cisplatin 
injury of tubular cells. 
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INTRODUCTION 
 
MSC are multipotent, non-hematopoietic adult stem cells, which can be isolated 
from almost all tissues and possess in vitro multilineage differentiation into 
mesodermic, endodermic and ectodermic lineages (Ullah et al., 2015, Crisan et 
al, 2011). During the last 10 years, these multipotent cells have generated 
considerable interest owing to their immunomodulatory activity and ability to 
escape the allogeneic immune response (Stoltz et al., 2015). Such unique 
properties make MSC an invaluable cell type for the repair of tissue/organ 
damage, attracting attention as a potential solution for tissue repair and wound 
healing (Gao et al., 2016). Multiple mechanisms identifying how MSC mediate 
their regenerative and immunomodulatory effects have been proposed, although, 
to date, several ambiguities and inconsistencies persist (Najar et al., 2016). 
The initially proposed differentiation-based rationale for MSC use has become 
increasingly untenable. MSC engraftment and subsequent differentiation into 
appropriate cell types were rare, with <1% of the administered cells surviving for 
more than one week (Ferrand et al., 2011; Spees et al., 2003; Vassilopoulos et 
al., 2003). Therefore, the predominantly short-lived paracrine effects of MSC 
became evident (Ringdén et al., 2006; Lee et al., 2009; Parekkadan and Milwid, 
2010). The paracrine effects of MSC were shown to include the release of both 
soluble factors, and extracellular vesicles (EVs) as parallel mechanisms for cell-
to-cell communication (Yáñez-Mó et al., 2015). 
EVs are composed of at least two distinct subtypes: exosomes (40?100 nm in 
diameter) formed within the endosomal network and microvesicles (100?1000 
nm) produced by outward budding of the plasma membrane. Cargo components 
and loading mechanisms are still a matter of debate, although it has become 
clear that specific subsets of lipid, protein, and nucleic factors may distinguish 
both EVs sub-populations and EVs secreted from different cell types (Yáñez-Mó 
et al., 2015). The emerging role for EVs as a shuttle of bioactive molecules, either 
as mediators to educate the surrounding environment or as screening markers in 
early-stage diagnosis, is being investigated, particularly by cancer researchers. 
In the stem cell field, a limited, albeit increasing, number of recent reports have 
demonstrated beneficial EVs effects in in vitro and animal models of kidney, liver, 
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and lung injury and wound healing (reviewed in Rani et al., 2015), together with a 
low propensity to trigger innate and adaptive immune responses (Yu et al., 2014). 
Because EVs appear to recapitulate the therapeutic effects of stem cell 
transplantation, the prevailing hypothesis is that MSC-EVs may exert their effects 
by transferring biologically active molecules such as proteins, lipids and various 
classes of nucleic acids including transcripts encoding therapeutic mediators. 
Therefore, the goal of our work was to characterize MSC-EV mRNAs and 
demonstrate a clear proof-of-concept for the efficient transfer of EV mRNAs to 
target cells and their subsequent translation in those cells as a novel mechanism 
of cellular communication. 
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MATERIALS AND METHODS 
 
Cell isolation and growth 
MSC from bone marrow aspirate and umbilical cord blood were obtained from 
healthy donors after informed consent. MSC isolation was performed as 
described in Ragni et al., 2016. MSC were propagated in alpha MEM 
supplemented with 20% FBS (Life Technologies, CA, USA). Stem cell identity of 
isolated BMMSC and CBMSC was confirmed by immunophenotype profile: cells 
were negative for the pan-hematopoietic marker CD45 and positive for the MSC 
cell-surface antigens CD73, CD90, and CD105, officially recommended for their 
concurrent use to define unambiguously a MSC type (Dominici et al., 2006). MSC 
were able to differentiate in vitro into adipocytes, osteocytes and chondrocytes 
following what reported in Ragni et al., 2013 (data not shown). All subsequent 
studies were carried out in technical triplicate on two independent cell lines 
named #1 and #2. Experiments were performed at passage 5. Human proximal 
tubular cells HKC8 were cultured in DMEM/F12 media supplemented with 10% 
FBS. 
 
EVs preparation 
MSC were grown to 80% confluence and then fresh medium without FBS was 
added. After 4-8-24 hours, conditioned culture medium was collected and serially 
centrifuged to remove floating cells and cellular debris (400 xg for 10 minutes and 
5,000 xg for 15 minutes for three times) before being ultracentrifuged at 100,000 
xg for 1 hour at 4°C with a fixed angle rotor (Fiberlite F37L-8x100) (Thermo 
Fisher Scientific, San Francisco, CA, USA). The pellet was suspended in PBS, 
dissolved in lysis buffer for RNA extraction or RIPA buffer for protein analysis. 
 
Scanning Electron Microscopy 
MSC grown on a glass coverslip were first fixed in 2% glutaraldehyde (Electron 
Microscopy Sciences, Hatfield, PA, USA) in PBS and then dehydrated through a 
graded series of ethanol solutions. Samples were critical-point dried and sputter 
coated with a SCD040 Balzer Sputterer (Balzers Union, Liechtenstein). A SEM 
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Philips 505 scanning electron microscope (Philips, Eindhoven, Netherlands) was 
used to examine the samples, using an accelerating voltage of 20 kV. 
 
Transmission Electron Microscopy 
According to proper dilutions, the EVs suspended in PBS were adsorbed to 300 
mesh carbon-coated copper grids (Electron Microscopy Sciences, Hatfield, PA, 
USA) for 5 minutes in a humidified chamber at room temperature. Vesicles on 
grids were then fixed in 2% glutaraldehyde in PBS for 10 minutes and then briefly 
rinsed in milli-Q water. Grids with adhered vesicles were examined with a Philips 
CM 100 transmission electron microscope TEM at 80kV, after negative staining 
with 2% phosphotungstic acid, brought to pH 7.0 with NaOH. Images were 
captured by a Kodak digital camera. 
 
Measurement of particle number and size distribution by nanoparticle 
tracking analysis (NTA) 
NTA was carried out using the Nanosight system (NanoSight, Wiltshire, UK) on 
EVs suspended in PBS that were further diluted 50-fold for analysis. NTA related 
the rate of Brownian motion to particle size. Vesicles were visualized by light 
scattering using a conventional optical microscope aligned perpendicularly to the 
beam axis. After a video was taken, NTA software tracked between frames the 
Brownian motion of individual vesicles and calculated total concentration and 
their size through application of Stokes-Einstein equation. 
 
PKH26-labeled EVs transfer 
EVs suspended in Diluent C were mixed with PKH26 (Sigma-Aldrich, St. Louis, 
MO, USA) and incubated for twenty minutes at RT in the dark. Labeling reaction 
was stopped by adding an equal volume of 1% BSA. EVs were ultracentrifuged at 
100???????????????our, washed with PBS, ultracentrifuged again at 100,000 xg for 
1 hour and finally suspended in PBS. Labeled vesicles were incubated with 
HKC8 cultured in a 20,000/1 (EVs/cell) ratio. PBS that received the same 
treatment as above was used as a control. Cells were observed after 24 hours 
under a Leica SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany) 
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or by flow cytometry with a FACSCanto II instrument (Becton Dickinson, San 
Diego, CA, USA) by measuring the fluorescence of PKH26 detected at 567 nm. 
 
Determination of the number of EVs incorporated by kidney tubular cells 
PKH26-labeled EVs were administrated to HKC8 cells with a 20,000/1 EVs/cell 
ratio. After 24 hours, cells were washed, detached and suspended in PBS to a 
concentration of 1,000,000 cell/mL. 0.1 mL was analyzed by ELISA in a 96-well 
plate with a 530 nm filter for PKH26 excitation and a 570 nm filter for PKH26 
emission. Cells treated with unlabeled EVs were used as negative CTRL and to 
subtract fluorescence background. In a separate well, 2.5exp9 PKH26-labeled 
vesicles suspended in 0.1 mL PBS were also scored for fluorescence. Signal 
intensity of EVs-treated cells after background subtraction was compared to 
labeled EVs fluorescence to determine the number of incorporated EVs. 
 
qRT-PCR analysis 
RNA was isolated using RNeasy Micro kit (Qiagen, Hilden, Germany). 
Quantitative PCR was carried out using SsoFast EvaGreen Supermix (Bio-Rad 
Laboratories, CA, USA). Gene specific primers (Neuroprotection: NGF, BDNF, 
GDNF, NTF3, CDNF, CNTF, MANF; Proliferation: FGF2, FGF7, ANGPT1, 
ANGPT2, CTGF, HGF, VEGF; Immunomodulation: IL-4, IL-6, IL-10, IL1RN, TGF-
???? ????; Stemness: ALCAM, BMP2, BMP7, KDR, PDGFRB, THY1, BGLAP, 
COL1A1, ICAM1; Housekeeping: GAPDH) were used. Triplicates of all reactions 
were analyzed. All replicates should be within 0.5 Ct of each other for further 
processing. To confirm product specificity, a melting curve analysis and an 
agarose gel electrophoresis for the less abundant transcripts were performed 
after each amplification. Relative gene expression was normalized in EVs using a 
combined method relying on GAPDH, mean Ct value and cDNA input (see 
Results). For MSC and to compare MSC and EVs, GAPDH was used. For 
statistical analysis and expression data generation, the Bio-Rad CFX Manager 
software was used. Primer sequences will be provided upon request. 
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RT-????????????????????? and full length IL-10 
RNA was isolated as previously described. cDNA was prepared using 
???????????? ??? ????? ???????? ??????? ???????????? ?????????? ???????????????
instructions. RT-PCR was carried out using GoTaq Green Master Mix (Promega, 
Madison, WI, USA). ??? ??????? ?? ??? ????????? ??? ????? ??????? ?????
http://utrdb.ba.itb.cnr.it/search ????????????????????????????? ????????????????IL-6, 
MANF, BGLAP and IL-4 transcripts. Then, Forward and Reverse primers were 
designed in the first or last 50 bp ????????? ????????????, respectively. Expected 
RT-PCR amplificates were: IL-6 392 bp out of 429 bp, MANF 296 bp out of 308 
bp, BGLAP 157 bp out of 158 bp, IL-4 79 bp out of 89 bp. For full length IL-10 
transcript, Forward and Reverse primers were designed in the first 50 bp of the 
?? ??? or last 50 bp of ?? ??? ?? IL-10 mRNA sequence deposited in NCBI 
Nucleotide database (NM_000572.2, http://www.ncbi.nlm.nih.gov/nucleotide). 
Expected amplicon was 1589 bp out of 1629 bp.  Primer sequences will be 
provided upon request. 
 
Pathway analysis 
?????? ??? ???? ????????????????miRNA binding sites within ?? ??? ???????? ??? ??s-
accumulated mRNA were identified using miRANDA algorithm (http:// 
www.microrna.org/microrna/home.do), with a mirSVR scores < -1.0 to exclude 
weak hits. Verified mRNA targets of selected miRNAs were identified using 
miRWalk database (http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/ 
index.html) (Dweep et al., 2011). Final target lists were then uploaded to 
GeneCodis tool (http://genecodis.cnb.csic.es/) to find statistically enriched 
biological processes with respect to the entries of the whole human genome. 
 
Flow cytometry 
To detect CFSE positive EVs, vesicles were first 1:50 diluted in PBS and then 
incubated for 30 minutes at RT with 5 μL of CFSE cell-permeable precursor 
carboxyfluorescein diacetate succinimidyl ester (CFDA-SE). Unlabeled samples 
were incubated with 5 μl PBS. Finally, stained and unstained EVs were analyzed 
on a FACSCanto II (BD). 
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To detect viable cells after 24 hours FBS depletion, MSC were detached with 
trypsin, washed with PBS and, after suspension, 1/20 volume 7-AAD (7-
Aminoactinomycin D) was added 10 minute incubation at RT. Labeled cells were 
immediately analyzed on a FACSCanto II (BD). At least 30,000 events were 
acquired. 
 
Immunostaining 
Immunofluorescence experiments were performed on HKC8 cells grown on 
fibronectin-coated coverslips using standard procedures. Briefly, 24 hours after 
cell seeding, EVs were delivered into two consecutive administrations (EVs/cell 
ratio 20,000/1), with a gap of 24 hours between them. 40 hours after first EVs 
administration, cell secretion was blocked by administration of Brefeldin A (final 
concentration 10 μg/mL); after 8 hours, Brefeldin A was removed and cells fixed 
in 4% PFA. Cell permeabilization was performed with 1% saponin for 15 minutes 
at RT, then a blocking solution of 3% BSA was added for 30 min at RT and finally 
the primary antibody was added in blocking solution at a final concentration of 5 
μg/mL (mouse anti-human IL-10, Santa Cruz Biotechnology, Santa Cruz, CA, 
USA????????????????????????????????????????????-mouse PE-conjugated antibody 
was used as secondary antibody, incubating cells for 1 hour at RT. Cell nuclei 
were stained with DAPI. Images were acquired using a Leica TCS SP5 confocal 
microscope with HCX PL APO 63x/1.25 objective (Leica). No primary antibody 
stained and no EVs incubated cells were used to set up experimental conditions 
and antibody dilutions. 
 
Western Blot 
Purified EVs or HKC8 collected 72 hours after EVs administration and 8 hours 
after Brefeldin A block were suspended in RIPA buffer supplemented with 
protease and phosphatase inhibitors and denatured in Laemmli Sample Buffer 
(Bio-Rad Laboratories) at 60 °C for 15 minutes. 10 μg of EVs proteins or 50 μg of 
cell extracts were separated by SDS-PAGE, transferred onto nitrocellulose 
membranes and incubated 1 hour at RT with blocking solution (5% BSA in TBS, 
0.1% Tween-20) (Sigma-Aldrich). Membranes were incubated overnight at 4 °C 
with the following primary antibodies: i) mouse anti-human IL-10 (Santa Cruz 
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Biotechnology cat. n° sc-8438, 1:200 dilution in 5% BSA in PBS, 0.1% Tween-
20), ii) mouse anti-human CD81 (BD cat. n° 551112, 1:200 dilution in 5% BSA in 
PBS, 0.1% Tween-20), iii) mouse anti-human CD63 (Santa Cruz Biotechnology 
cat. n° sc-5275, 1:100 in 5% BSA in PBS, 0.1% Tween-20), iv) mouse anti-
human CD90 (Abcam cat. n° ab133350, 1:100 in 5% BSA in PBS, 0.1% Tween-
20), v) mouse anti-human CD105 (Dako cat. n° M3527, 1:200 in 5% BSA in PBS, 
0.1% Tween-20), vi) mouse anti-GAPDH (Millipore cat. n° CS204254, 1:10000 in 
5% BSA in PBS, 0.1% Tween-20). Proteins of interest were detected with HRP-
conjugated sheep anti-mouse IgG antibody (1:3000, Bio-Rad Laboratories) and 
visualized with the Amersham ECL Western Blotting Analysis System (GE 
Healthcare, UK). 
 
MTT assay 
1.25exp4 HKC8 cells were seeded into 96-well plates and, after 24 hours, treated 
for 6 hours ??????????????????????????????????????????????????????????????????????
100 μL phenol red-free medium added and this time point was set as 0. At time 0, 
24 and 48 hours 20,000 EVs/cell were added. At time 0, 24, 48 and 72 hours 
MTT assay was performed. Briefly, 25 μL of a 3 mg/mL Thiazolyl Blue 
Tetrazolium Bromide (Sigma-Aldrich) were added to each well and the 
colorimetric reaction was allowed to proceed for 4 hours at 37°C. Then, 25 μL of 
40% SDS were added and the plate incubated overnight at 37°C in the dark. The 
next day, viable cells with MTT dye uptake were determined by measuring the 
optical density at 570 nm after background subtraction scored at 650 nm. Values 
shown are the mean of at least six measurements. 
 
Statistical Analysis 
Comparison of variances for the expression of distinct genes was used to 
analyze the significance of differences using one-way analysis of variance 
(ANOVA) (GraphPad Prism Software version 6, San Diego, CA, USA). A p-value 
< 0.05 was considered statistically significant. 
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RESULTS 
 
Characterization of MSC-derived EVs 
Electron microscopy on MSC showed structures resembling EVs protruding from 
the cell surface (Fig. 1A). Interestingly, EV secretion was located in the peripheral 
protrusions and concentrated at the edges of the plasma membrane for both 
MSC types. Then, we followed the capacity of the different MSC to secrete EVs 
by nanoparticle tracking analysis (NTA) at 4 h, 8 h, and 24 h after FBS removal 
(to remove vesicles present in serum). In all MSC, the number of secreted 
vesicles increased as a function of time with a significant gain at 24 h (p < 0.05, N 
= 5; Fig. 1B). Because no cell toxicity was observed in FBS starved BMMSC and 
CBMSC ??????????????????????????????????????????????????? ????????????????????
the 24 h FBS starvation time point for EVs harvesting. 
Using NTA we determined that the EVs of CBMSC and BMMSC ranged in size 
from 40?50 nm to 600?700 nm, indicating the presence of both exosomes and 
microvesicles. The mean values for the size of CBMSC-EVs and BMMSC-EVs 
laid between 230 nm and 275 nm and did not differ significantly (p > 0.05, N = 10; 
Fig. 1C). Interestingly, the observed particle size suggests the absence of 
apoptotic bodies, which usually fall into the size range of 1????????????????????
NTA quantification to determine the number of EVs secreted per MSC line as 
function of the number of seeded cells (Fig. 1C). Notably, the CBMSC samples 
secreted 1.5?2 times more vesicles than BMMSC (p < 0.05, N = 10). The 
CBMSC #2 sample produced the most EVs/cell within a 24 h period (5,000 
secreted EVs/cell; Fig. 1C). Similar results were obtained after monitoring 
vesicles released by other independent BMMSC (N = 4) and CBMSC (N = 4) cell 
lines (CB/BM EVs ratio of 1.6, p < 0.01, N = 12), suggesting no major variability 
between donors. 
To confirm the integrity of analyzed EVs, carboxyfluorescein diacetate 
succinimidyl ester (CFDA-SE) staining was performed directly on EV-containing 
supernatants. Flow cytometry analysis showed that > 90% of the particles were 
positive for staining, indicating that vesicles are intact and contain cytoplasmic 
esterase reacting with CFDA-SE (Fig. 1D). Purification by ultracentrifugation at 
100,000 × g yielded a similar percentage of positive EVs, confirming that the 
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centrifugation step of the isolation protocol does not damage EVs (data not 
shown). Western blot analysis of BMMSC- and CBMSC-EVs confirmed the 
expression of both exosome (CD63 and CD81) and MSC (CD90 and CD105) 
specific markers (Fig. 1E). Finally, transmission electron microscopy images 
showed an expected morphology consistent with pure extracellular vesicle 
preparations (Fig. 1F). 
 
Molecular analysis of MSC-EVs 
It has been reported previously that MSC-EVs contain mRNAs (Deregibus et al, 
2007; Valadi et al., 2007; Bolstad et al., 2003; Bruno et al., 2009; Ragni et al., 
2016). While these studies identified some of the encapsulated transcripts, they 
did not assess their relative expression levels or the ratios between different EV 
isolates. As detailed in the Materials and Methods, 30 mRNAs characteristic of 
mesenchymal cells (functions involved in neuroprotection, control of proliferation, 
and immunomodulation; see Materials and Methods for more details) were 
quantified in parallel by qRT-PCR. We were able to amplify (Ct < 40) 18 
transcripts from the EVs of BMMSC #1 and CBMSC #1, and 19 transcripts from 
the EVs of BMMSC #2 and CBMSC #2. To confirm the specificity of the assay, 
melting curve tests and agarose gel electrophoresis of amplified DNA were 
performed comparing EVs and cell extracts (ALCAM, NGF, TGFB1 and VEGFA) 
(Fig. 2A). Interestingly, 11 candidates were always undetectable (GDNF, NTF3, 
CDNF, ANGPT1, ANGPT2, IL-1RN, TNF, BMP2, PDGFRB, BMP7 and ICAM1). 
HGF gave positive amplification from EVs from samples BMMSC #2 and CBMSC 
#2 (both with Ct values > 35). FGF7, COL1A1, CNTF, CTGF and IL-6 transcripts 
had the highest expression levels in the MSC-EVs (Supplementary Table 1). 
To obtain reliable EV molecular signatures, we had to decide on a method for 
normalization. To date, no universal reference mRNA has been identified to 
compare transcript levels in EVs isolated from independent cell lines. Recently, 
GAPDH mRNA has been proposed as a housekeeping transcript for MSC-EVs 
(Zhu et al., 2014). To increase reliability of our analysis, we decided to combine 
three different and independent normalization approaches. First, we measured 
GAPDH mRNA levels in parallel with the target transcripts.  Second, we 
employed a global mean normalization procedure based on the positively 
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amplified mRNAs. This method has a higher accuracy than the multiple reference 
gene normalization method when no reliable data about housekeepers are 
available; however, this method is restricted by the number of detected 
???????????? ??????????????????????????????????????????????????? ??????????????????
normalized expression to EV volumes, calculated as EV number × EV mean size, 
assuming that identical EV volumes contain comparable nucleic acid levels. Each 
t 
value with respect to BMMSC #1-EVs. Notably, the values obtained from the 
independent methods were similar and therefore averaged for a final 
normalization value to analyze the qRT-PCR data of the four MSC-EVs under 
analysis (BMMSC #1-EVs: 1.00; BMMSC #2-EVs: 1.06 ± 0.25; CBMSC #1-EVs: 
0.87 ± 0.17; CBMSC #2-EVs: 2.10 ± 0.26).  
To exclude potential erroneous mRNA expression detection due to low cDNA 
input or technical issues, we performed random individual qRT-PCRs on a few 
selected genes (IL-6, FGF7, and TGFB1) to increase the amount of available 
template. Notably, results were consistent with those obtained in the initial 
screening (within 2-fold modulation) (Fig. 2B). Finally, to confirm that the target 
mRNAs are present within the vesicles and not just bound to the external 
membrane surface, isolated EVs were treated with proteinase K and RNAse A. 
No decrease in the amount of CTGF and FGF7 transcripts was observed, 
confirming that isolated EVs are intact with mRNA engulfed in the lumen (Fig. 
2C). 
 
MSC-EV mRNA cargo comparison 
The four EV molecular signatures were then compared in order to identify 
mRNAs that vary significantly in expression between EVs from BMMSC and 
CBMSC (fold change > 2 with p < 0.05). After normalization, no major differences 
were observed, with few exceptions. CBMSC-EV IL-4 expression was > 2-fold 
higher, and THY1 expression was reduced compared to expression levels in 
BMMSC-EVs (Fig. 3A). Interestingly, VEGFA and HGF resulted to have opposite 
trend, with vascular endothelial growth factor significantly more abundant (2- to 4-
fold higher) in EVs from BMMSC #1 and CBMSC #1 compared to EVs from 
BMMSC #2 and CBMSC #2, and hepatic growth factor absent in EVs from 
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BMMSC #1 and CBMSC #1 while it was readily detectable in EVs from BMMSC 
#2 and CBMSC #2 (Fig. 3A). 
The molecular signatures observed for EV types was also found in the 
corresponding cell extracts, with a few exceptions (Fig. 3B): FGF7 expression 
levels were higher in BMMSC (50?100 fold), whereas KDR expression levels 
were more abundant in CBMSC. Therefore, we observed a strong correlation in 
specific mRNA levels between donor cells and the EVs derived from them, 
indicating a consistent transcript distribution within these distinct cellular 
compartments. 
The next step was to assess whether some mRNAs were preferentially loaded 
into EVs with respect to random incorporation from the cytoplasm. Because of its 
reliability in the previous EV qRT-PCR experiments, GAPDH expression was 
used as a normalization factor. A > 4-fold enrichment or exclusion was chosen as 
the threshold for analyses. Seven mRNAs were clearly and consistently 
accumulated in EVs (Table 1). IL-4 and IL-10 showed the highest incorporation 
ratios followed by BGLAP, CNTF and FZD9. Notably FGF7 always resulted 
between the two most detected transcripts despite its low expression in CBMSC 
cell extracts. In contrast, despite their elevated expression in the cytoplasm, 
TGFB1 and ALCAM resulted under expressed in all four EVs. Finally, of the 
mRNAs that were not detected in the qRT-PCR assays in EVs, we could not find 
candidates with high cellular expression, suggesting that their absence of 
detection was due mainly to low cytoplasm abundance rather than selective 
exclusion. Altogether, these results suggest preferential loading of some mRNAs 
into EVs. 
 
????????????????????????????????????????????? ???? 
???????????????????????????????????????????????????????? ??????????????????????
variations CTGC, CTCCC, CGCCC, TGCC) within the wider consensus 
sequence (CCCCTGCCTGGACC) and/or a miR-1289 binding site may enhance 
targeting of mRNAs into EVs (Bolukbasi et al., 2012). After confirmation of full 
length ?? ?????????????????EVs-embedded transcripts as assessed for randomly 
selected candidates (IL-6, MANF, BGLAP and IL-4), multiple alignment 
(http://www.ebi.ac.uk/Tools/msa/muscle/) showed the presence of a conserved 
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??????? ??????? ??? ???? KDR, CNTF, BGLAP, and FZD9, with FGF7 transcripts 
harboring the variation CTGC. Notably, the CTGCC region was found four times 
??? ?????? ??????COL1A1, the most abundant mRNA in all of the MSC-EVs. On 
the contrary, the miR-???????????????????????????????????????????? ???????????? 
To further identify other potential elements involved in mRNA enrichment, we 
??????????? ?????????????????????????????? ????????????????????????????????
using the miRANDA algorithm (http://www.microrna.org/microrna/home.do), using 
a threshold mirSVR score < -1.0 to exclude weak hits. A total of 73 unique sites 
were identified: 34 miRNA sequences were identified for FGF7, 19 for IL-10, 19 
for KDR, 5 for CNTF, 3 for IL-4, and 2 for BGLAP for a total of 73 unique sites. A 
deeper analysis showed the absence of conserved miRNA binding patterns, with 
????? ?? ?? ??? ?????? ??????? ??? ???? ?? ???? ????????? ???????? ???? ???????????
proposed specific sequence motifs (ACCAGCCU, CAGUGAGC and 
UAAUCCCA) that may potentially function as cis-acting elements targeting RNAs 
to EVs in glioblastoma cells (Batagov et al., 2011). None of the five most 
enriched EV mRNAs contained these elements. Therefore, preferential mRNA 
loading into EVs may rely on cell type, still unidentified specific motifs, or 
selectively engulfed mRNA binding proteins able to discriminate between 
different transcripts, as suggested by Waris et al., 2014. 
Moreover, it was shown recently that multiple sites for regulatory miRNA binding 
????? ???????????????????? recipient cell RNAs for binding of miRNA or RNA-
binding proteins so as to regulate their stability and translation in recipient cells 
(Batagov et al., 2013). Accordingly, we performed a literature-validated gene 
target identification for the pool of 73 previously identified miRNA using miRWalk, 
a database of experimentally validated miRNA-gene interactions (Dweep et al., 
2014). The 73 submitted micro-RNAs generated a list of 2,294 potentially 
regulated targets. Then, we ran these results through the GeneCodis program 
(http://genecodis.cnb.csic.es/) to find statistically enriched biological processes. 
We focused our attention on the top five ranked biological processes which were 
primarily RNA generation and stability GO:0006355 (DNA-dependent regulation 
of transcription, p-value 8.57801e-48), GO:0010467 (gene expression, 3.79091e-
44), GO:0016070 (RNA metabolic process, 2.57193e-39), GO:0016071 (mRNA 
metabolic process, 9.8859e-35) and GO:0006915 (apoptotic process, 4.91476e-
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34) with the majority of apoptosis-related genes being anti-apoptotic 
(GO:0006916, anti-apoptosis 1.42074e-17). Notably, out of the first 15 
categories, 8 were related to various aspects of RNA processing. These results 
suggest that the inclusio?? ?????????????? ????????? ?? ?????????? ????? ????????
have significant effects on the regulation of gene expression in target cells. 
 
mRNA translation in recipient cells 
??????? ???? ??? ??? ???????? ????????? ??? ???? ?? ???? ???????? ???????????? ????????
intercellular communication is that EVs may shuttle functional mRNAs that can be 
internalized and translated. Therefore, immunomodulatory transcripts embedded 
in MSC-EVs, together with secreted factors, could be important players for the 
paracrine properties of mesenchymal stem cells. To test this hypothesis, we used 
a human-derived renal proximal tubular cell line (HKC-8) as the target cell; in a 
previous publication we assessed the in vivo anti-inflammatory action of BMMSC 
and CBMSC supernatants in mice with Acute Kidney Injury (AKI) induced by 
cisplatin treatment (Morigi et al., 2010). 
EVs were labeled with the membrane-dye PKH26 without altering membrane 
integrity (data not shown). After a 24 h co-culture, the labeled EVs were engulfed 
by 100% of HKC8 cells, as shown by FACS analysis and confocal microscopy 
(Fig. 4A and 4B). In our experimental settings, both EVs were incorporated into 
HKC8 cells with a similar efficiency (4,100 ± 1,400 BMMSC-EVs/cell and 4,000 ± 
1,500 CBMSC-EVs/cell). The PKH26 signal was preferentially accumulated in the 
perinuclear area. Intriguingly, incubation of PKH26-stained EVs with parental 
MSC resulted in dramatically lower incorporation rates than for HKC8 cells (e.g. 
for BMMSC #1 EVs: Mean Fluorescence Intensity-Ratio, stained vs unstained: 
HKC8 18.1 ± 4.3, BMMSC #1 2.9 ± 0.7, BMMSC #2 2.1 ± 0.8, CBMSC #1 1.9 ± 
0.4, and CBMSC #2 2.3 ± 0.3, n = 3). Similar results were obtained with the other 
combinations of EV and MSC, suggesting a conserved and preferential targeting 
to non-mesenchymal cells, independently of the MSC type. 
As a proof-of-concept of the anti-inflammatory paracrine activity of MSC-EVs, we 
chose to track the expression of IL-10, which is absent in target HKC8 cells and 
is present in EVs only as mRNA (Fig. 5A) and not as protein (Fig. 5B). Full-length 
IL-10 mRNA was demonstrated to be engulfed in EVs through RT-PCR, being 
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this a prerequisite for efficient translation into a functional protein (Fig. 5C). Then, 
after EV/HKC8 co-culture, IL-10 mRNA was identified in HKC8 target cells as 
confirmation of positive transcript transfer (Fig. 5A). Finally, de novo IL-10 protein 
expression was detected in tubular HKC8 cells that were co-cultured with either 
of the MSC-EV type by western blot (Fig. 5D) and immunofluorescence analyses 
(Fig. 5E). The observed perinuclear localization of IL-10 resembling the ER 
compartment was due to Brefeldin A treatment to block transport from the ER to 
the Golgi apparatus to increase the amount of detectable protein (Fig. 5E). 
Intriguingly, Soranno and colleagues showed in vivo that delivery of IL-10 
following AKI mitigates the local and systemic pro-inflammatory cascade, 
reducing fibrosis and eventually cell death (Soranno et al., 2016). Similarly, in 
vitro IL-10 production after EV administration may resemble such a mechanism 
for 6 hours to mimic acute injury. After drug removal, EVs were added and cell 
viability was scored by the MTT assay. Although at 24 h no major EV-protective 
effects were detected, higher viability was observed at 48 h (70% with respect to 
60% of  cisplatin-treated cells) and even further pronounced at 72 h (80% viability 
vs. 40% viability in cisplatin-treated cells), possibly due to an additional 
proliferative stimulus (Fig. 5F). These results are in agreement with the kinetics of 
EVs incorporation and mRNA translation, explaining the delay between EVs 
supplementation and the appearance of protective effects. Altogether, these 
results demonstrate that mRNAs incorporated into MSC-EVs are efficiently 
transferred to target cells and eventually translated, contributing to the well-
known paracrine activities of MSC (Fig. 6). 
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DISCUSSION 
 
A significant body of literature has shown that the molecular constituents of 
extracellular vesicles, especially proteins and microRNAs (miRNA), hold great 
promise as novel biomarkers for clinical diagnosis (Liu and Lu, 2015; Fujita et al., 
2016). On the contrary, less attention has been devoted to the role of EVs in cell-
to-cell communication and fate determination, especially in the stem cell and 
regenerative medicine fields (Quesenberry et al., 2015; Nawaz et al., 2016). A 
major inadequacy for studying MSC-EVs is that there is no data comparing their 
clinical efficacy and production feasibility. The majority of studies used only one 
MSC type, generating controversy on most favorable MSC (Yu et al., 2014; Rani 
et al., 2015). A few studies have described efficacy of EVs isolated from different 
tissues on the same model. For example, ???????????????? ???????????????MSC 
were studied for their effects on acute lung injury (ALI) showing similar outcomes 
(Lee et al., 2012; Zhu et al., 2014). Similarly, BMMSC and umbilical cord-MSC 
were tested in Liver Injury models (Li et al., 2013; Tan et al., 2014). Furthermore, 
BMMSC- and CBMSC-EVs were shown to protect against ischemic AKI (Bruno et 
al., 2009; Kilpinen et al., 2013). Despite that the different protocols and 
experimental settings do not allow for direct comparisons, the similar efficacies 
observed between these studies suggested conserved properties of MSC-EVs. 
Our data show, for the first time, that CBMSC and BMMSC are able to secrete 
vesicles that are almost identical in their physical properties and cargo content, 
especially for transcripts involved in immunomodulation and proliferation. The 
only striking difference was the higher EV/cell ratio displayed by CBMSC. This 
may be relevant for MSC type selection in future clinical applications where it is 
often desirable to have the highest production rate to minimize cost, space, and 
time. Furthermore, the kinetics of CBMSC proliferation are substantially higher 
than those of either adipose derived- or BM-MSC (Zhang et al., 2011; Barilani et 
al., 2015). Therefore, due to their higher proliferation and vesicle secretion rates, 
CBMSC may be the preferred choice for MSC-EV production. 
Despite several reports that MSC-EVs have functions similar to those of MSC, 
very few of these work have tried to link EV efficacy with the identification of the 
shuttled active components, mainly proteins (Shentu et al., 2016). In the context 
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of nucleic acid transfer, main attention has been focused on miRNAs (Chen et al., 
2010). Very recently, the Camussi group nicely demonstrated the crucial role in 
miRNA enrichment during EV biogenesis of Alix, an accessory protein of ESCRT, 
through the interaction with the miRNA binding protein Ago2 (Iavello et al., 2016). 
Similarly, EV enrichment of other extracellular RNAs, including mRNAs, may 
depend on their association with specific subsets of RNA-binding proteins. 
Intriguingly, EVs released from the human liver stem-like cells were shown to 
contain members of several families of RNA-binding proteins, each specific for a 
different transcript motif (Waris et al., 2014). Consistent with this hypothesis, 
Bruno and coworkers suggested that BMMSC-EVs may also engulf a specific 
subset of mRNAs rather than a random sample of cellular mRNA (Bruno et al., 
2009). 
In this study, we identified a subgroup of mRNAs that are preferentially loaded 
into MSC-EVs, thus potentiating their role in intercellular communication. FGF7, 
which is expressed at very low levels in donor CBMSC, was among most 
enriched transcripts in both types of MSC-EVs, suggesting a pivotal function. 
Supporting this notion, Zhu and coworkers demonstrated that BMMSC-EVs were 
therapeutically effective following E. coli endotoxin-induced ALI in mice through 
the expression of EV-transferred FGF7 mRNA in the injured alveolus (Zhu et al., 
2014). Therefore, FGF7 protein expression from MSC-EV mRNA restored lung 
protein permeability and reduced alveolar inflammation, though through a still 
unknown mechanism. Similar functions may be postulated for IL-10 mRNA, which 
we demonstrated to be highly enriched in EVs and efficiently translated in kidney 
tubular cells. We have demonstrated previously that MSC supernatant 
administration in mice with cisplatin-induced AKI ameliorated both renal function 
and tubular cell injury, and prolonged survival (Morigi et al., 2010). Moreover, 
MSC-EVs treatment after kidney injury prevents renal fibrosis (Bruno et al., 
2009). These effects were intriguingly similar to those observed upon IL-10 
administration (Soranno et al., 2016), that in the adult kidney is secreted by 
mesangial cells (Jin et al., 2013). Thus, due to absence of IL-10 protein in MSC-
EVs, IL-10 mRNA transfer and translation may be a novel mechanism of the 
complex recovery and anti-inflammatory processes recently proposed for in vivo 
kidney repair by MSC (Morigi and Benigni, 2013). In fact, existence of such new 
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paradigm in tubular cells has been confirmed by the in vitro MSC-EV mediated 
transfer of IGF-1R mRNA that, after translation, potentiates tubular cell sensitivity 
to locally produced IGF-1 (Tomasoni et al., 2013). Similarly, translated IL-10 may 
enhance IL-10/IL-10R1R2 anti-inflammatory pathway at tubular cell level, 
suggesting a potential therapeutic role for IL-10 mRNA transfer from EVs. 
Altogether, these data provide a new mechanism to explain how the restricted 
homing of mesenchymal stem cells at the site of injury may still result in 
enhanced protective effects via gene-based communication amplified through the 
enrichment of therapeutic mRNAs in EVs. 
In addition to the transfer of therapeutic mRNAs, the enrichment of mRNAs with 
sp??????? ?? ??? ?????????? ????? ???????? ????? ????? ?? ????? ?????????????? ???????
cells, as was reported in glioblastoma-EVs (Batagov et al., 2013). One intriguing 
???????????? ??? ??????? ??????????? ?????? ??? ?? ????????? ????????????? ??????? ?????
RNAs for binding in order to alter mRNA stability and translation. Our in silico 
????????? ??????? ????? ?????? ???????????????????????????????????????? ?????????
with at least 73 different miRNAs, potentially affecting the stability and thus 
translation of more than 2,000 transcripts. Intriguingly, the top biological 
processes altered by their products were related to RNA transcription and 
metabolism, gene expression and anti-apoptotic processes. These categories are 
strictly related, because increase in RNA synthesis and translation have potent 
inhibitory effects on apoptotic processes (Bushell et al., 2004). Consistently, 
MSC-EV administration resulted in strong anti-apoptotic and pro-proliferative 
outcomes in both in vitro (Bruno et al., 2009; Bruno et al., 2012; Zhang et al., 
2015) and in vivo experimental models (Gatti et al., 2011; Tan et al., 2014). Thus, 
transcripts incorporated into MSC-EVs may regulate target cells to different 
levels, increasing the array of targets addressed by vesicles and shuttled factors. 
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CONCLUSION 
 
In summary, we demonstrated that MSC load specific transcripts into secreted 
EVs independently of their cytosolic abundance, suggesting purposeful transfer 
to target cells. These transferred molecules may act directly through their protein 
products or interact with other nucleic acids or nucleic acid-binding proteins. 
These results shed new light on the knowledge of a complex and still 
uncharacterized mechanism involving EVs as factors of MSC autocrine and 
paracrine action. 
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Table 1. Differentially enriched mRNA in MSC-EV. 
BMMSC #1 BMMSC #2 CBMSC #1 CBMSC #2 
GENE 
EV/ 
CELL  
GENE 
EV/ 
CELL  
GENE 
EV/ 
CELL  
GENE 
EV/ 
CELL  
IL-10 6472.02 IL-10 3769.09 IL-4 9026.81 IL-10 11425.74 
IL-4 2610.30 KDR 3104.19 IL-10 6517.03 IL-4 10226.32 
KDR 1964.57 IL-4 792.35 BGLAP 955.43 FGF7 744.43 
BGLAP 352.14 BGLAP 162.02 FGF7 245.57 BGLAP 680.29 
CNTF 125.37 CNTF 78.25 CNTF 123.64 KDR 188.71 
FZD9 31.12 FZD9 64.89 FZD9 119.43 CNTF 139.10 
FGF7 14.93 FGF7 5.43 KDR 36.25 FZD9 64.89 
IL-6 8.82 NGF 4.17 BDNF 4.28 BDNF 5.82 
NGF 2.99 BDNF 1.77 FGF2 1.68 NGF 4.17 
BDNF 2.62 IL-6 1.59 NGF 1.38 FGF2 2.45 
FGF2 1.57 FGF2 1.19 MANF 0.56 IL-6 1.16 
MANF 0.81 THY1 0.44 VEGFA 0.41 THY1 0.38 
THY1 0.42 MANF 0.40 IL-6 0.24 MANF 0.31 
VEGFA 0.37 CTGF 0.24 CTGF 0.12 COL1A1 0.13 
COL1A1 0.31 COL1A1 0.12 COL1A1 0.12 CTGF 0.08 
CTGF 0.26 ALCAM 0.07 TGFB1 0.08 VEGFA 0.07 
TGFB1 0.15 VEGFA 0.03 THY1 0.08 TGFB1 0.03 
 
Supplementary Table 1. Normalized qRT-PCR Ct data. 
  CELLS EV 
  BMMSC #1 
BMMSC 
#2 
CBMSC 
#1 
CBMSC 
#2 
BMMSC 
#1 
BMMSC 
#2 
CBMSC 
#1 
CBMSC 
#2 
GENE Ct Ct Ct Ct Ct Ct Ct Ct 
ALCAM 22.5 22.9 22.7 22.8 33.9 34.7 34.7 36.1 
BDNF 23.9 24.2 25.4 24.4 30.5 31.4 31.1 29.9 
BGLAP 32.9 32.3 34.0 33.9 32.4 32.9 32.1 32.5 
CNTF 29.4 29.1 29.4 29.1 30.4 30.8 30.4 30.0 
COL1A1 18.4 18.0 18.5 18.5 28.0 29.0 29.6 29.4 
CTGF 20.1 20.4 19.6 19.2 30.0 30.4 30.6 30.8 
FDZ9 29.8 31.6 31.3 31.3 32.8 33.6 32.4 33.3 
FGF2 24.1 24.7 24.6 24.9 31.4 32.4 31.8 31.6 
FGF7 24.3 23.3 29.9 29.7 28.4 28.9 29.9 28.1 
HGF 27.9 27.9 33.9 25.9 ND 38.0 ND 35.8 
IL-10 36.0 35.7 36.7 36.7 31.4 31.8 32.0 31.2 
IL-4  35.1 33.9 35.7 36.1 31.7 32.2 30.5 30.8 
IL-6 25.2 23.7 20.8 22.8 30.0 31.0 30.9 30.5 
KDR 35.2 36.8 28.7 31.8 32.2 33.2 31.5 32.2 
MANF 23.4 23.3 22.8 23.1 31.7 32.6 31.6 32.8 
NGF 27.5 28.4 26.3 27.1 33.9 34.3 33.8 33.1 
TGFB1 22.8 22.9 22.9 22.8 33.5 36.2 34.6 35.8 
THY1 22.0 22.6 23.3 24.4 31.2 31.8 34.9 33.7 
VEGFA 23.7 22.5 23.4 23.4 33.1 35.8 32.7 35.1 
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FIGURE LEGENDS 
Figure 1. Kinetics and physical properties of MSC-EVs. A) Scanning Electron 
Microscopy of BMMSC and CBMSC showing EVs shedding from cell protrusions. 
Arrows point out representative examples of vesicles dismissed from the cell 
surface. B) EVs secretion kinetics normalized on values at 4 hours set as 1 (n = 5 
per cell population, errors as SD). Significant differences between groups are noted 
as *** (p-value < 0.001). C) EVs mean size obtained from Nanosight analysis (n = 
10 per cell population, errors as SD) together with quantification of EVs secreted 
per seeded cell at 24 hours after medium change (n = 10 per cell population, errors 
as SD). D) CFSE staining of a representative EVs sample showing high integrity 
of isolated vesicles. P1 = total EV; P2 = CFSE positive EVs. E) Western Blot 
analysis of exosome (CD63 and CD81) and MSC (CD90 and CD105) surface 
markers in purified EVs from BM- and CB-MSC supernatants. F) Transmission 
electron microscopy performed on isolated vesicles to visualize their ultrastructural 
morphology. EVs are indicated with black arrows. 
Figure 2. Validation of EV-embedded mRNA transcriptional analysis. A) Validation 
of qRT-PCR specificity for low abundant transcripts ALCAM (expected 148 bp), 
NGF (85 bp), TGFB1 (81 bp) and VEGFA (105 bp). Agarose gel electrophoresis 
and representative melting curve tests for BMMSC cell and EVs amplicons are 
shown. B) Comparison of IL-6, FGF7 and TGFB1 abundance in BMMSC and 
CBMSC EVs between multiple transcripts analysis (A) and individual qRT-PCR (B) 
(n = 3 per cell population, errors as SEM). Expression in A was set as 1. C) CTGF 
and FGF7 mRNA detection in MSC-EVs analysis after Proteinase K and RNAse A 
treatment (treated) (n = 3 per cell population, errors as SEM). Cell RNA was used 
as control for positive enzymes digestion, as showed by significant (*** p-value < 
0.001) reduction in Real-Time PCR amplification. Expression of untreated cell RNA 
was set as 1. 
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Figure 3. Molecular differences in MSC and secreted EVs. A) EV-embedded 
transcripts (IL-4 and THY1) differentially incorporated in CBMSC vs BMMSC 
(BMMSC set as 1; n=6, errors as SD; *** p-value < 0.001). VEGFA and HGF 
showed alternative expression in a cell line dependent fashion (BMMSC #1 set as 
1 for VEGFA and BMMSC #2 set as 1 for HGF, n = 3, errors as SD; *** p-value < 
0.001). B) FGF7 and KDR resulted to have significant differential expression in 
MSC cell extracts (CBMSC set as 1 for FGF7 and BMMSC set as 1 for KDR; n = 
6, errors as SD; *** p-value < 0.001). C) Agarose gel electrophoresis analysis of 
RT-?????????????????????????????????????????????? ??????IL-6 (expected 392 bp), 
MANF (296 bp), BGLAP (157 bp) and IL-4 (79 bp) EV-embedded transcripts. 
Figure 4. PKH26 EVs labeling and HKC8 incorporation. A) FACS analysis of HKC8 
cells after 24 hours co-culture with PKH26-EVs or vehicle (negative control). B) 
Confocal microscopy images of HKC8 after 24 hours co-culture with labeled EVs. 
Figure 5. Incorporation and translation of IL-10 mRNA into HKC8 cells. A) Agarose 
gel electrophoresis analysis of IL-10 mRNA RT-PCR amplification. GAPDH mRNA 
detection is shown as internal control for positive cDNA synthesis. Lane 1, DNA 
molecular weights. B) Molecular confirmation of absence of IL-10 protein loading 
into EVs by Western Blotting analysis. EVs preparations were confirmed for their 
positivity for the exosomal markers CD81. Purified IL-10 was used as positive 
control for primary antibody. C) Agarose gel electrophoresis analysis of IL-10 intact 
full-length mRNA (expected 1589 bp) embedded in MSC-EVs. Lane 3, DNA 
molecular weights. D) Western Blot analysis showing absence of IL-10 protein in 
HKC8 and its appearance after EVs administration. GAPDH was used as positive 
control for loading. E) Confocal microscopy images of translated IL-10 protein after 
MSC-EVs administration to tubular cells. All IL-10 panels show HKC8 cells (with or 
without EVs supplementation) treated with both primary and secondary antibodies. 
HKC8 CTRL (not treated with MSC-EVs) confirms endogenous IL-10 absence. F) 
MTT test assaying viable cells after cisplatin treatment (Cisplatin) or after drug 
injury and vesicles administration every 24 h (BM-EVs and CB-EVs). Both vesicle 
types are able to increase recovery and reduce acute injury-driven cell death. 
Values are related to control cells (HKC8 CTRL) that were not damaged and set 
as 100% viability for each time point. 
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Figure 6. Model of horizontal transfer of EV-embedded mRNA as part of paracrine 
and autocrine communication network. 
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TABLE LEGEND 
Table 1. Differentially enriched mRNA in MSC-EVs. The amount ratios for indicated 
gene transcripts in EVs versus cell extracts (EVs/CELL) are shown. The dashed 
line separates the seven transcripts that are consistently and preferentially 
accumulated in EVs for all 4 cell lines used in the study. Values higher than 2 
indicate transcripts present in EVs with at least a double amount of what expected 
from a random internalization from the cytoplasm, whereas values lower than 0.5 
indicate messengers excluded in secreted vesicles. 
Supplementary Table 1. qRT-PCR Ct data are shown. Presented values are the 
mean of three independent experiments. 
 
III. Protocols 
 
a. Induced cellular reprogramming 
 
Reprogramming System 
CytoTune-iPS 2.0 Reprogramming System vectors (Thermo Fisher Scientific, 
Waltham, MA, USA) are based on the genome of a non-transmissible form of 
Sendai virus (SeV) to deliver and to express the genetic factors (OCT4, SOX2, 
KLF4, cMYC) necessary to reprogram somatic cells into human induced 
pluripotent stem cells (iPSCs). These vectors are non-integrating and they 
remain in the cytoplasm, meaning they are zero-footprint. The reprogramming 
factors are expressed by three different vectors: one contains the KLF4, OCT4 
and SOX2 sequences (KOS vector); one contains only KLF4 sequence (K 
vector); the last contains only cMYC sequence (M vector). An important 
modification introduced in the SeV genome is that the gene encoding for the F 
protein, essential for the viral envelope to fuse with cell membranes, is deleted 
from all reprogramming vectors. Therefore, they are unable to produce 
infectious particles from infected cells. 
 
Transduction feasibility 
CytoTune-EmGFP Reporter Control Transduction (Thermo Fisher Scientific) 
was used to assess feasibility of long living (LL)-cord blood (CB) multipotent 
mesenchymal stromal cell (MSC) transduction. This reporter system consists in 
the same modified SeV vector used to deliver reprogramming factors, but it 
expresses emerald green fluorescent protein (EmGFP). 
Briefly: 
1) On day -1, LL-CBMSCs were plated in four wells of a 6-well plate at 
15,000 cells/cm2 in αMEM-GlutaMAX (Thermo Fisher Scientific) 20% 
fetal bovine serum (FBS, Thermo Fisher Scientific) (LL-CBMSC 
medium); 
2) On day 0, LL-CBMSCs had reached 70–80% confluence, and cell count 
was performed on one well; 
  
3) Then, the volumes of virus (V) to reach the chosen multiplicity of infection 
(MOI) were calculated as follows: 
V(μL) = MOI (cell infection units, CIU/cell) X number of cells/ 
titer of virus (CIU/mL) X 103 (μL/mL) 
MOI 3, 5 and 7 were tested; 
4) A volume of 2 mL of culture medium was warmed for each well to be 
transduced in a 37 °C water bath; 
5) One tube of CytoTune-EmGFP Sendai Fluorescence Reporter was 
thawed immediately before transduction by an initial immersion in a 37 
°C water bath for 10 seconds and subsequent thawing at room 
temperature. Once thawed, the tube was briefly centrifuged and placed 
on ice; 
6) The calculated volumes of virus were added to the pre-warmed cell 
culture medium and thoroughly mixed by pipetting; 
7) Rapidly, the cell culture medium from LL-CBMSCs was aspirated and the 
viral solution added; 
8) The cells were then incubated overnight at 37 °C, 5% CO2; 
9) On day 2, transduced LL-CBMSCs were visualized on a fluorescence 
microscope (Nikon Eclipse Ti; Nikon, Tokyo, Japan) using a standard 
FITC filter set. EmGFP expression was visible in 35% (MOI=3), 50% 
(MOI=5) and 60% (MOI=7) of total infected cells, measured by standard 
flow cytometry (FACSCantoII; BD, Franklin Lakes, NJ, USA). 
 
Reprogramming protocol 
1) On day -2, LL-CBMSCs were plated into two wells of a 6-well plate in LL-
CBMSC medium; 
2) On day 0, 70-80% confluent LL-CBMSCs were transduced using the 
CytoTune-iPS 2.0 Sendai reprogramming vectors at MOI=5 (KOS and M 
vectors) and MOI=3 (K vector), following the procedure previously 
described for the CytoTune-EmGFP Sendai Fluorescence Reporter; 
3) LL-CBMSCs were then incubated overnight at 37 °C, 5% CO2; 
4) On day 1, the medium was replaced with fresh medium to remove viral 
particles; 
5) On day 2-6, the medium was replaced every other day; 
6) On day 7, the transduced cells were detached and seeded on matrigel 
(BD)-coated culture Petri dishes in LL-CBMSC medium; 
7) On day 8, the LL-CBMSC medium was switched to StemMACS iPS-
Brew XF medium (Miltenyi Biotec, Bergisch Gladbach, Germany); 
8) On day 9-28, the medium was replaced every day and the culture 
vessels were monitored for the emergence of human (h) iPSC colonies; 
9) When hiPSC colonies were ready for transfer, manual mechanical 
picking using a 150 μm diameter needle mounted on a stripper 
micropipette was performed. Colony clumps of 20-200 cells were seeded 
in StemMACS medium onto matrigel-coated culture Petri dishes for 
expansion; 
10) Bright field images of colonies from established hiPSC lines were taken 
with a Nikon Eclipse Ti microscope (Nikon). 
 
Karyotype 
Karyotyping was performed in collaboration with the Laboratory of Cytogenetics 
and Molecular Genetics, Fondazione IRCCS Ca' Granda, Ospedale Maggiore 
Policlinico, Milan, Italy. In order to prepare hESCs and hiPSCs for karyotyping, 
the cells were seeded onto matrigel-coated amniodish (Euroclone, Pero, Italy), 
following a 1:3 split ratio was performed, so that many little and not too compact 
colonies were attached to the culture surface by the day after. The colonies 
were allowed to grow for 48 hours and then they were processed for metaphase 
analysis. Conventional karyotyping was carried out according to the standard 
laboratory protocols (Hsu TC, , 1972). All karyotyping was achieved using Q-
banding technique. Numerical and structural abnormalities have been analysed 
at 400 banding level, according to the international system for human 
cytogenomic nomenclature and the european general guidelines and quality 
assurance for cytogenetics. Moreover, the analysis included a minimum of 20 
cells to exclude clonal rearrangiaments. The capture of metaphase images was 
performed by the automated sample analysis system IKAROS (MetaSystems, 
Altlussheim, Germany). 
 
Stem cell immunophenotype 
Colonies of hiPSCs (passage 3) and hESC (passage 43), and LL-CBMSCs 
(passage 4) were detached by a 5 minute TrypLE select enzyme (Thermo 
Fisher Scientific) incubation at 37 °C, 5% CO2, to produce a single cell 
suspension, which was then collected with PBS (Thermo Fisher Scientific) and 
centrifuged at 350 xg for 7 minutes at room temperature (RT). The cell pellets 
were incubated for 20 minutes in the dark at RT with 10 μL of the antibodies or 
isotype controls specified in table 1, in a total volume of 200 μL of PBS. Then, 
the cells were washed with PBS to remove the unbound antibodies, centrifuged 
at 350 xg for 7 minutes, and resuspended in 350 μL of PBS. The 
immunophenotype was assessed using a FACSCantoII cytometer (BD), 
acquiring at least 10,000 total events. Flow cytometry data were analyzed using 
FACSDiva software version 7.0 (BD). 
 Fluorochrome 
 FITC PE PerCP-Cy5.5 APC 
Tube 1 IgG (BD) IgG (BD) IgG (BC)  IgG (BD) 
Tube 2 CD45 (BC) CD271 BD) CD34 (BC)  
Tube 3 HLA-DR BD)   CD90 (MB) 
Tube 4 CD31 (BD) CD105 BC)  CD73 (MB) 
Tube 5 HLA-ABC (BD) CD44 (BD)   
Table 1. Flow cytometry experimental layout. BC, Beckman Coulter, Brea, CA, USA; BD, 
Becton Dickinson, Franklin Lakes, NJ, USA; MB, Miltenyi Biotec, Bergisch Gladbach, Germany. 
III. Protocols 
 
b. Culture and characterization of pluripotent stem cells 
 
Cell culture 
Human embryonic stem cells (hESC) and hiPSCs were cultured in StemMACS 
iPS-Brew XF medium (Miltenyi Biotec (MB), Bergisch Gladbach, Germany) onto 
matrigel (BD, Franklin Lakes, NJ, USA)-coated culture dishes. The medium was 
changed every day. At 80% confluence, the colonies were detached by 
ethylenediaminetetraacetic acid (EDTA; Thermo Fisher Scientific, Waltham, 
MA, USA ) passaging. Briefly, the medium was removed and the cells washed 
with PBS (Thermo Fisher Scientific). Then, the cells were incubated with 5 mM 
EDTA for 4 minutes in a 37 °C, 5% CO2 incubator. EDTA was gently removed 
and the colonies detached and disgregated in 20-200 cell clumps by pipetting, 
using StemMACS iPS-Brew medium (MB). The cells were seeded in new 
matrigel(BD)-coated culture dishes, observing a 1:3-1:8 split ratio, depending on 
experimental needs. Freezing medium was composed of StemMACS iPS-Brew 
XF medium (MB) supplemented with 10% DMSO (Bioniche Pharma, Costelloe, 
Ireland); thawing medium was composed of StemMACS iPS-Brew XF medium 
(MB) supplemented with 10 μM Rock inhibitor (Stemcell technologies, 
Vancouver, Canada). The day after passaging and thawing, the medium was 
not changed. 
 
Alkaline phosphatase activity 
Direct alkaline phosphase activity was assessed using the Alkaline 
Phosphatase (AP) Live Stain kit (Life Technologies, Carlsbad, CA United 
States). The analysis was performed on hiPSC and hESC colonies (positive 
control) and on LL-CBMSCs (negative control). All cells were grown on 
chamber slides (BD, Franklin Lakes, NJ, USA), following the cell culture 
conditions previously described. The following steps were performed: 
? The medium was removed, and the cells were washed with PBS; 
? The cells were incubated for 15 minutes at room temperature (RT) with a 
4% paraformaldehyde (PFA; Thermo Fisher Scientific) fixative solution 
(PBS-diluted); 
? The fixative solution was removed and the cells were washed with PBS; 
? The cells were incubated 30 minutes at RT with 1 μL of AP Live Stain 
solution in 0.5 mL of DMEM/F-12 (Sigma-Aldrich, Saint Louis, MO, USA); 
? The AP Live Stain solution was removed and the cells were washed 
twice with DMEM/F-12 to reduce background signal. 
The detection of fluorescent colonies was performed on an inverted phase-
contrast microscope (Nikon Eclipse Ti; Nikon, Tokyo, Japan). 
 
RNA extraction 
The RNeasy Plus Mini kit (Qiagen, Hilden, Germany) was used to extract RNA 
from cell pellets previously frozen at -20 °C. The samples were first lysed and 
homogenized in RNeasy Plus lysis buffer (Qiagen). Then, the lysate was filtered 
through a gDNA-eliminator spin column (Qiagen), which allows efficient removal 
of genomic DNA after a centrifugation at ≥ 8000 xg for 30 seconds. Next, the 
flow-through was collected and 350 μL of 70% ethanol were added. The 
samples were then transferred to an RNeasy spin column (Qiagen), and 
centrifuged for 15 seconds at 800 xg. Then, 700 μL of Buffer RW1 (Qiagen) 
were added to the RNeasy spin column and centrifuged again for 15 seconds at 
≥ 8000 xg to wash the spin column membrane. The flow-through was 
discarded. Then, 500 μL RPE Buffer (Qiagen) were added to the RNeasy spin 
column and centrifuged for 15 seconds at ≥ 8000 xg to wash again the spin 
column membrane. This passage was repeated one more time with a 2 minute 
centrifugation. RNA was then eluted in 30 μL of distilled water. RNA 
quantification was performed with a Nanodrop 1000 instrument (ND-1000 
Spectrophotometer; Cellbio, Pero, Italy), reading absorbance at 260 nm; purity 
was assessed by A260/A230 (organic compound contamination) and 
A260/A280 (protein contamination) ratios. Integrity of GelRed (Biotium, 
Fremont, CA USA)-stained RNA was assessed by 1% agarose gel 
electrophoresis at 100 V (1 hour), after staining detection using the GelDoc XR 
instrument (Bio-Rad, Hercules, CA, USA). 
 
Retrotranscription  
Each RNA sample (800 ng) was retrotranscribed with the iScript cDNA 
synthesis kit (Bio-Rad). Briefly, 4 μL of 5x iScript reaction mix (salts, dNTPs, 
oligo(dT), examer random primers) and 1 μL of iScript reverse transcriptase 
were added to 15 μL of RNA in a PCR tube. Then, the tubes were placed in a 
thermal cycler (DNA Engine Peltier Thermal Cycler PTC-200; Bio-Rad) and the 
following steps were performed: 25 °C for 5 minutes, 42 °C for 30 minutes, 85 
°C for 5 minutes and 4 °C until storage. 
 
Real time quantitative polymerase chain reaction  
To assess gene expression, Real Time quantitative reverse transcription-
polymerase chain reaction (Real Time qRT-PCR) was performed. A 10 μL PCR 
reaction mix was prepared with 5 μL of 2x SsoFast EvaGreen Supermix (Bio-
Rad), 500 nM of forward and reverse primers and 12 ng of cDNA. Then, the 
reaction mix for each sample was loaded into a Real Time qRT-PCR 96-well 
plate, in triplicate. Amplification data were studied using the Bio-Rad CFX 
Manager software (Bio-Rad); technical replicate values were checked for 
differences inferior to 0.5 threshold cycles (Ct). The melting curve relative to 
every reaction was examined to exclude aspecific amplification. In addition, 
amplification reactions with Ct values higher than 35 were not considered. 
Finally, gene expression was calculated with the ΔΔCt method, using GAPDH 
as house-keeping gene and normalizing to hESC (positive control). When 
feasible, the primers were designed to anneal to exon-exon junction regions of 
the mature transcripts and amplificate exons separated by at least one intron, to 
decrease the risk of unspecific amplification of genomic DNA. PCR cycling 
conditions and primer sequences are provided in table 1 and 2. 
 
 
 
 
 
 
 
Temperature Time  Cycles 
Initial denaturation 98 °C 30 seconds 1 
Denaturation 95 °C 5 seconds 
46 Annealing and 
Polymerization 60 °C 20 seconds 
Melting curve  
65 °C 
5 seconds 1 
95 °C 
Hold 4 °C > 5 minutes 1 
 Table 1. PCR thermal profiles. 
 
Name Sequences 
House-keeping 
gene GAPDH 
forward primer: CCCTTCATTGACCTCAACTACATG 
reverse primer: TGGGATTTCCATTGATGACAAGC 
Target genes 
KLF4  
forward primer: ACGATCGTGGCCCCGGAAAAGGACC 
reverse primer: TGATTGTAGTGCTTTCTGGCTGGGCTCC 
LIN28A 
forward primer: TTCGGGTTCCAGGGAGAC 
reverse primer: CGTTTCAACACAGTAAGGTAGG 
cMYC 
forward primer: GCGTCCTGGGAAGGGAGATCCGGAGC 
reverse primer: TTGAGGGGCATCGTCGCGGGAGGCTG 
NANOG 
forward primer: GAGATGCCTCACACGGAGACTG 
reverse primer: GGGTTGTTTGCCTTTGGGACTG 
OCT4A 
forward primer: CAGCCTGAGGGCGAAGCAG 
reverse primer: GCTTTGATGTCCTGGGACTCCTC 
SOX2 
forward primer: GTACTGGCGAACCATTCTTG 
reverse primer: AAATTACCAACGGTGTCAACCTG 
Table 2. Primer sequences. 
 
Immunofluorescence 
Immunofluorescence analyses were performed on undifferentiated and 
differentiated (see in vitro differentiation paragraph) hiPSC and hESC (positive 
control) colonies; the same procedure was also carried out on LL-CBMSCs 
(negative control). The cells were grown on chamber slides (BD, as previously 
described. 
The following protocol was used: 
- The medium was removed, and the cells were washed with PBS; 
- The cells were fixed with a 4% PFA (Thermo Fisher Scientific) solution 
for 15 minute at RT; 
- Then, the cells were permeabilized with 1% saponin (Thermo Fisher 
Scientific) for 15 minute at RT; 
- Next, the cells were incubated with a blocking solution (3% bovine serum 
albumin (BSA; Sigma-Aldrich), diluted in PBS) for 30 minutes at RT; 
- Primary antibodies (Table 3) were added directly to the blocking solution 
still covering the cells; 
- An overnight incubation at 4 °C, or alternatively a 3 hour incubation at 
RT, followed; 
- Then, the solution was removed and the cells were washed with PBS for 
3 minutes in gentle agitation at RT. This washing step was repeated 3 
times; 
- The washing buffer was removed and secondary antibodies (Table 4), 
diluted in blocking solution, were added; 
- The cells were then incubated with the secondary antibody solution for 1 
hour at RT; 
- The solution was removed and the cells were washed as previously 
described; 
- 2 drops of 4',6-diamidino-2-phenylindole (DAPI; Thermo Fisher Scientific) 
were added to the last washing step and incubated for 5 minutes at RT. 
The samples were imaged using a Nikon Eclipse 80i VideoConfocal microscope 
(ViCo; Nikon) and analyzed with Image-Pro Plus 6.2 analysis software (Media 
Cybernetics, Rockville, MD, USA). 
 
  Primary antibody Host Dilution 
Stemness 
anti-OCT4 (Thermo Fisher Scientific) Rabbit 
1:100 
anti-SSEA4 (Thermo Fisher Scientific) Mouse 
anti-TRA 1-60 (Thermo Fisher Scientific) Mouse 
anti-SOX2 (Thermo Fisher Scientific) Rat 
Germ layer 
derivatives 
Endoderm anti-AFP (Thermo Fischer Scientific)  Mouse 1:500 
Neuroectoderm anti-NCAM (Thermo Fischer Scientific)  Mouse 1:100 
Mesoderm anti-SMA (Thermo Fischer Scientific)  Mouse 
Table 3. Primary antibodies. 
 
 
 
 
  Secondary antibody Host Dilution 
Stemness 
TRITC-conjugated anti-rabbit 
(Thermo Fischer Scientific) Donkey 
1:250 
FITC-conjugated anti-mouse 
(Thermo Fisher Scientific) Goat 
TRITC-conjugated anti mouse 
(Thermo Fisher Scientific) Goat 
FITC-conjugated anti-rat 
(Thermo Fisher Scientific) Donkey 
Germ layer 
derivatives 
Endoderm FITC-conjugated  
anti-mouse 
(Thermo Fisher Scientific) 
Goat 
Mesoderm 
Neuroectoderm 
TRITC-conjugated  
anti-mouse 
(Thermo Fisher Scientific) 
Goat 
Table 4. Secondary antibodies. 
 
DNA extraction 
Cell pellets were collected from subconfluent LL-CBMSC, hESC H9 or hiPSC 
cultures and immediately frozen at -80 °C until use. DNA was extracted by the 
QIAamp DNA Blood Mini Kit (51104; Qiagen, Hilden, Germany). Briefly, 200 μL 
of buffer AL were added to the sample and mixed by pulse-vortexing for 15 
seconds. Then, the samples were incubated at 56 °C for 10 minutes, after 
which 200 μL of ethanol (96-100%) were added to the sample and mixed again 
by pulse-vortexing for 15 seconds. The mixture was applied to the QIAamp Mini 
spin columns and centrifuged at 6000 x g for 1 minute, after which the filtrate 
was discarded. Then, 500 μL of buffer AW1 were added to the QIAamp Mini 
spin columns and centrifuged at 6000 x g for 1 minute, after which the filtrate 
was discarded. The same procedure was repeated for buffer AW2, but at full 
speed (20,000 xg) for 3 minutes. To elute the filter-bound DNA, 200 μL of buffer 
AE were added to the QIAamp Mini spin columns, which were incubated at 
room temperature for 1 minute, before they were centrifuged at 6000 x g for 1 
minute. DNA quantification was performed with a Nanodrop 1000 instrument, 
reading absorbance (A) at 260 nm; purity was assessed by A260/A230 (organic 
compound contamination) and A260/A280 (protein contamination) ratios; 
integrity was assessed by agarose gel electrophoresis, as previously described. 
 
Bisulfite conversion 
Each sample DNA (500 ng) was treated with the EZ DNA Methylation-Gold Kit 
(Zymo Research, Orange, CA, USA) to obtain bisulfite conversion. Briefly, 130 
μL of the CT conversion reagent were added to 20 μL of DNA in a PCR tube. 
Then, the tube was placed in a thermal cycler and the following steps were 
performed: 98 °C for 10 minutes, 64 °C for 2.5 hours and 4 °C for storage. 
Then, 600 μL of M-binding buffer were added to a Zymo-Spin IC column, which 
was placed into a collection tube. The sample was loaded into the column and it 
was mixed by inverting the column several times. Centrifugation at full speed 
(>10,000 x g) for 30 seconds was performed and the flow-through discarded. 
Then, 100 μL of M-wash buffer were added to the column and centrifugation at 
full speed for 30 seconds was performed. Next, 200 μL of M-desulphonation 
buffer were added to the column, which was let stand at room temperature for 
20 minutes. After the incubation, centrifugation at full speed for 30 seconds was 
performed, followed by two washing steps with 200 μL of M-wash buffer. The 
column was placed into a 1.5 mL microcentrifuge tube. Finally, bisulfite-treated 
DNA was eluted in 30 μL of M-elution buffer and stored at -20 °C for later use. 
 
Pyrosequencing 
To analyze DNA methylation, a 50 μL PCR reaction was carried out with 25 μL 
of GoTaq Hot Start Green Master mix (Promega, Madison, WI, USA), 10 μM of 
forward primer, 10 μM of biotinylated reverse primer and 500 ng of bisulfite-
treated DNA. PCR cycling conditions and primer sequences are provided in 
table 1 and 2, respectively. Biotin-labeled primers were used to purify the final 
PCR product with sepharose beads: 10 μL of PCR product were bound to 1 μL 
of Streptavidin Sepharose HP affinity chromatography medium (Amersham 
Biosciences, Uppsala, Sweden) in presence of 40 μL of binding buffer 
(Amersham Biosciences), after a 10 minute incubation in agitation. Sepharose 
beads containing the immobilized PCR product were purified, washed, 
denatured with 0.2 M NaOH and washed again with the Pyrosequencing 
Vacuum Prep Tool (Pyrosequencing, Inc., Westborough, MA, USA), according 
to the manufacturer’s instructions. Pyrosequencing primer (0.3 μM) was 
annealed to the purified single-stranded PCR product in presence of 15 μL of 
annealing buffer, during an incubation of 2 minutes at 85 °C, then 
pyrosequencing was performed in duplicate with the PyroMark MD System 
(Pyrosequencing, Inc. Westborough, MA, USA). The percentage of methylated 
cytosines was calculated as the number of methylated cytosines divided by the 
sum of methylated and unmethylated cytosines, multiplied by 100%. 
 
Temperature Time Cycles 
95 °C 5 minutes 1 
95 °C 30 seconds 
45 
54 °C for NANOG promoter 
59 °C for OCT4 promoter 
56 °C for OCT4 proximal enhancer 
45 seconds 
72 °C 45 seconds 
72 °C 5 minutes 1 
6 °C For ever 1 
Table 1. PCR thermal profiles. 
 
Assay Sequences 
NANOG promoter 
Forward TTGTTGTTGGGTTTGTTTTTAGG 
Reverse BIO-ACCTTAAACCCACCCCTCCTA 
Sequencing TTTGGTGAGATTGGTAGA 
OCT4 promoter 
Forward AAGTTTTTGTGGGGGATTTGTAT 
Reverse BIO-CCACCCACTAACCTTAACCTCTA 
Sequencing 1 TGAGGTTTTGGAGGG 
Sequencing 2 GTTATTATTATTAGGTAAATATTTT 
OCT4 proximal 
enhancer 
Forward AGTTTTAGGATATTTAGGTTAGGTTTAGAA 
Reverse BIO-CAACAACCCCCCTCTACAAT 
Sequencing 1 GGATATTTAGGTTAGGTTTAGAAA 
Sequencing 2 GTATATTTTTTAATTTGTTAGGTT 
Table 2. Primer sequences. 
 
 
 
In vitro differentiation 
To obtain endoderm and mesoderm cell derivatives, an initial embryoid body 
(EB) formation step was performed. Briefly, hiPSC and hESC colonies were 
detached using the previously described non-enzymatic method. Next, cell 
aggregation was promoted by transferring 150 μL of cell suspension per well 
into a low-attachment V-bottom 96-well plate. The cells were cultured in KO-
DMEM (Sigma-Aldrich) supplemented with 20% KO-Serum Replacement (KO-SR; Life 
Technologies), 2mM Glutamax (Life Technologies), 50 μM 2-mercaptoethanol (Life 
Technologies), 10 mL/L penicillin/streptomycin (Sigma-Aldrich) and 1mM non-essential 
amminoacids (Life Technologies) (KO medium) for 3-4 days to allow EB formation. 
Then, EBs were transferred into low-attachment 24-well plate and maintained in 
suspension in KO medium for 2-3 supplementary days. Finally, the EBs were 
transferred onto 0.1% gelatin (StemCell Technologies, Vancouver, Canada)-
coated glass chamber slides (BD). Endodermal differentiation medium was 
composed of DMEM (Sigma Aldrich), 20% FBS (Life Technologies), 2 mM L-
glutamine (Capricorn Scientific; Ebsdorfergrund, Germany), 0.1 mM 2-
mercaptoethanol (Life Technologies), 1 mM non-essential aminoacids (Life 
Technologies) and 10 mL/L penicillin/streptomycin (Sigma-Aldrich). The 
mesodermal differentiation medium was the same used for endodermal 
differentiation, supplemented with 100 mM ascorbic acid (Sigma-Aldrich). The 
EBs were maintained onto the gelatin-coated glass chamber slides for 2-3 
weeks. The medium was replaced twice a week. 
In order to obtain differentiation to early neuro-epithelial cells, Neurobasal (Life 
Technologies), 1X N2 (Life Technologies), 1X B27 (Life Technologies), 10 mL/L 
penicillin/streptomycin (Sigma-Aldrich), 2 mM L-glutamine (Capricorn Scientific) 
(N2-B27 medium) was used. The following protocol was carried out: 
- hESCs and hiPSCs were grown in chamber slides (BD), in the previously 
described culture conditions; 
- At 80% confluence, the medium was removed and KO medium was 
added to the cells; 
- The KO medium was not changed for 5 days; 
- At day 5, the medium was carefully aspirated and replaced entirely with 
75% KO medium, 25% N2-B27 medium; 
- At day 7, the medium was changed to 50% KO medium, 50% N2-B27 
medium; 
- At day 9, the medium was changed to 25% KO medium, 75% N2-B27 
medium; 
- At day 12, the medium was carefully aspirated and replaced entirely with 
100% N2-B27 medium; 
- Between day 12 and day 15, the medium was partially changed once: 
1/3 of medium was kept and 2/3 of fresh N2-B27 medium was added; 
- When the cells acquired an early neuro-epithelial-like morphology, the 
medium was removed and the samples were processed for 
immunofluorescence. 
 
Extracellular vesicle isolation  
In order to isolate extracellular vesicles (EVs), different approaches were used 
for LL-CBMSCs, hESCs and hiPSCs, due to the different cell culture conditions. 
LL-CBMSCs were grown in 75 cm2 flasks (BD). At 80%-90% confluence LL-
CBMSC culture medium was removed, the cells were washed twice with PBS to 
remove bovine EVs present in the serum and αMEM (Sigma-Aldrich) without 
FBS (Life Technologies) was added (starving step). After 24 hours, EV-
containing medium was collected and serially centrifuged to remove dead cells 
(350 xg for 10 minutes) and cellular debris (5,000 xg for 15 minutes). Then, EVs 
were collected with a 3 hour 100,000 xg ultracentrifugation at 4 °C (F37L 8X100 
rotor, Sorvall WX 80+ ultracentrifuge; Thermo Fisher Scientific ). Since hESC 
and hiPSC growth medium did not contain serum, the starving step was not 
performed. hESCs and hiPSCs were grown in Petri dishes (100 mm) in 
standard culture medium, until they reached 80% confluence. Then, 24 hour 
conditioned medium was collected and serially centrifuged, as already 
described. The supernatant was discarded and the EV pellets resuspended in 
150 μL of PBS, for both LL-CBMSCs and pluripotent stem cells. Finally, EVs 
were stored at -20 °C for subsequent studies. 
 
 
Nanoparticle tracking analysis 
To estimate the number and size of isolated EVs, Nanoparticle Tracking 
Analysis (NTA) was performed using the NanoSight LM10 instrument 
(NanoSight, Malvern, UK), which exploits light scattering of a laser beam 
caused by nanoparticle Brownian movements to count EVs. Immediately after 
isolation, EVs diluted 1:100 in 500 μL of PBS were analyzed. The EV number 
was calculated from the mean of n=5 independent counts on the same sample. 
The culture media were checked for absence of a significant number of 
nanoparticles. 
 
Flow cytometry protocol for extracellular vesicles 
Integrity of EVs was investigated by carboxyfluorescein diacetate succinimidyl 
ester (CFDA-SE) staining (BD). CFDA-SE is a cell-permeable precursor which 
can be converted into a fluorescent molecule, carboxyfluorescein succinimidyl 
ester (CFSE), by cytoplasmic esterases. In addition, the EV immunophenotype 
was also assessed. To stain EVs, 50 μL of starved LL-CBMSC- or pluripotent 
stem cell-conditioned medium were collected. Next, EVs were incubated with 5 
μL of 100 μM CFDA-SE for 30 minutes in the dark at RT. Alternatively, EVs 
were incubated with 10 μL of CD63 (BD), CD81 (BD) or isotype (BD) antibodies 
for 15 minutes at RT. Right after incubation, 300 μL of PBS were added to each 
sample and EVs were analyzed immediately. In order to visualize EVs on a 
FACSCantoII standard cytometer (BD), its physical parameters were pushed to 
their limit of detection. Moreover, forward scatter (FSC) and side scatter (SSC) 
were set on a logarithmic scale and the FSC threshold was set to a value of 
200-350. The data were analyzed with the FACS Diva version 7 analysis 
software (BD). 
 
Electron microscopy 
For Scanning Electron Microscopy (SEM), LL-CBMSCs, hESCs and hiPSCs 
were cultured on glass coverslips, fixed in 2% glutaraldehyde (Sigma-Aldrich) 
diluted in PBS, washed twice with PBS and stored at 4 °C. For Transmission 
Electron Microscopy (TEM), EVs were collected, resuspended in 200 μL PBS 
and analyzed within 24 hours. SEM and TEM analyses were performed in 
collaboration with Università degli Studi dell'Aquila, Dipartimento di Medicina 
Clinica, Sanità Pubblica, Scienze della Vita e dell'Ambiente. 
For SEM analysis, the samples were dehydrated through a graded series of 
ethanol solutions. Samples were critical-point dried and sputter coated with a 
SCD040 Balzer Sputterer (Balzers Union, Liechtenstein). A Philips 505 SEM 
microscope (Philips, Eindhoven, Netherlands) was used to examine the 
samples, using an accelerating voltage of 20 kV. For TEM analysis, the EVs 
resuspended in PBS were adsorbed to 300 mesh carbon-coated copper grids 
(Electron Microscopy Sciences, Hatfield, PA, USA) for 5 minutes in a humidified 
chamber at RT. EVs on grids were then fixed in 2% glutaraldehyde (Sigma-
Aldrich) in PBS for 10 minutes and then briefly rinsed with milliQ water. Grids 
with adhered EVs were examined with a Philips CM 100 TEM microscope 
(Philips) at 80kV, after negative staining with 2% phosphotungstic acid (Sigma-
Aldrich), brought to pH 7.0 with NaOH. Images were captured by a Kodak digital 
camera. 
 
miRNA extraction 
Isolated extracellular vesicles (EVs) were lysed with 700 μL of QIAzol Lysis 
Reagent (Qiagen, Hilden, Germany), vortexed and stored at -20 °C until use. To 
extract miRNA, the miRNeasy Mini Kit (Qiagen) and the RNeasy MinElute 
Cleanup Kit (Qiagen) were used. Briefly, 140 μL of chloroform were added to 
the samples, which were shaken vigorously for 15 seconds and let stand for 3 
minutes at room temperature (RT). Then, the samples were centrifuged for 15 
minutes at 12,000 xg at 8 °C. The resulting upper aqueous phase was 
transferred to a new collection tube, and 350 μL of 70% ethanol were added. 
After vortexing, the samples were transferred in RNeasy spin columns, placed 
in 2 mL collection tubes at RT, and centrifuged for 15 seconds at speed speed 
at 20 °C. The filters were discarded and 450 μL of 100% ethanol were added to 
the miRNA-containing flow-through. Next, 700 μL of samples were transferred 
to RNeasy MinElute spin columns and centrifuged for 15 seconds at speed 
speed at 20 °C; the flow-through was discarded. This step was repeated for the 
remaining 700 μL of samples. Then, 500 μL of RPE Buffer were added to the 
RNeasy MinElute spin columns and centrifuged for 15 seconds at speed speed. 
The flow-through was discarded and the columns were placed into new 
collection tubes. Next, 500 μL of 80% ethanol were added to the columns and 
centrifuged for 2 minutes at speed speed. The flow-through was discarded and 
the columns were transferred into new collection tubes. An additional 
centrifugation at speed speed for 5 minutes was performed with open lids. To 
elute miRNAs, the columns were transferred into 1.5 mL collection tubes and 20 
μL of RNase free-water were added to the filters. The filters were let stand at 
RT for 5 minutes and then the samples were centrifuged for 1 minute at full 
speed. RNA quality and quantification were assessed on a 2100 Bioanalyzer 
instrument (Agilent, Santa Clara, CA, USA). The samples were stored at -80 °C 
until further use. 
 
miRNA Real Time PCR-array 
The miRNome analysis was performed in collaboration with Dipartimento di 
Scienze Cliniche e di Comunità, University of Milan, Milan, Italy. The complete 
miRNome was investigated using the Real Time PCR TaqMan OpenArray 
Human MicroRNA Panel array (Thermo Fisher Scientific, Waltham, MA, USA), 
covering a total of 754 human miRNAs. The array allowed the simultaneous 
automated manipulation and analysis of the 3 samples. The experiment was 
carried out on a QuantStudio 12K Flex Real Time PCR System (Thermo Fisher 
Scientific). Statistical analysis was performed with R free software version 3.3.1 
(https://cran.r-project.org), using VennDiagram package venn.diagram() 
function and gplots package heatmap.2() function. 
 
Statistical analysis 
Online interrogation of miRTarBase experimentally-validated miRNA version 7 
database was performed using DIANA miRPath version 3 tool (http://snf-
515788.vm.okeanos.grnet.gr/), considering KEGG pathway database. The 
results were merged by pathways union; 0.05 p-value threshold; 0.8 microT 
threshold; FDR correction on. 
III. Protocols 
 
c. Setting up and analysis of an ex vivo organotypic 
mouse model of brain ischemia 
 
Animals 
Experimental procedures involving animals and their care were conducted in 
conformity with the institutional guidelines at the IRCCS Institute for 
Pharmacological Research “Mario Negri” in compliance with national (Decreto 
Legge nr 116/92, Gazzetta Ufficiale, supplement 40, February 18,1992; 
Circolare nr 8, Gazzetta Ufficiale, July 14, 1994) and international laws and 
policies (EEC Council Directive 86/609, OJL 358, 1, Dec. 12, 1987; Guide for 
the Care and Use of Laboratory Animals, U.S. National Research Council 
(Eighth Edition) 2011). Mice (Harlan Laboratories, Italy) were housed in a 
specific pathogen-free vivarium (room temperature (RT) 21±1 °C, 12 hour light-
dark cycle, free access to food and water). All efforts were made to minimize 
animal suffering and to reduce the number of animals used. 
 
Mouse brain slice preparation 
Organotypic cortical brain slices (named cortical slices from now on) were 
obtained from prefrontal cortex of C57BL/6 mouse pups (P1-3). Mouse pup 
brains were removed from the skull under sterile conditions and were immersed 
into a 3% agar solution. Tissue blocks containing mesencephalic and forebrain 
levels were dissected out, fixed onto a specimen stage of a vibratome (VT 
1000S; Leica Biosystems, Nussloch, Germany) with Super Attack glue, and 
placed in ice-cold (4 °C) artificial cerebral spinal fluid (ACSF) solution (NaCl=87 
mM, NaHCO3=25 mM, NaH2PO4=1.25 mM, MgCl2=7 mM, CaCl2=0.5 mM, 
KCl=2.5 mM, D-glucose=25 mM, sucrose=75 mM, Penicillin=50 U/ml, 
Streptomicin=50 μg/ml, equilibrated with 95% O2 and 5% CO2, pH=7.4). 
Prefrontal cortex coronal sections of 200 μm thickness were cut. Cortical slices 
were transferred into Petri dishes filled with ice-cold ACSF. Only intact cortical 
slices were placed on membranes of tissue culture inserts (0.4 μm pore size 
Millicell Culture insert; Merk Millipore, Darmstadt, Germany) with two slices per 
insert and placed in 6-well plate wells, each filled with 1 mL of culture medium 
(MEM-Glutamax 25%, basal medium eagle 25% (Life Technologies, Carlsband, 
CA, USA), horse serum 25% (Euroclone, Pero, Italy), glucose 0.6%, penicillin 
100 U/mL, streptomicin 100 μg/mL (Euroclone); pH=7.2). All the cultures were 
maintained at 37° C in 5% CO2. After two days, the incubation medium was 
changed with neurobasal medium (Life Technologies) supplemented with B27 
(1:50) (Life Technologies), L-glutamine (1:100) (Life Technologies), penicillin 
(100 U/mL), streptomycin (100 μg/mL) (Euroclone) (NB/B27 medium) and 
replaced there after every two days. 
 
Ischemic insult 
After one week in culture, cortical slices were subjected to oxygen and glucose 
deprivation (OGD), an in vitro model of brain ischemia. The culture medium was 
removed, cortical slices were washed twice with PBS (Euroclone) and 
transferred into a temperature?controlled (37±1 °C) hypoxic chamber (InvivO2 
400; Baker Ruskinn, Bridgend, UK) at [O2]=0.1%, [CO2]=5%, [N2]=95%. Once in 
the hypoxic chamber, the PBS was replaced with deoxygenated glucose?free 
medium. After a 2 hour OGD insult, cortical slices were transferred to a 
normoxic incubator and the medium was replaced with NB/B27 medium. 
Control cortical slices, not exposed to ischemic injury, were maintained in 
normoxic incubator with NB/B27 medium. The rescue experiment was 
conducted according to the experimental plan depicted in figure 5.1. 
 
Propidium iodide incorporation 
To evaluate cell death 48 hours after injury, the inserts with cortical slices were 
moved to new plates and fresh NB/B27 medium containing 2 μM of propidium 
iodide (PI; Sigma-Aldrich, Saint Louis, MI, USA) was added. After a 30 minute 
incubation, images were captured at X4 magnification, using the TRITC filter of 
an Olympus IX71 microscope (Olympus, Tokyo, Japan). Images were then 
analyzed with Fiji software (University of Wisconsin-Madison, WI, USA) for 
quantification of PI-positive cells. 
 Extracellular vesicle labeling 
Extracellular vesicles (EVs) resuspended in Diluent C (Sigma-Aldrich) were 
mixed with PKH26 (Sigma-Aldrich) and incubated for 20 minutes at RT in the 
dark. The reaction was stopped by adding an equal volume of 1% BSA (Sigma-
Aldrich). EVs were then ultracentrifuged at 100,000 xg for 1 hour and 
resuspended in PBS (Euroclone). PBS (Euroclone) that received the same 
treatment as above was used as negative control. Cortical slices which received 
labeled EVs and PBS were observed after 24 hours. Images were captured at 
X4 magnification, using the TRITC filter of an Olympus IX71 microscope 
(Olympus, Tokyo, Japan). 
 
Gene expression 
Forty-eight hours after injury, cortical slices were collected and total RNA was 
extracted by miRNeasy mini kit (Qiagen, Hilden, Germany). The samples were 
treated with DNase (Life Technologies) and reverse-transcribed with random 
hexamer primers using Multi-Scribe Reverse Transcriptase (Life Technologies). 
Real time reverse transcription quantitative PCR was performed and relative 
gene expression determined by the ΔΔCt method; β-Act, Rpl27 and B2m were 
used as house-keeping genes. Data are expressed as log2 of the fold difference 
compared to the control group. Genes and primer sequences are reported in 
Table 1; the primer pairs were designed not to amplify human sequences. 
Gene Forward Primer Reverse Primer 
β-act CGCGAGCACAGCTTCTTT GCAGCGATATCGTCATCCAT 
Rpl27 TCATGAAACCCGGGAAAGT GAGGTGCCATCGTCAATGT 
B2m CTGACCGGCCTGTATGCTAT TATGTTCGGCTTCCCATTCT 
Map2 TCAGCTGACAGAGAAACAGCA TTGTGTTGGGCTTCCTTCTC 
Cd31 GTCGTCCATGTCCCGAGAA GCACAGGACTCTCGCAATCC 
Gfap GAAACCGCATCACCATTCC TCGGATGGAGGTTGGAGA 
Cd11b GAGCAGCACTGAGATCCTGTTTAA ATACGACTCCTGCCCTGGAA 
Bdnf AGGCACTGGAACTCGCAATG AAGGGCCCGAACATACGATT 
Vegf CATTCCTGGCCCTGAGTCAA TCGC TGGTTGGAACCGGCATCTTT 
Bcl2 GTGCCTGTGGTCATGGATCTG CCTGTGCCACTTGCTCTTTAG 
Bax GAGAGGCAGCGGCAGTGAT TGCTCGATCCTGGATGAAACC 
Mki67 GATAACGCCACCGAGGACAA ATGGATGCTCTCTTCGCAGG 
Pcna ACCTTTGAAGATTGCTCCTGAGA ACTTGGTGACAGAAAAGACCTC
Table 1. List of primers used for real-time reverse transcription polymerase chain reaction. 
 
Evaluation of metabolic and oxidative stress 
To investigate levels of metabolites and parameters of oxidative stress in 
cortical slice conditioned medium, colorimetric or fluorescence reaction-based 
assays were used for ATP (Abcam, Cambridge, UK), adenosine (Biovision, 
Milpitas, CA, USA), glutamate (Fitzgerald Industries International, North Acton, 
MA, USA), malondialdehyde (Fitzgerald Industries International), superoxide 
dismutase (Biovision) and glutathione (Fitzgerald Industries International). 
 
Multiplex quantification of inflammatory factors 
The Cytokine 1 mouse Cyraplex assay (Aushon BioSystems, Billerica, MA, 
USA) was used to detect inflammatory cytokines present in cortical slice 
conditioned medium. The assay allowed the simultaneous quantification of 
murine TNFα, INFγ, IL1β, IL2, IL6, IL10, IL12p70 and IL17. The cell culture 
supernatants were centrifuged at 350 xg for 10 minutes to remove dead cells, 
and then they were stored at -80 °C. The samples were thawed completely and 
mixed by gently vortexing, before performing the assay. Also, unconditioned 
NB/B27 medium was used as blank. All the samples were used undiluted and 
diluted 1:10 in Sample Diluent (Aushon BioSystems) Lyophilized analyte 
standards were reconstituted in Sample Diluent (Aushon BioSystems) and 
standard curves were prepared by serial dilution, following manufacturer’s 
instructions. Briefly, the MicroClime Lid (Aushon BioSystems) was filled with 
distilled water and stored until use. The assay plate was washed four times with 
300 μL of wash buffer (Aushon BioSystems), then it was dried by firmly patting 
on absorbent paper. Next, 50 μL of standards or sample were pipetted into 
each well. The plate was covered with the MicroClime Lid (Aushon BioSystems) 
and then it was incubated for 3 hours at RT on a plate shaker set at 60 rpm. 
Another wash step was performed as previously described. Next, 50 μL of 
Biotinylated Antibody Reagent (Aushon BioSystems) were added to each well. 
The plate was covered with the MicroClime Lid (Aushon BioSystems) and then 
it was incubated for 30 minutes at RT on a plate shaker set at 60 rpm. A final 
washing step was performed as previously described. The wells were then filled 
with Block/Stabilizing Solution (Aushon BioSystems) and incubated for 30 
minutes at RT. Next, the solution in excess was removed, avoiding to dry 
completely the wells. The final steps for imaging and analysis were performed 
at the laboratories of “Tema Ricerca”, located in Castenago, Bologna, Italy. The 
detection of chemiluminescence was performed on the Cyrascan instrument 
(Aushon BioSystems) and analyzed by the Cyrasoft software (Aushon 
BioSystems). 
 
Statistical analysis 
All statistical analyses were performed using Prism software (GraphPad, La 
Jolla, CA, USA). Online interrogation of miRTarBase experimentally-validated 
miRNA version 7 database was performed using DIANA miRPath version 3 tool 
(http://snf-515788.vm.okeanos.grnet.gr/), considering KEGG pathway database. 
The results were merged by pathways union; 0.05 p-value threshold; 0.8 microT 
threshold; FDR correction on. 
 
This appendix is partially a modified excerpt of a recent paper by the 
collaborators for the ex vivo experiments (Pischiutta F et al., Critical care 
medicine, 2016). 
